PYRAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF

Abstract: The present invention provides novel pyrazole derivatives having the chemical formula (I), wherein the moiety (A) is (a), (b) or (c); and R is (B), which are useful for preventing or treating hypertension, congestive heart failure, renal failure, glaucoma and hyperuricemia and have high activity, provide rapid onset of action upon intravenous injection, can be administered orally, have low toxicity, and have a long duration of action.

Description: PYRAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF BACKGROUND OF THE INVENTION Field of Industrial Applicability The present invention relates to novel pyrazole derivatives or pharmacologically acceptable esters or salts thereof, and phaπnaceutical compositions that contain them as active ingredients for preventing or treating hypertension, congestive heart failure, renal failure, glaucoma and hyperuricemia. It is widely known that tlie renin-angiotensin-aldosterone system is closely associated with tlie pathogenesis and pathology of hypertension through the control of blood pressure and with the balance between levels of electrolyte and body fluid. It has long been tlie subject of many studies to control this system with a view to preventing and treating hypertension including essential hypertension and, further, congestive heart failure. While several control metiiods have been proposed, tlie following may be worth particular mention: i) suppressing the synthesis or secretion of renin which is believed to be situated tlie most upstream of die system; ii) suppressing the reaction between renin and renin substrate (angiotensinogen), thereby reducing tlie production of angiotensin I; iii) inhibiting the angiotensin converting enzyme (ACE) which converts angiotensin I to angiotensin II having strong vasoconstrictive action, aldosterone secretion stimulating action, sympathetic nerve function enhancing action, etc.; iv) blocking the receptor binding of the produced angiotensin II, thereby suppressing its action; and v) activating angiotensinase which is capable of rapidly degrading tlie produced angiotensin II. Of tlie studies conducted so far, tiiat of ACE inhibitors is the most advanced and many drugs are being used to prevent or treat hypertension or congestive heart failure. However, ACE inhibitors are not selective and will also act on other systems such as the kalliklein-kinin system, causing the problem of frequent occurrence of side effects such as skin rash and dry cough in clinical applications. Under the circumstances, many attempts have been made to develop a more "selective" renin inhibitor but none have met with commercial success. Ever since the discovery by D. T. Pals et al. of the fact that saralasin prepared by modifying tlie terminal portion of angiotensin II has an antagonistic action on die receptor of angiotensin II, the study of receptor antagonists has been conducted actively. The study is not directed to peptides such as salarasin that have a partial agonist activity, but concerned with a search for a compound that is not a peptide, that has no partial agonist activity, that can be administered orally and that has a long lasting action. Early receptor antagonists were reported in Japanese Patent Laid-Open Publication (Kokai). Sho Nos. 54-148788, 56-71073, 57-98270 and 58-157768; however, their pharmacological activity was only about 1/10000 of the practical level. Success in increasing that activity to die practical level was reported in EP-0253310 and EP-0291969 and clinical tests are currently in progress on a compound named "Dup753" which is represented by the following formula: 753 However, selective synthesis of Dup753 is impossible without adopting a special process because Uie production of this compound involves die formation of regio-isomcrs, typically al die ratio 1:1, during N-alkylation and Uiis is held as a problem that must be solved before the compound can be mass produced. On the otiier hand, it was generally held in the past dial modifying an imidazole witii a polar group at the 5-position was effective in increasing its angiotensin II receptor binding activity. This working hypothesis had to be modified significantly as a consequence of the discovery of the benzimidazoles that are taught in EP- 0392317 (later reported in EP-0400835 and EP-0399732, too), followed by development of imidazopyridines (see EP-0399731, EP-0400974 and EP-0415886): Besides these imidazoles, compounds having a pyrazole ring that are represented by the following formula have been reported to have an antagonistic action on tlie receptor of angiotensin II in a similar manner as imidazoles (EP 0323841): The compounds shown above have a nitrogen atom in the pyrazole ring carrying a biplienyl group or die like and it has been reported diat compounds represented by the following formula in which the hydrogen atom at the 4-position is substituted by a biphenyl group or the like also have an antagonistic action on the receptor of angiotensin II (EP 0446062): Similar pyrazole derivatives were also reported in EPO 449699 and WO 91/15479. Furthermore, there have been reported compounds that have pyrazoles condensed widi nitrogen contining rings as shown below (EP 0490587): On die other hand, compounds represented by die following formulas have been reported as tiiose which have a bridgehead hydrazine structure as does die compound of tlie present invention (EP 3317290 and EP 0042100); however, these are angiotensin converting enzyme inhibitors and no bridgehead hydrazine derivatives =are yet to be known as angiotensin II antagonists: In this connection, it is interesting to note that the present inventors found that imidazole derivatives represented by the following formula and which have a bridgehead hydrazine structure had high antagonistic activity against angiotensin II. See PCT published application WO 93/08913 (29 April 1993). INFORMATION DISCLOSURE Renin-angiotensin-aldosterone inhibitors are described in die references listed above. Those stated to be active at a practical level include those described in EP 0253310; 0291969; 0400835; 0399732; 0399731; 0400974; 0415886; 0323841; 446062; 449699; 3317290; 00421000; WO 91/15479 and WO 93/08913. SUMMARY OF THE INVENTION Problems to be Solved by the Invention Noting an angiotensin II antagonist as a candidate for agents that would be effective in preventing or treating hypertension, congestive heart failure, renal failure, glaucoma and hyperuricemia, the present inventors continued their studies in search for drugs that could withstand prolonged storage, that had high activity, that would be capable of rapid manifestation of the intended action upon intravenous injection, that would exhibit efficient absorption by the body upon oral administration, that had low toxicity and that would work effectively for a prolonged time. As a result, novel pyrazole derivatives having a certain kind of bridgehead hydrazine structure were found to be effective and the present invention has been accomplished on the basis of this finding. Means for Solving the Problems The present invention provides a pyrazole derivative represented by the general formula (1): wherein R 1 is: (a) a hydrogen atom, (b) -CF 3 , (c) C-- alkyl group, (d) C,-C 8 alkoxy group, (e) C,-C 8 alkylthio group, (t) C.-Q. alkylamino group, (g) C,-C R alkenyl group, (h) C„-C lπ aryl group, (i) C 6 -C ιn aralkyl group, or (j) a C.- alkyl, C,-C 8 alkoxy, C*-C 8 alkyldiio, C,-C 8 alkylamino, C 2 -C 8 alkenyl, C 6 -C 10 aryl or C 6 -C* n aralkyl substituted by a (i) halogen atom, (ii) C.-C 8 alkyl group, (iii) fluoroalkyl group, (iv) cycloalkyl group, (v) hydroxy group, (vi) a C,-C 8 alkoxy group, (vii) nitro group, (viii) carboxyl group, (ix) C,-C 8 alkoxycarbonyl group, (x) amino group, or (xi) cyano group; wherein the moiety is (a) -CIKR 1 ) -C!H-Z-, (b) -C(R 1 )=CI-Z- or I I or (c) -CHKR 1 ) -C=Z-; with the provisos that when -C(R 1 )^C^Z- is -CH(R 1 )-C IH-Z- or -C(R1)=CI-Z- -Z- is a single bond, -CHR'-, -NR'-, an oxygen I I atom or -S(θ) n -; and when -C(R 1 ) :: C : -Z- is -CIKR 1 ) -C=Z-, =Z- is a double bond, =CR'- or =N-, (where R' is a hydrogen atom or a alkyl group and n is 0, 1 or 2) ; wherein R is a hydrogen atom or a group selected from among the following groups: wherein X is (a) -CH , (b) -NR\ (c) an oxygen atom, or (d) -S(O),,-, (wherein R' is a hydrogen atom or a C,-C 8 alkyl group and n is 0, where each occurrence of X 1 , X * and X 3 can be die same or different and is a (a) hydrogen atom, (b) halogen atom, (c) C--Q* alkyl group, (d) C,-C 8 alkoxy group, (e) nitro group, (f) cyano group, (g) lH-tetrazol-5-yl group or an alkali metal salt thereof, (h) -C0 2 R 3 group, (i) -CONR'R" group, (j) -CONHSOoR 4 group, (k) amino group, (I) -NHS0 2 CF 3 group (m) -S0 3 H group, or (II) a group selected from among the following groups: wherein Y is a (a) cyano group, (b) lH-tetrazol-5-yI group or an alkali metal salt thereof, (c) -C0 2 R 3 group, (d) -CONR'R" group, (e) -CONHS0 2 R 4 group, (f) amino group, (g) -NHS0 2 CF*, group or (h) -S0 3 H group; wherein R 2 is a (a) hydrogen atom, (b) halogen atom, (c) C,-C 8 alkyl group, (d) -CF 3 group or (e) -CF 2 CF., group; wherein R 3 is a (a) hydrogen atom, (b) alkali metal atom, or (c) C,C 8 alkyl group; where each occurrence of R' and R" can be the same or different and is (a) hydrogen atom, (b) Q-Q alkyl group, or (c) R' and R" taken togetiier to form an alicyclic structure; wherein R 4 is a (a) C.-Q alkyl group, (b) Q-Q cycloalkyl group, or (c) C 6 -C 10 aryl group; wherein R 5 is a (a) C,-Q alkyl group, (b) C,-Q alkoxy group, (c) Q-Q cycloalkyl group, (d) Q-Q cycloalkoxy group, (e) C 6 -C 10 aryl group or (f) C 6 -C 10 aryloxy group; where each occurrence of R 6 , R 7 and R 8 is the same or different and is a (a) hydrogen atom, (b) halogen atom, (c) Q-Q alkyl group, (d) Q-Q alkoxy group, (e) nitro group, (f) cyano group, (g) -C0 2 R 3 group or (h) -CONR'R" group; wherein m is 1 when =Z- represents a double bond and in all other cases, m is 2; wherein -P- is represented as A-B-C-D, A-B=C-D or A=B-C=D, which, in die absence of A or D, are B-C-D, B=C-D, B-C=D, A-B-Q A-B=C or A=B-C and represent (a) -CH(R 9 )-CH(R κ ')-CH(R n )-, (b) -C(R )=C(R ,U )-CH(R")-, (c) -CH(R 9 )-C(R U) )=C(R n )-, (d) -CH(R 9 )-CH(R lϋ )-C(=0)-, (e) -C(=0)-CH(R ll, )-CH(R u )-, or (f) -CH(R )-C(=0)-CH(R π )- and which, in the presence of A and D, are A-B-C-D, A-B=C-D or A=B-C=D and represent (g) -C(R )(R 12 )-CH(R ,υ )-CH(R' ')-C(R 13 )(R 14 )-, (h) -C(R 9 )(R 12 )-C(R u ')=C(R")-C(R 13 )(R 14 )-, (i) -C(R )=C(R ,u )-C(R π )=C(R 13 )-, 0) -C(=O)-CH(R 10 )-CH(R' ')-C(R 13 )(R 14 )-, (k) -C(R 9 )(R 12 )-C(=0)-CH(R' ')-C(R 13 )(R' 4 )-, (I) -C(R 9 )(R 12 )-CH(R lυ )-C(-=0)-C(R 13 )(R 14 )-, or (m) -C(R 9 )(R 12 )-CH(R 10 )-CH(R")-C(=O)- where each occurrence of R 9 , R 1 ", R 11 , R 12 , R 13 and R 14 is the same or different and is a (a) hydrogen atom, (b) QQ alkyl group, (c) Q-Q fluoroalkyl group, (d) -rC(R 19 )(R 2ϋ )] r X-R 15 group, (e) -[C(R 1 )(R 2υ )] r C0 2 R 10 group, (f) -[C(R 1 )(R 2u )] r R 17 group, (g) -[C(R 19 )(R u )] r C(=0)R' group, (h) -[C(R 19 )(R 20 )] j -CONR 21 R 22 group, or (i) -[C(R 19 )(R 20 )] j -C(=O)NR'C(=O)NR'R" group; provided that R 9 and R 1 ", R lϋ and R" or R 11 and R 13 may combine together to form (a) an alicyclic structure, (b) 5- or 6-membered heteroaryl ring containing from one to three hcteroatom. s (O, N, S), (c) Q,-Q„ heteroaryl ring, (d) an alicyclic structure, C 6 -Q n aryl ring, or 5- or 6- me bered heteroaryl ring containing one to three heteroatoms (O, N, S) substituted by a (i) a halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group or (ix) a cyano group; provided further that R 12 and R 14 may combine togetiier to form -(CH^),- group, where j is 0, 1 , 2, 3 or 4, i is 1, 2 or 3, and R' and R" each independendy represent a hydrogen atom or a Q-Q alkyl group, or they may combine togetiier to form an alicyclic structure; where each occurrence of R 19 and R 2U in each [C(R 1 )(R 20 )1 unit are the same or different and represent a (a) hydrogen atom, (b) Q-Q alkyl group, (c) Q-Q alkoxy group, (d) Q-Q alkoxycarbonyl group or (e) Q-Q 0 aralkyl group or, (f) they may combine togetiier to form an alicyclic structure that is optionally substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (ix) -NR'R" group or (x) cyano group, provided that R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or diey may combine together to form an alicyclic structure; wherein X is (a) -CH : -, (b) -NR'-, (c) oxygen atom, or (d) -S(O),,-, provided that R' is a hydrogen atom or a Q-Q alkyl group and n is 0, 1 or 2; wherein R 15 is a (a) hydrogen atom or (b) Q-Q alkyl group diat is optionally substituted by a (i) hydroxy group, (ii) cyano group, (iii) -COOR' group, (iv) -CONR'R" group, (v) lH-tetrazol-5-yl group, or (vi) ether group, provided diat R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or tiiey may combine together to form an alicyclic structure; wherein R 10 is a (a) hydrogen atom, (b) alkali metal atom, or (c) Q-Q alkyl group, (d) Q-Q cycloalkyl group, (e) C 6 -C H , aralkyl group, (f) Q-Q cycloalkyl or C 6 -Q 0 aryl group substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group, (ix) cyano group, or a straight-chained or branched Q-Q alkyl or alkenyl group that are optionally substituted by -0-C(=0)-R 18 , -O- C(=0)-0-R 18 or -C(=0)-0- R 18 , where R 18 is a Q-Q alkyl group or a Q-Q cycloalkyl group, provided that R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or they may combine together to form an alicyclic structure; wherein R 17 is a (a) cyano group or (b) lH-tetrazol-5-yl group or (c) Q-Q cycloalkyl group, (d) Q-Q cycloalkenyl group, (e) Q-Q 0 aryl group, or (f) 5- or 6-membered heteroaryl ring containing from one to tiiree heteroatoms (0, N, S), (g) Q-Q cycloalkyl, Q-Q cycloalkenyl, Q,-Q ( , aryl, or 5- or 6-membered heteroaryl ring containing from one to three heteroatoms (O, N, S) substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group or (ix) cyano group, provided that R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or they may combine together to form an alicyclic structure; where each occurrence of R 21 and R 22 is the same or different and represent a (a) hydrogen atom, (b) Q-Q alkyl group, (c) Q-Q alkyl group substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) amino group, (ix) cyano group, (x) -0-C(=0)-R ls , or (xi) they may combine togetiier to form an alicyclic structure; wherein R 18 is a (a) Q-Q alkyl group or (b) Q-Q cycloalkyl group; or a pharmacologically acceptable ester or salt of said pyrazole derivative. The present invention also provides a pharmaceutical composition that contains die pyrazole derivative of die general formula (I) or pharmacologically acceptable ester or sail thereof as an active ingredient for preventing or treating hypertension, congestive heart failure, renal failure, glaucoma and hyperuricemia. The carbon atom content of the various hydrocarbon containing moieties is depicted as "Q-Q," where "i" indicates die lowest number of carbon atoms, and "j" indicates the highest number of carbon atoms. Pyrazole derivatives that are represented by die following general formula (II), in which -Z- and R in the general formula (I) are a single bond and a hydrogen atom, respectively, can be reacted with various substituted or unsubstituted benzyl halides or biphenyl methyl halides in die presence of a base and, hence, are also useful as intermediates for die synthesis of the compounds of the general formula (I): (where R 1 and -P- are the same as defined above). Compounds represented by die following general formula (III) are also useful as intermediates for the synthesis of tlie compounds of the general formula (I): I I (where Z is a single bond, -NH-, an oxygen atom or -S(0) n -, where n is 0, 1 or 2; R 1 and -P- are die same as defined above). Examples of tlie Q-Q alkyl group represented by R 1 in the general formula (I) for tlie compounds of the present invention are alkyl groups having 1-8 carbon atoms, such as mediyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isoamyl, n-hexyl, n-heptyl, n-octyl, etc. Examples of the Q-Q alkoxy group represented by R' include metiioxy, etiioxy, n- propoxy, isopropoxy, n-butoxy, isobutoxy, t-butoxy, n-pentoxy, isoamyloxy, n-hexyloxy, n- heptyloxy, n-octyloxy, etc. Examples of the Q-Q alkyldiio group represented by R 1 include methylti io, ethylthio, n-propylthio, isopropyld io, n-butyltiiio, n-pentylthio, n-hexyltiiio, n- heptyltliio, n-octylthio, etc. Examples of the Q-Q alkylamino group represented by R' include mediylamino. dimediylamino, ethylamino, diethylamino, n-propylamino, di(n-propyl)amino, isopropylamino, n-butylamino, n-pentylamino, pyrrolidino, piperidino, piperazino, mo holino, etc. Examples of the Q-Q alkenyl group represented by R' include vinyl, 1-propenyl, 2- propenyl, 2-medιyl-l-propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 1-hexenyl, 1- heptenyl, 1-octenyl, etc. Examples of die Q-Q alkynyl group represented by R 1 include an acetylene group, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 1- hexynyl, 1-heptnynyl, 1-octynyl, etc. Examples of the aryl and aralkyl groups represented by R 1 include tiiose having 6-10 carbon atoms, such as phenyl, naphtliyl, benzyl, phenetiiyl, 3- phenylpropyl, 4-phenylbutyl, etc. These Q-Q alkyl, Q-Q alkoxy, Q-Q alkyldiio, Q-Q alkylamino, Q-Q alkenyl, C 6 -C 10 aryl or aralkyl group may optionally be substituted by substituents such as a halogen atom, a Q-Q alkyl group, a fluoroalkyl group, a cycloalkyl group, a hydroxy group, a Q-Q alkoxy group, a nitro group, a carboxyl group, a Q-Q alkoxycarbonyl group, an amino group or a cyano group, wherein the Q-Q alkyl. Q-Q alkoxy and Q-Q alkoxycarbonyl groups for the substituents are the same as defined above. Examples of the fluoroalkyl group include trifluoromethyl, trifluoroetiiyl, pentafluoroethyl, etc. and examples of die cycloalkyl group include 3- to 7- membered ring compounds such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. In the case where R in the general formula (I) representing die compounds of the present invention is a substituted or unsubstituted phenylmediyl group, examples of the halogen atom defined by X 1 , X 2 and X 3 include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom, and examples of die Q-Q alkyl group and Q-Q alkoxy group include the Q-Q alkyl and alkoxy groups defined above. In the case where X 1 , X 2 and X 3 are each a lH-tetraxol- 5-yl group, examples of alkali metal salts thereof include a sodium salt, a potassium salt, etc. In the case where X 1 , X 2 and X 3 are each a -C0 2 R 3 group, examples of R 3 in that group include a hydrogen atom, an alkali metal atom such as lithium, sodium or potassium, alcohol ester groups of die Q-Q alkyl groups defined above, etc. In the case where X 1 , X 2 and X 3 are each a - CONR'R" group, examples of -NR'R" in diat group include amino, mediylamino, dimethylamino, ethylamino, dietiiylamino, n-propylamino, di(n-propyl)amino, diisopropylamino. dibutylamino. In diat -NR'R" group, an alicyclic structure which is formed by combining R' and R" togetiier means a 3-7 membered carbohydrate ring that may contain N atoms and/or oxygen atoms. Examples of such alicyclic structure include pyrrolidyl, piperidino, piperazino. morpholino, etc. Examples of R 4 in die -CONHS0 2 R 4 group include methyl, trifluoromethyl, ethyl, n-propyl, n-butyl, isobutyl, t-butyl, cyclopentyl, cyclohexyl, phenyl, etc. In d e case where X 1 , X 2 and X 3 are each selected from the following groups: examples of die alkali metal salt of Y if it is a lH-tetrazol-5-yl group, as well as examples ol R\ NR'R" and R 4 if Y is a -C0 2 R 3 group, -CONR'R" group or a -CONHS0 2 R 4 are die same as defined above. The Q-Q alkyl and alkoxy groups defined by R 5 are the same as defined above. In the case where R 5 is a cycloalkyl group or a cycloalkoxy group, it represents 3- to 7- membered ring compounds such as cyclopropyl, cyclobutyl, and cyclopentyl. Examples of die aryl and aryloxy groups represented by R 5 include substituted or unsubstituted phenyl compounds such as phenyl, p-hydroxyphenyl, p-carboxyphenyl, o-nitrophenyl, etc. Examples of die case where R 6 , R 7 are R 8 are each a Q-Q alkyl group, a Q-Q alkoxy group, a -C0 2 R 3 group or a -CONR'R" group include those which are already defined above. In the case where R in the general formula (I) is a substituted biphenylmetiiyl group, examples of die alkali meial salt of Y if it is lH-tetrazol-5-yl, and examples of R 3 , -NR'R" and R 4 if Y is a -CO-R 3 group, a -CONR'R" group or a -CONHS0 2 R 4 group are die same as defined above. In d e case where R in die general formula (I) is represented by: examples of the Q-Q alkyl R' in X which is represented by -NR'-, examples of die halogen atom or die Q-Q alkyl group which are represented by R 2 , examples of d e alkali metal salt of Y when it is lH-tetrazol-5-yl, or examples of R 3 . NR'R" and R 4 when Y is represented by a - C0 2 R 3 group, -CONR'R" group or a -CONHS0 2 R 4 group are also die same as defined above. Further referring to the general formula (1) representing the compounds of the present invention, if R 9 , R 10 , R", R 12 , R 13 and R 14 in the atomic group A-B-C-D are each a Q-Q alkyl group, examples of such Q-Q alkyl group include those having 1-8 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isoamyl, n-hexyl, n-heptyl, n-octyl, etc. If R 9 , R ιυ , R", R 12 , R 13 and R 14 are each a Q-Q fluoroalkyl group, examples of such Q-Q fluoroalkyl group include trifluoromethyl. 2,2,2-trifluoroethyl, pcntafluoroethyl, etc. In the case where R 9 , R lu , R u , R 12 , R 13 and R 14 are each -fC(R 19 )(R 20 )l r X-R ls , - [C(R 19 )(R 2l, )l r CO,R 1( \ -[C(R 19 )(R 2 ")],-R 17 , -[C(R 1 )(R 2 ")1 J -C(=0)R\ -|C(R 19 )(R 2u )],-CONR 21 R 22 or -[C(R 19 )(R 20 )] J -C(=O)NR'C(=O)NR'R", the Q-Q alkyl group, Q-Q alkoxy group. Q-Q alkoxycarbonyl group or aralkyl group which are represented by R 19 and R 2 " are the same as defined above. The alicyclic structure which is formed by R 19 and R 2 " when taken together means a 3-7 membered carbohydrate ring which is either saturated or unsaturated in die presence of 1 or 2 double bonds. Examples of such alicyclic structure include cyclopropane, 2- cyclopropene, cyclobutane, 2-cyclobutene, cyclopentane, 3-cyclopentenc, cyclohexane, 3- cyclohexene, 2,4-cyclohexadiene, cycloheptane, 2,4-cycloheptadiene, etc. These alicyclic structures may optionally be substituted by die above-defined halogen atom, Q-Q alkyl group, hydroxy group, Q-Q alkoxy group, nitro group, carboxyl group, Q-Q alkoxycarbonyl group, - NR'R" or cyano group. It should also be noted that the Q-Q alkyl group as represented by R' and R" is the same as defined above and diat example of -NR'R" are also die same as listed above. In the case where R 9 , R lϋ , R 11 , R 12 , R 13 and R 14 is -[C(R 19 )(R 20 )] X-R 15 , the Q-Q alkyl group represented by R 15 is die same as defined above. It should be noted that the Q-Q alkyl group as represented by R' and R" is die same as defined above and that examples of -NR'R" are also die same as listed above. In the case where R 9 , R lϋ , R", R 12 , R 13 and R 14 are each -[C(R 19 )(R 20 )] r CO 2 R"\ examples of R 16 include not only a hydrogen atom, an alkali metal atom such as lithium, sodium and potassium and die alcohol ester groups of the Q-Q alkyl, cycloalkyl or aralkyl defined above, but also a pivoxil group, an axetil group, a proxetil group, a hexetil group, a pentexil group, a bopentil group, etc. which are used as the ester portion of carboxylic acid ester derivatives in antibiotics and other compounds in order to improve their absorption through mouth. These cycloalkyl and aralkyl groups may optionally be substituted by the above-defined halogen atom, Q-Q alkyl group, hydroxy group, Q-Q alkoxy group, nitro group, carboxyl group, Q-Q alkoxycarbonyl group, -NR'R" or cyano group. It should also be noted that die Q-Q alkyl group as represented by R' and R" is die same as defined above and diat examples of -NR'R" are also the same as listed above. In die case where R 9 , R 10 , R u , R 12 , R 13 , and R 14 are each -[C(R 1 )(R 2ϋ )] f R 17 , tlie Q-Q alkyl group, Q-Q alkoxy group, Q-Q alkoxycarbonyl group and cycloalkyl group which are represented by R 17 are the same as defined above; die cycloalkenyl group means a 3-7 membered carbohydrate ring having 1 or 2 double bonds, as exemplified by cyclopropa-2-enyl, cyclobuta-2-enyl, cyclopenta-3-enyl, cyclohexa-3-enyl, cyclohexa-2,5-dienyl, cyclohepta-2,6- dienyl, etc. Examples of the aryl group include phenyl and naphthyl, and die heteroaryl group means a 5- or 6-membercd aromatic ring diat can contain any 1-3 hetero atoms that are selected from d e group consisting of oxygen, nitrogen and sulfur atoms; examples of such heteroaryl group include pyridyl, pyrimidyl, pyridazinyl, furyl, thenyl, pyrazolyl, oxazolyl, thiazolyl, oxadiazolyl, isoxazolyl, etc. These cycloalkyl, cycloalkenyl, aryl and heteroaryl groups may optionally be substituted by die above-defined halogen atom, Q-Q alkyl group, hydroxy group, Q-Q alkoxy group, nitro group, carboxyl group, Q-Q alkoxycarbonyl group, -NR'R" or cyano group. It should also be noted diat die Q-Q alkyl group as represented by R' and R" is die same as defined above and diat examples of -NR'R" are die also d e same as listed above. In die case where R 9 , R 10 , R", R'\ R 13 , and R 14 are each -[C(R 19 )(R 2ϋ )j r CONR 21 R 22 , the Q-Q alkyl group represented by R 21 and R 22 is the same as defined above and this Q-Q alkyl group may optionally be substituted by die above-defined halogen atom, Q-Q alkyl group, hydroxy group, Q-Q alkoxy group, nitro group, carboxyl group, Q-Q alkoxycarbonyl group, amino group, cyano group or -0-C(=0)-R 18 . It should be noted diat die Q-Q alkyl group and cycloalkyl group which are represented by R ιs and die same as defined above. It should also be noted diat die alicyclic structure which is formed by R 21 and R 22 when taken together is the same as defined above in connection witii -NR'R", with examples of such alicyclic structure including pyrrolidyl, piperidino, piperazino, morpholino, etc. In the case where R 9 , R lϋ , R", R 12 , R 13 and R 14 are each or - [C(R l9 )(R 20 )] J -C(=O)NR'C(=O)NR'R", tlie Q-Q alkyl group represented by R' and R" in these groups is the same as defined above and examples of -NR'R" are also the same as listed above. In die case where R 9 and R lu , or R lu and R J 1 , or R" and R 13 , when taken together, fomi an optionally substituted alicyclic structure, aryl ring or heteroaryl ring, the alicyclic structure means a 3-7 membered carbohydrate ring which is either saturated or unsaturated in the presence of 1 or 2 double bonds, as exemplified by cyclopropane, cyclopropene, cyclobutanc, cyclobutene, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptadiene, as well as norpinane and norbornane which are bridged hydrocarbons. Examples of the aryl ring include a benzene ring, and the heteroaryl ring means a 5- or 6-membered aromatic ring that can contain any 1 to 3 hetero atoms mat are selected from the group consisting of oxygen, nitrogen and sulfur atoms; examples of such heteroaryl ring include pyridine, pyrimidine, pyridazine, furan, thiophene, pyrazole, oxazoline, tliiazolc, oxadiazole and isoxazoline rings, etc. These alicyclic structures, aryl rings and heteroaryl rings may optionally be substituted by die above-defined halogen atom, Q-Q alkyl group, hydroxy group, Q-Q alkoxy group, nitro group, carboxyl group, Q-Q alkoxycarbonyl group, -NR'R" or cyano group. It should also be noted that die Q-Q alkyl group as represented by R' and R" is the same as defined above and that examples of -NR'R" are also the same as listed above. The compounds of tlie present invention can be optionally be converted to esters or sails thereof in the usual manner. Such esters or salts include pharmacologically acceptable nontoxic chemical species; advantageous esters include esters of straight or branched lower alcohols such as methanol and edianol, and advantageous salts include alkali metal or alkaline earth metal sails (e.g. sodium salt and potassium salt), hydrohalogenic acid salts (e.g. hydrofluroridc and hydrochloride), inorganic acid salts (e.g. nitrate and sulfate), lower alkylsulfonic acid salts (e.g. medianesulfonate), organic acid salts (e.g. maleate and fumarate), and amino acid salts (e.g. aspartate). Examples of compounds represented by the general formula (1) are as follows: 1) 3-propyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro- pyrazolo[ 1 ,2-a]pyridazin- 1 -one, 2) 3-butyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl|-5,6,7,8-tetrahydro- pyrazolol l ,2-a]pyridazin-l-onc, 3) 3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-5,6,7,8-tetrahydro- pyrazolof 1 ,2-a]pyridazin- 1 -one, 4) 3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-pyrazolo[ 1.2- a]pyridazin-l-one, 5) 3-butyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-pyrazolo[ l,2- aJpyridazin-1-one, 6) 3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-pyrazolof l ,2- aJpyridazin-1-one, 7) 3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ-pyrazolo[ l,2-aJpyridazin- 1-one, 8) 3-butyl-2-r2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ-pyrazolo[ l,2-aJpyridazin- l - one, 9) 3-ρentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ-pyrazolo[ l ,2-aJpyridazin- 1-onc, 10) 6,7-dimethyl-3-propyl-2-f2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmetiιyl]-5,6J,8- tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 1 1) 3-butyl-6J-dimetlιyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 12) 6,7-dimethyl-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-pyrazolo[ 1 ,2-a]pyridazin- 1 -one, 13) 6J-dimetiιyl-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydπ>- pyrazolo [ 1 ,2-a]pyridazin- 1 -one . 14) 3-butyl-6J-dimethyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5.8-dihydro- pyrazo!o[ l,2-a]pyridazin-l-one, 15) 6,7-dimcthyl-3-pentyl-2-|2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5.8-dihydro- pyrazolo[ 1 ,2-aJpyridazin- 1 -one, 16) 6,7-dimethyl-3-propyl-2-f2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmethyl |- pyrazolυl 1 ,2-aJpyridazin- 1 -one, 17) 3-butyl-6J-dimethyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιylJ-pyrazolo| 1.2- a]pyridazin-l-one, 18) 6,7-dimethyl-3-pentyI-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ-pyrazolo[ l,2- a]pyridazin-l-onc, 19) 3-propyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6,7,8-teU-alιydro-5,8- ethano-pyrazolo[ 1 ,2-aJpyridazin- 1 -one, 20) 3-butyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-5,6,7,8-tetralιydro-5,8- ed ano-pyrazolo[ l,2-a|pyridazin-l-one, 21) 3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-5,6,7,8-tetrahydro-5,8- ethano-pyrazolo[ 1 ,2-a]pyridazin- 1 -one, 22) 3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyπ-5,8-dihydro-5.8-edιano- pyrazolof 1 ,2-a]pyridazin- 1 -one, 23) 3-butyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-5,8-ethano- pyrazolo[ 1 ,2-a]pyridazin- 1 -one, 24) 3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-5,8-ethano- pyrazolof 1 ,2-a]pyridazin- 1 -one, 25) 5,8-dimethyl-3-propyl-2-[2'-(lH-terxazol-5-yl)-biphenyl-4-ylmethyl)-5,6,7,8- tetrahydro-5,8-ethano-pyrazolo[ l,2-a]pyridazin-l-one, 26) 3-butyl-5,8-dimethyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-5,8-ethano-pyrazolo[ 1 ,2-a]ρyridazin- 1 -one, 27) 5,8-dimethyl-3-ρentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-5,8-ethano-pyrazolo[ 1 ,2-a]pyridazin- 1 -one, 28) 5,8-dimetiιyl-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmeti yI]-5,8-dihydro- 5.8-ethano-pyrazolo[ 1,2-aJpyridazin-l-one, 29) 3-butyl-5,8-dimethyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro- 5,8-ethano-pyrazolo[ l,2-a]pyridazin-l-one, 30) 5,8-dimethyl-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro- 5,8-ed ano-pyrazolo[ 1 ,2-a]pyridazin- 1 -one, 31) 5,8-diethyl-3-propyl-2-[2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-5,8-ethano-pyrazolo[ l,2-a]pyridazin-l-one, 32) 3-butyl-5,8-diethyl-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetralιydro-5,8-edιano-pyrazolυ[ l,2-aJpyridazin-l-one, 33) 5,8-dietiιyl-3-pentyl-2-f2'-( lH-tetra7.ol-5-yl)-biphenyl-4-ylmethyll-5.6J,8- tetralιydro-5,8-etiιano-pyrazolo[ 1 ,2-aJpyridazin- 1 -one, 34) 5,8-diethyl-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,8-dihydro- 5,8-edιano-pyrazolo[ l,2-aJpyridazin-l-onc, 35) 3-butyl-5,8-diethyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,8-dihydro-5,8- ed ano-pyrazolof 1 ,2-a]pyridazin- 1 -one, 36) 5,8-diethyl-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyl]-5,8-dihydro- 5,8-etiιano-pyrazolo[ l,2-a]pyridazin-l-one, 37) 3-oxo-l-propyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetrahydro- 3H-pyrazolof 1 ,2-aJpyridazin-5-carboxylic acid, 38) l-butyl-3-oxo-2-[2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetrahydro- 3H-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid, 39) 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetralιydro- 3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid, 40) l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5.6J,8-tetrahydro- 1 H-pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid, 41) 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetrahydro- lH-pyrazolori,2-a]pyridazin-5-carboxylic acid, 42) l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmeti yl]-5,6,7,8-tetrahydro- lH-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid, 43) 3-oxo-l-propyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-3H- pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid, 44) l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-3H- pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid, 45) 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5.8-dihydro-3H- pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid, 46) l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-lH- pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid, 47) 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-lH- pyrazolol 1 ,2-a]pyridazin-5-carboxylic acid, 48) l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-lH- pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid, 49) 3-oxo- 1 -propyl-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-pyrazolo[ 1 ,2- a]pyridazin-5-carboxylic acid, 50) l-butyl-3-oxo-2-[2'-(lH-teu-azol-5-yl)-biphenyl-4-ylmetiiyl]-3H-pyrazolo| 1.2- a]pyridazin-5-carboxylic acid, 51 ) 3-oxo- 1 -pentyl-2-f 2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyll-3H-pyra7olo| 1 ,2- aJpyridazin-5-carboxylic acid, 52) l-oxo-3-propyl-2-[2'-( lH-tetra7.ol-5-yl)-biphenyl-4-ylmethyll-lH-pyrazolo| 1.2- aJpyridazin-5-carboxylic acid, 53) 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-lH-pyrazolo[ l ,2- a]pyridazin-5-carboxylic acid, 54) l-oxo-3-pentyI-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-lH-pyrazolo| l ,2- a]pyridazin-5-carboxylic acid, 55) 8-medιyl-3-oxo-l-propyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo| l,2-a]pyridazin-5-carboxylic acid. 56) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid, 57) 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetralιydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid, 58) 8-methyl-l-oxo-3-propyI-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6,7,8- tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid, 59) 3-butyl-8-methyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid, 60) 8-medιyl-l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid, 61) 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid, 62) l-butyl-8-metiιyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid, 63) 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid, 64) 8-methyl-l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid, 65) 3-butyl-8-methyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5.8- dihydro-1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid, 66) 8-methyl-l-oxo-3-pentyl-2-[2'-(lH-teu-azol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-lH-pyrazolo[l,2-a]pyridazin-5-carboxylic acid, 67) 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyll-3H- pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid, 68) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyn-3H- pyrazolof l,2-a]pyridazin-5-carboxylic acid, 69) 8-methyl-3-oxo- l-penlyl-2-|2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmethyll-3H- pyrazolo[ l,2-a]pyridazin-5-carboxylic acid, 70) 8-methyl- 1 -oxo-3-propyl-2-[ 2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl 1- 1 H- pyrazolo[ l,2-aJpyridazin-5-carboxylic acid, 71 ) 3-butyl-8-methyl- 1 -oxo-2-f2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyll- 1 H- pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid, 72) 8-metiιyl-l-oxo-3-ρentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-l H- pyrazolof 1 ,2-aJpyridazin-5-carboxylic acid, 73)3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6J,8-tetrahydro-5,8- ethano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid, 74) l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-3,6,7.8-tetrahydro- 5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid, 75) 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-3,6,7.8-tetralιydro- 5,8-ethano-pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid, 76) l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-l,6J,8-tetrahydro- 5,8-ethano-pyrazolof l,2-a]pyridazin-5-carboxylic acid, 77) 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyI]-l,6J,8-tetrahydro- 5,8-ethano-pyrazolo[ l,2-a]ρyridazin-5-carboxylic acid, 78) l-oxo-3-pentyI-2-[2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmethyl]-l,6,7,8-tetrahydro- 5,8-ethano-pyrazoIof 1 ,2-a]pyridazin-5-carboxylic acid, 79) 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6,7,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-carboxylic acid mediyl ester, 80) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetral ydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid methyl ester, 81 ) 8-metlιyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-carboxylic acid methyl ester, 82) 8-methyl-l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6,7,8- tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid mediyl ester, 83) 3-butyl-8-methyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyI]-5,6J,8- tetrahydro-lH-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid methyl ester, 84) 8-metiιyl-l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-lH-pyrazolo[l,2-a]pyridazin-5-carboxylic acid methyl ester, 85) 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid mediyl ester, 86) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid methyl ester, 87) 8-methyl-3-oxo-l-pentyI-2-f2'-(lH-tetray.ol-5-yI)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolof l,2-aJpyridazin-5-carboxylic acid methyl ester, 88) 8-methyl-l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5.8- dilιydro-lH-pyrazolo| l,2-aJpyridazin-5-carboxylic acid methyl ester, 89) 3-butyl-8-methyl- l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-lH-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid mediyl ester, 90) 8-methyl-l-oxo-3-pentyl-2-[2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro- 1 H-pyrazolof 1 ,2-aJpyridazin-5-carboxylic acid mediyl ester, 91 ) 8-methyl-3-oxo- 1 -propyl-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl 1-5,6.7.8- tetralιydro-3H-pyrazolo| l ,2-aJpyridazin-5-carboxylic acid ethyl ester, 92) l-butyl-8-metl yl-3-oxo-2-|2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6J,8- tetrahydro-3H-pyrazolo| l,2-aJpyridazin-5-carboxylic acid ethyl ester, 93) 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid ethyl ester, 94) 8-methyl- 1 -oxo-3-propyl-2-[2 '-( 1 H-tetrazol-5-yl)-biphenyI-4-ylmethyl ]-5,6,7,8- tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid ethyl ester, 95) 3-butyl-8-methyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid ethyl ester, 96) 8-methyl-l-oxo-3-pentyl-2-l2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid ethyl ester, 97) 8-metiιyl-3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyll-5,8- dihydro-3H-pyrazolo[l,2-a]pyridazin-5-carboxylic acid ethyl ester, 98) l-butyl-8-metiιyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,8- dihydro-3H-pyrazolof l,2-aJpyridazin-5-carboxylic acid etiiyl ester, 99) 8-methyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid ethyl ester, 100) 8-methyl-l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,8- dihydro- 1 H-pyrazolof l,2-aJpyridazin-5-carboxylic acid ethyl ester, 101) 3-butyl-8-methyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,8- dihydro-lH-pyrazolof l ,2-a]pyridazin-5-carboxylic acid etiiyl ester, 102) 8-methyl-l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-5,8- dihydro- 1 H-pyrazolof 1, 2- a]pyridazin-5-carboxylic acid ethyl ester, 103) 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6J,8-tetrahydro- 5,8-ethano-pyrazolof l,2-a]pyridazin-5-carboxylic acid methyl ester, 104) l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-3.6J,8-tetrahydro- 5,8-edιano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid mediyl ester, 105) 3-oxo- 1 -pentyl-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyll-3.6J,8-tctrahydro- 5,8-etiιano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid methyl ester, 106) 3-oxo- l-propyl-2-|2'-( l H-tetrazol-5-yl)-biphenyl-4-ylmethyll-3,6J,8-tetralιydro- 5,8-etiιano-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid ethyl ester, 107) l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-3,6,7,8-tetralιydro- 5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid ethyl ester, 108) 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ-3,6,7,8-tetralιydro- 5,8-eti ano-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid ethyl ester, 109) 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-3H,8H-5,8-eihano- pyrazolof ] l ,2-aJpyridazin-5-carboxylic acid, 1 10) l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyI]-3H,8H-5,8-edιano- pyrazolof l,2-aJpyridazin-5-carboxylic acid, 111) 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyI-4-ylmethyl]-3H,8H-5,8-ethano- pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid, 112) l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-lH,8H-5,8-ethano- pyrazolo[ 1.2-a]pyridazin-5-carboxylic acid, 1 13) 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyI]-lH.8H-5,8-ethano- pyrazolof l,2-a]pyridazin-5-carboxylic acid, 1 14) l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-lH.8H-5.8-etiιano- pyrazolof 1 ,2-aJpyridazin-5-carboxylic acid, 1 15) 3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-3H,8H-5,8-edιano- pyrazolo[ l,2-a]pyridazin-5-carboxylic acid methyl ester, 1 16) l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H,8H-5,8-ethano- pyrazolo[ l,2-a]pyridazin-5-carboxylic acid mediyl ester, 1 17) 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H,8H-5,8-etiιano- pyrazolo[ l,2-a]pyridazin-5-carboxyIic acid methyl ester, 118) l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyI]-lH.8H-5,8-etiιano- pyrazolo[ l,2-a]pyridazin-5-carboxylic acid methyl ester, 119) 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-lH,8H-5,8-edιano- pyrazolo[ l,2-a]pyridazin-5-carboxylic acid mediyl ester, 120) l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-lH,8H-5,8-ethano- pyrazolo[ l,2-aJpyridazin-5-carboxylic acid methyl ester, 121) 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid 2-ethoxycarbonylphenyl ester, 122) l-butyl-8-methyl-3-oxo-2-I2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6J,8- tetralιydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 2-ethoxycarbonylphenyl ester, 123) 8-methyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6,7,8- tetralιydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid 2-edιoxycarbonylphenyl ester, 124) 8-methyl-3-oxo-i-propyI-2-[2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmethyIl-5,8- dihydro-3H-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid 2-ethoxycarbonylphenyl ester, 125) l-butyl-8-metiιyl-3-oxo-2-|2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmedιyll-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 2-ethoxycarbonylphenyl ester, 126) 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyll-5,8- dihydro-3H-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid 2-etiιoxycarbonylphenyl ester, 127) 8-methyl-3-oxo-l-propyl-2-|2'-(lH-tetrazol-5-y])-biphenyl-4-ylmethyll-5,6,7,8- tetrahydro-3H-pyrazolo| l,2-aJpyridazin-5-carboxylic acid 3-edιoxycarbonylphenyl ester, 128) l-butyl-8-methyl-3-oxo-2-|2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-5,6,7,8- tetralιydro-3H-pyrazolof l,2-aJpyridazin-5-carboxylic acid 3-ethoxycarbonylphenyl ester, 129) 8-methyl-3-oxo-l-pentyl-2-I2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 3-ethoxycarbonylphenyl ester, 130) 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyI]-5,8- dihydro-3H-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid 3-ethoxycarbonylphenyl ester, 131) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 3-edιoxycarbonylphenyl ester, 132) 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,8- dihydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid 3-edιoxycarbonylphenyl ester, 133) 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyπ-5,6,7.8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid 4-etiιoxycarbonylphenyl ester, 134) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyl]-5,6J,8- tetrahydro-3H-pyrazolof l,2-aJpyridazin-5-carboxylic acid 4-ethoxycarbonylphenyl ester, 135) 8-methyI-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid 4-etiιoxycarbonylphenyl ester, 136) 8-methyl-3-oxo-l-propyI-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid 4-etiιoxycarbonylphenyl ester, 137) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyI-4-ylmethyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 4-ethoxycarbonylphenyl ester, 138) 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-letrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 4-edιoxycarbonylphenyl ester, 139) 3-oxo-l-propyI-2-[2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmethyl]-3,6J,8-tetrahydro- 5,8-etiιano-pyrazolo[l,2-a]pyridazin-5-carboxylic acid 2-etiιoxycarbonylphenyl ester, 140) l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biplιenyl-4-ylmethy]l-3,6J,8-tetrahydro- 5,8-etlιano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 2-ethoxycarbonylphenyl ester, 141 ) 3-oxo- 1 -pentyl-2-[2'-( 1 H-tetrazoI-5-yl)-biphenyl-4-ylmethyl]-3.6J,8-tetralιydro- 5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 2-ethoxycarbonylphenyl ester, 142) 3-oxo-l-propyI-2-f2'-( l H-tetrahydro-5-yl)-biphenyl-4-ylmethyll-3,6J.8- tetrahydro-5,8-etiιano-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid 3-etiιoxycarbonylphenyl ester. 143) l-butyl-3-oxo-2-f2'-(lH-tetrahydro-5-yl)-biphenyl-4-ylmethyll-3,6J,8-tetrahydro- 5,8-edιano-pyrazolof 1 ,2-aJpyridazin-5-carboxylic acid 3-etlιoxycarbonylphenyl ester, 144) 3-oxo-l-pentyl-2-[2'-(lH-tetrahydro-5-yl)-biphenyl-4-ylmethyl]-3,6J,8- tetrahydro-5,8-ethano-pyrazolo| l,2-aJpyridazin-5-carboxylic acid 3-etiιoxycarbonylphenyl ester, 145) 1 -oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphcnyl-4-ylmedιyl ]- l ,6,7, 8-tctralιydro- 5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 2-ethoxycarbonylphenyl ester, 146) 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-l,6,7,8-tetrahydro- 5,8-edιano-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid 2-ethoxycarbonylphenyl ester, 147) l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-l,6,7,8-tetrahydro- 5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 2-etiιoxycarbonylphenyl ester, 148) l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1.6J,8-tetrahydro- 5,8-ethano-pyrazolori,2-aJpyridazin-5-carboxylic acid 3-ethoxycarbonylphenyl ester, 149) 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-l,6,7,8-tetrahydro- 5,8-edιano-pyrazolo[l,2-aJpyridazin-5-carboxylic acid 3-ethoxycarbonylphenyl ester, 150) l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-l,6J,8-tetrahydro- 5,8-edιano-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid 3-edιoxycarbonylphenyl ester, 151 ) l-ox()-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-l ,6J,8-tetrahydro- 5,8-ethano-pyrazolo[l,2-a]pyridazin-5-carboxylic acid 4-etiιoxycarbonylphenyI ester, 152) 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-l,6,7,8-tetrahydro- 5,8-etiιano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 4-ethoxycarbonylphenyl ester, 153) l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-l,6,7,8-tetralιydro- 5,8-ethano-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid 4-ethoxycarbonylphenyI ester, 154) 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmethyl]-5,6,7.8- tetrahydro-3H-pyrazoloI l,2-aJpyridazin-5-carboxylic acid dimetiiylamide, 155) l-butyl-8-metiιyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetl yll-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid dimethylamide, 156) 8-methyl-3-oxo-l-pentyI-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetralιydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid dimethylamide, 157) 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,8- dihydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid dimethylamide, 158) l-butyl-8-methyl-3-oxo-2-|2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,8- dihydro-3H-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid dimediylamide, 159) 8-methyl-3-oxo- 1 -pentyl-2-[2 '-( 1 H-tctrazol-5-yl)-biphenyl-4-ylmethyl ]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid dimediylamide, 160) 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl 1-5,6,7,8- ιctrahydro-3H-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid diethylamide, 161 ) l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyIl-5,6,7,8- tetralιydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid dieUiylamidc, 162) 8-methyl-3-oxo-l-pentyI-2-[2'-(lH-tetrazoI-5-yI)-biphenyl-4-ylmethyl 1-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid diethylamide, 163) 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmethyl |-5,8- dihydro-3H-pyrazolof l,2-aJpyridazin-5-carboxylic acid dietliylamide, 164) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl|-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid diethylamide, 165) 8-methyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid diethylamide, 166) 8-methyl-3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid t-butylamide, 167) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyI-4-ylmethyl]-5,6J,8- tetralιydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid t-butylamidc, 168) 8-methyl-3-oxo- l-pentyl-2-f2'-(lH-tetrazoI-5-yI)-biphenyl-4-ylmedιyl 1-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid t-butylamide, 169) 3-oxo-l-propyl-2-[2'-(lH-tetraz.ol-5-yl)-bipheιιyl-4-ylmethyI]-3,6J.8-tetralιydro- 5.8-ed ano-pyrazolo[ l ,2-a]pyridazin-5-carboxylic acid diethylamide, 170) l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6,7,8-tetrahydro- 5,8-etiιano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid diethylamide, 171) 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-3,6J.8-tetralιydro- 5,8-ethano-pyrazolof l ,2-aJpyridazin-5-carboxylic acid dietliylamide, 172) 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6,7.8-tetralιydro- 5,8-etiιano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid t-butylamide, 173) l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-3,6,7,8-tetrahydro- 5,8-ethano-pyrazolo[l,2-a]pyridazin-5-carboxylic acid t-butylamide, 174) 3-oxo-l-pentyl-2-t2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6J,8-tetrahydro- 5.8-ethaιιo-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid t-butylamide, 175) 2-({ 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,7,8-tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-carbonyl }-amino)-benzoic acid ediyl ester, 176) 2-({ l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carbonyl }-amino)-benzoic acid ediyl ester, 177) 2-( { 8-methyI-3-oxo- 1 -pentyI-2-[2 '-( 1 H-tetrazol-5-yI)-biphenyl-4-ylmethyl 1- 5,6J,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carbonyl }-amino)-benzoic acid ediyl ester, 178) 2-({ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmethyll-3,6,7,8- tetralιydro-5,8-ethano-pyrazolo[ l,2-aJpyridazin-5-carbonyl }-amino)-benzoic acid ediyl ester, 179) 2-({ l-butyl-3-oxo-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6J,8- tetrahydro-5,8-ethano-pyrazolo[ l,2-aJpyridazin-5-carbonyl }-amino)-benzoic acid ethyl ester, 180) 2-({ 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6,7,8- tetrahydro-5,8-ethano-pyrazolo| l,2-ajpyridazin-5-carbonyl }-amino)-benzoic acid ediyl ester, 181 ) { 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmethyll-5,6,7,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl ) -acetic acid, 182) { l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6J,8- tetrahydro-3H-pyrazolof l,2-aJpyridazin-5-yl } -acetic acid, 183) { 8-methyl-3-oxo-l-pentyI-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl } -acetic acid, 184) 3- { 8-meti yl-3-oxo- 1 -propyl-2- f 2 '-( 1 H-tetrazol-5-yl)-bipheny 1-4-ylmethy 1 ] - 5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl}-propionic acid, 185) 3-{ l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetralιydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl }-propionic acid, 186) 3-{ 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmethyl]- 5,6J,8-tetrahydro-3H-pyrazolori,2-a]pyridazin-5-yl }-propionic acid, 187) 4-{ 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmeUιyl]- 5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-aJpyridazin-5-yl) -butyric acid, 188) 4-{ l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl } -butyric acid, 189) 4- { 8-methyl-3-oxo- 1 -pentyl-2-[2'-( lH-tetrazol-5-yI)-biphenyl-4-ylmetiιyl]- 5,6,7, 8-tetralιydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl} -butyric acid, 190) { 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl } -acetic acid ethyl ester, 191) { l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetralιydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl ) -acetic acid ethyl ester, 192) { 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl } -acetic acid ethyl ester, 193) 3-{ 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,7,8-tetrahydro-3H-pyrazolo[l,2-a]pyridazm-5-yl}-propionic acid ethyl ester, 194) 3-( l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl )-propionic acid etiiyl ester, 195) 3-{ 8-methyl-3-oxo-l-pentyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl ]- 5,6J,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl }-propionic acid ethyl ester, 196) { 3-oxo-l-propyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6.7.8-tetrahydro- 3H-pyrazolol l,2-a]pyridazin-5-yl } -acetic acid etiiyl ester, 197) { l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro- 3H-pyrazolo[ l,2-a]pyridazin-5-yl) -acetic acid etiiyl ester, 198) { 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro- 3H-pyrazolo[ l,2-aJpyridazin-5-yl } -acetic acid ediyl ester, 199) 3-( 3-oxo- l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-aJpyridazin-5-yl }-propionic acid etiiyl ester, 200) 3-( l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl}-propionic acid etiiyl ester, 201) 3-{ 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl }-propionic acid ediyl ester, 202) 8-hydroxymethyl-5-methyl-3-propyl-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4- ylmethyI]-5,6,7,8-tetrahydro-pyrazolo[ 1 ,2-a]pyridazin- 1 -one, 203) 3-butyl-8-hydroxymethyl-5-methyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ- 5,6,7,8-tetrahydro-pyrazolo[ l,2-a]pyridazin-l-one, 204) 8-hydroxymethyl-5-methyl-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-pyrazolo[ 1 ,2-a]pyridazin-l-one, 205) ( 8-metlιyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-ylmethoxy} -acetic acid ethyl ester, 206) ( l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-bipheny]-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-ylmethoxy) -acetic acid etiiyl ester, 207) { 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6,7,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-ylmethoxy} -acetic acid ethyl ester, 208) 2-{8-methyl-3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ- 5,6J,8-tetralιydro-3H-pyrazolo[ l,2-aJpyridazin-5-ylmethoxy}-benzoic acid ethyl ester, 209) 2-{ l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetral ydro-3H-pyrazolo[ l,2-a]pyridazin-5-ylmed oxy}-benzoic acid ethyl ester, 210) 2-{ 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ- 5,6J,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridaz_n-5-ylmethoxy}-benzoic acid ethyl ester, 211) 3-{8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,7,8-tetrahydro-3H-pyrazolori,2-a]pyridazin-5-ylmethoxy}-benzoic acid ethyl ester. 212) 3-{ l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyll-5.6,7.8- tetralιydro-3H-pyrazolof l,2-aJpyridazin-5-ylmethoxy}-benzoic acid ethyl ester, 213) 3-{ 8-methyl-3-oxo- 1 -pentyl-2-12'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl ]- 5,6,7,8-tetrahydro-3H-pyrazolof l,2-aJpyridazin-5-ylmethoxy}-benzoic acid ethyl ester, 214) 2-( 8-medιyl-3-oxo-l-propyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmctlιyl ]- 5,6J,8-tetrahydro-3H-pyrazolo[ l,2-aJpyridazin-5-ylmetiιoxy-methyl}-benzoic acid etiiyl ester, 215) 2-{ l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyπ-5,6J,8- tetralιydro-3H-pyrazolo[ l,2-aJpyridazin-5-ylmethoxy-methyI }-benzoic acid ethyl ester, 216) 2-{ 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]- 5,6J.8-tetrahydro-3H-pyrazolof l,2-aJpyridazin-5-ylmedιoxy-metiιyl )-benzoic acid ethyl ester, 217) 3-( 8-methyl-3-oxo-l-propyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ- 5,6J,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-ylmethoxy-methyl }-benzoic acid ethyl ester, 218) 3-{ l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl|-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-ylmethoxy-methyl }-benzoic acid ethyl ester, 219) 3- { -methyl-3-oxo- 1 -pentyl-2-[2 '-( 1 H-tetrazoI-5-yl)-biphenyl-4-ylmethyl 1- 5,6J,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-y_methoxy-methyl }-benzoic acid ethyl ester, 220) 8-hydroxymethyl-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmethyI]-5,6J,8- tetralιydro-5 ,8-ethano-pyrazolo[ 1 ,2-a]pyridazin- 1 -one, 221) 3-butyl-8-hydroxymethyl-2-[2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmethyll-5,6J,8- tetrahydro-5,8-ethano-pyrazolo[ 1 ,2-a]pyridazin- 1 -one, 222) 8-hydroxymethyl-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-5 ,8-ethano-pyrazolo [ 1 ,2-a]pyridazin- 1 -one, 223) 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-3,6.7,8-tetrahydro- 5,8-ethano-pyrazolof l,2-a]pyridazin-5-ylmethoxy}-acetic acid ethyl ester, 224) l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6,7,8-tetrahydro- 5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-ylmethoxy}-acetic acid ediyl ester, 225) 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6J,8-tetrahydro- 5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-ylmethoxy}-acetic acid etiiyl ester, 226) 2-{ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6J,8- tetrahydro-5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-ylmethoxy-methyl }-benzoic acid ethyl ester, 227) 2-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmethyl]-3,6,7,8- tetrahydro-5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-ylmethoxy-medιyl )-benzoic acid ethyl ester. 228) 2-{ 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6,7,8- tetrahydro-5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-ylmetJιoxy-methyl }-benzoic acid ethyl ester, 229) 2-{ 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,7,8-tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl}-benzoic acid ethyl ester, 230) 2-{ l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl|-5.6,7.8- tctrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl }-benzoic acid ethyl ester, 231) 2- { 8-methyl-3-oxo- 1 -pentyI-2-f 2 '-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyl ]- 5.6J,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl }-benzoic acid ethyl ester, 232) 3-{ 8-methyl-3-oxo- l-propyl-2-[2'-( l H-tetrazol-5-yl)-biphenyl-4-ylmethyl |- 5,6J,8-tetralιydro-3H-pyrazolo[ l,2-aJpyridazin-5-yl }-benzυic acid etiiyl ester, 233) 3-( l-butyl-8-metlιyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5.6J,8- tctrahydro-3H-pyrazolo[ l,2-aJpyridazin-5-yl }-benzoic acid ethyl ester, 234) 3-{ 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ- 5.6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl }-benzoic acid ethyl ester, 235) 2-{ 8-meuιyl-3-oxo-l-propyI-2-[2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmethyl |- 5,6J,8-tetraliydro-3H-pyrazolof l,2-aJpyridazin-5-ylmethyl }-benzoic acid ediyl ester, 236) 2-{ l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl 1-5,6.7,8- tetrahydro-3H-pyrazolo| l,2-aJpyridazin-5-ylmetiιyl }-benzoic acid ethyl ester, 237) 2-{ 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl |- 5,6J,8-tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-ylmethyl }-benzoic acid etiiyl ester, 238) 3- { 8-methyl-3-oxo- 1 -propyl-2-[2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl ]- 5.6J,8-tetrahydro-3H-pyrazolof l ,2-a]pyridazin-5-ylmethyl }-benzoic acid ediyl ester, 239) 3-( l-butyl-8-metlιyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-bipheny]-4-ylmedιyll-5,6J,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-ylmethyl}-benzoic acid etiiyl ester, 240) 3-( 8-methyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyl]- 5.6J,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-ylmedιyl }-benzoic acid ethyl ester, 241) { 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl } -acetonitrile, 242) { l-butyl-8-medιyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl } -acetonitrile, 243) { 8-medιyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmeti yl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl } -acetonitrile, 244) l-methoxy-8-methyl-3-oxo-2-[2'-(lH-teu * azol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid methyl ester, 245) l-ethoxy-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid methyl ester, 246) 8-methyl-3-oxo-l-propoxy-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-5,8- dihydro-3H-pyrazolo[l,2-a]pyridazin-5-carboxylic acid mediyl ester, 247) 8-methyl-l-methylsulfanyI-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,8-dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid methyl ester, 248) l-ethylsulfanyl-8-metiιyl-3-oxo-2-[2'-( l H-tetrazol-5-yl)-biphenyl-4-ylmetlιyll-5,8- dihydro-3H-pyrazolof l,2-aJpyridazin-5-carboxylic acid mediyl ester, 249) 8-methyl-3-oxo-l-propylsulfanyl-2-[2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,8-dihydro-3H-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid methyl ester, 250) { 3-oxo- 1 -propyl-2-f 2'-( 1 H-tetrazol-5-yl)-biphenyl-4-yimethyl ]-3.6J.8-tetrahydro- 5.8-etiιano-pyrazolof l,2-a]pyridazin-5-ylmetiιoxy }-acetic acid mediyl ester, 251 ) { 1 -butyl-3-oxo-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyll-3,6,7,8-tetrahydro- 5,8-ethano-pyrazolof l ,2-aJpyridazin-5-ylmedιoxy } -acetic acid methyl ester, 252) { 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyπ-3,6J,8-tetralιydro- 5, -etlιano-pyrazolo[ l,2-a]pyridazin-5-ylmedιoxy } -acetic acid mediyl ester, 253) { 8-metlιyl-l-oxo-3-propyl-2-[2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmethyl 1-5,6,7,8- tetrahydro-lH-pyrazolo[ l,2-aJpyridazin-5-yl } -acetonitrile, 254) ( 3-butyl-8-methyl- l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6,7,8- tetrahydro- 1 H-pyrazolo[ 1 ,2-a]pyridazin-5-yl } -acetonitrile, 255) { 8-methyl-l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6,7,8- tetrahydro- 1 H-pyrazolo[ 1 ,2-a]pyridazin-5-yl } -acetonitrile, 256) 3- { 8-methyl- 1 -oxo-3-propyl-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl ]- 5,6,7, 8-tetrahydro-l H-pyrazolof l,2-a]pyridazin-5-yl}-propionic acid ethyl ester, 257) 3-{ 3-butyl-8-methyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl* -ylmethyl]-5,6J,8- tetrahydro-lH-pyrazolo[ l,2-aJpyridazin-5-yl }-propionic acid ethyl ester, 258) 3-{ 8-methyl-l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyI-4-ylmethyl]- 5, 6,7,8-tetrahydro-l H-pyrazolof l,2-a]pyridazin-5-yl}-propionic acid ethyl ester, 259) 3-butyl-5,8-dimethyl-2-{ [2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-amino }- 5,6,7,8-tetrahydro-pyrazolo[ l,2-a]pyridazin-l-one, 260) l-butyl-8-methyl-3-oxo-2-{ f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}- 5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid ethyl ester, 261) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethoxy]-5,6,7,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-carboxylic acid etiiyl ester, 262) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylsulfanyl]- 5,6J,8-tetralιydro-3H-pyrazolo[l,2-aJpyridazin-5-carboxylic acid ethyl ester, 263) l-butyl-8-methyl-3-oxo-2-r2'-(lH-tetrazol-5-yl)-biphenyl-4-yl]-ethylidene- hexahydro-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid etiiyl ester, 264) 2-{ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-3H- pyrazolo[ l,2-a]pyridazin-5-yl}-benzoic acid methyl ester, 265) 2-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-3H- pyrazolo[l,2-a]pyridazin-5-yl}-benzoic acid mediyl ester, 266) 2-{ 3-oxo- l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5.8-dihydro-3H- pyrazolo[ l,2-aJpyridazin-5-yl }-benzoic acid methyl ester, 267) 3-{ 3-oxo- l-propyl-2-f2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmethyl]-5.8-dihydro-3H- pyrazolo[ l,2-a]pyridazin-5-yl }-benzoic acid mediyl ester, 268) 3-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphcnyl-4-ylmethyll-5,8-dihydro-3H- pyrazolo| I ,2-aJpyridazin-5-yl )-benzoic acid methyl ester, 269) 3-{3-oxo-l-pentyI-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-3H- pyrazoIo[ l,2-aJpyridazin-5-yl }-benzoic acid mediyl ester, 270) 3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro- 3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid methyl ester, 271) l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro- 3H-pyrazolor i ,2-aJpyridazin-5-carboxylic acid methyl ester, 272) 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-bipheny]-4-ylmetiιyll-5,6J,8-tetrahydro- 3H-pyrazolo[ l,2-ajpyridazin-5-carboxylic acid methyl ester, 273) 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid l-(2,2-dimethyl-propionyloxy)-etlιyl ester, 274) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ 1 ,2-aJpyridazin-5-carboxylic acid 1 -(2,2-dimetiιyl-propionyloxy)-ethyl ester, 275) 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxyIic acid l-(2,2-dimethyl-propionyloxy)-ethyl ester, 276) Piperidine-1-carboxylic acid { 8-methy]-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-carbonyl} -amide, 277) Piperidine-1-carboxylic acid { l-butyl-8-metliyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolof l,2-aJpyridazin-5-carbonyl }-amide, 278) Piperidine-1-carboxylic acid { 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6J,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-carbonyl } -amide, 279) 2,2-dimethyl-propionic acid 2-{ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl- 4-ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl }-acetoxy methyl ester, 280) 2,2-dimethyl-propionic acid 2-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmetiιyl]-5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl }-acetoxy methyl ester, 281) 2,2-dimethyl-propionic acid 2-{ 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl- 4-ylmetiιyl]-5,6J.8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl )-acetoxy mediyl ester, 282) { 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro- 3H-pyrazolof l,2-a]pyridazin-5-yl } -acetic acid 2-isopropyl-5-methyl-cyclohexyl ester, 283) { l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetralιydro- 3H-pyrazolof l ,2-a]pyridazin-5-yl ) -acetic acid 2-isopropyl-5-methyl-cyclohexyl ester. 284) {3-oxo-l-pentyI-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5.6J,8-tctrahydro- 3H-pyrazolo| l ,2-a]pyridazin-5-yl | -acetic acid 2-isopropyl-5-methyl-cyclohexyl ester, 285) 8-acetyl-5-methyl-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl ]-5.6.7,S- tetrahydro-pyrazolo[ 1 ,2-a]pyridazin- 1 -one, 286) 8-acetyl-3-butyl-5-metiιyI-2-|2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl 1-5.6,7,8- tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 287) 8-acetyl-5-methyl-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-pyrazoIof l,2-a]pyridazin- l-one, 288) 2-{ 8-methyl-3-oxo-l-propyl-2-[2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmedιyl ]- 5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-ylmethyl }-malonic acid dietiiyl ester, 289) 2-{ l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-ylmethyl } -malonic acid dietiiyl ester, 290) 2-{ 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyI]- 5,6,7,8-tetτahydro-3H-pyrazolo[l,2-a]pyridazin-5-ylmethyl }-malonic acid diethyl ester, 291) 2-{ 3-oxo-l-ρropyl-2-[2 , -(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl }-3-phenyl-propionic acid etiiyl ester, 292) 2-( l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetralιydro-3H-pyrazolor i,2-aJpyridazin-5-yl }-3-phenyl-propionic acid ethyl ester, 293) 2-{ 3-oxo-l-ρentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6J,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl }-3-phenyl-propionic acid ethyl ester, 294) 2-methyl-2-{ 3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl}-propionic acid ediyl ester, 295) 2-{ l-butyl-3-oxo-2-t2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l ,2-a]pyridazin-5-yl }-2-me yl-propionic acid ethyl ester, 296) 2-methyI-2-{ 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyll- 5,6J,8-tetrahydro-3H-pyrazoIo[ l,2-a]pyridazin-5-yl}-propionic acid ethyl ester, 297) 2-ethyl-2-{ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J.8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl } -butyric acid etiiyl ester, 298) 2-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l ,2-a]pyridazin-5-yl }-2-ethyl-butyric acid ethyl ester, 299) 2-ethyl-2-{3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl } -butyric acid ediyl ester, 300) l-{ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazoloI I,2-a]pyridazin-5-yl }-cyclohexanecarboxylic acid ediyl ester, 301) l-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetralιydro-3H-pyrazolof l,2-a]pyridazin-5-yI )-cyclohexanecarboxylic acid ethyl ester, 302) l-{ 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5.6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl )-cyclohexanecarboxylic acid ethyl ester, 303) l-{ 3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-5,6J,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl}-cyclopentanecarboxylic acid ethyl ester, 304) 1 - { 1 -butyl-3-oxo-2-f 2'-( 1 H-tetrazoI-5-yl)-biphenyl-4-ylmetiιyl 1-5.6,7,8- tetral ydro-3H-pyrazolof l,2-aJpyridazin-5-yl)-cyclopentanecarboxylic acid etiiyl ester, 305) l-{ 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl* -ylmeti yl]-5,6J,8- tetrahydro-3H-pyrazolof l,2-aJpyridazin-5-yl }-cyclopentanecarboxylic acid ethyl ester, 306) 2-methyl-2-{3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll- 3,6,7,8-tetrahydro-5,8-edιano-pyrazolo[ l,2-aJpyridazin-5-yl }-propionic acid ethyl ester, 307) 2-( l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyI]-3,6J,8- tetralιydro-5,8-ethano-pyrazoloI l,2-aJpyridazin-5-yl }-2-medιyl-propionic acid ethyl ester, 308) 2-methyl-2-{ 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 3,6J,8-tetrahydro-5,8-ethano-pyrazolof l,2-a]pyridazin-5-yl}-propionic acid etiiyl ester, 309) { l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-bipheny]-4-ylmethyl]-5,6J,8-tetrahydro- lH-pyrazolo[ l,2-a]pyridazin-5-yl) -acetic acid etiiyl ester, 310) {3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6,7,8-tetralιydro- lH-pyrazolo[l,2-a]pyridazin-5-yl ) -acetic acid ethyl ester, 311) { l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetrahydro- lH-pyrazolo[ l, 2- a]pyridazin-5-yl } -acetic acid ethyl ester, 312) l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetrahydro- lH-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid mediyl ester, 313) 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J.8-tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid methyl ester, 314) l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetralιydro- lH-pyrazolo[l,2-a]pyridazin-5-carboxylic acid methyl ester, 315) 8-methyl-l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid 1 -(2,2-dimetiιyl-propionyloxy)-edιyl ester, 316) 3-butyl-8-methyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6J,8- tetralιydro-lH-pyrazolo[l,2-a]pyridazin-5-carboxylic acid l-(2,2-dimethyl-propionyloxy)-ethyl ester, 317) ' 8-methyl-l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid 1 -(2,2-dimethyl-propionyloxy )-edιyl ester, 31 ) 2-methyl-2-f l-oxo-3-propyl-2-[2'-( 1 H-tetrazol-5-yl)-biphcnyl-4-ylmethyl |- 5,6,7,8-tetrahydro-l H-pyrazolof l,2-a]pyridazin-5-yl )-propionic acid ethyl ester, 319) 2-{ 3-butyl-l-oxo-2-f2'-(l H-tetra7.ol-5-yl)-biphenyl-4-ylmethyIl-5.6,7,8- tetralιydro-lH-pyrazolo[ l,2-a]pyridazin-5-yl }-2-medιyl-propionic acid ediyl ester, 320) 2-methyl-2-f l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,7,8-tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-yl }-propionic acid ediyl ester, 321) 8-methyl-l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid t-butyl-amide, 322) 3-butyl-8-methyl- l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyll-5,6J,8- tetrahydro- 1 H-pyrazolof l,2-aJpyridazin-5-carboxylic acid t-butyl-amide, 323) 8-methyl-l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyl 1-5,6,7,8- tetrahydro-1 H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid t-butyl-amide, 324) 2-ethyl-2-f l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyI]-5,6J,8- tetrahydro-lH-pyrazolo[l,2-a]pyridazin-5-yl ) -butyric acid etiiyl ester, 325) 2-{ 3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-yl }-2-eUιyl-butyric acid ethyl ester, 326) 2-ethyl-2-( l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl ) -butyric acid etiiyl ester, 327) 2,2-dimethyl-propionic acid 2-{ l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl- 4-ylmethyl]-5,6J,8-tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-yl }-acetoxymethyl ester, 328) 2,2-dimethyl-propionic acid 2-{ 3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphcnyl-4- ylmethyl]-5,6,7,8-tetrahydro- lH-pyrazolo[ l,2-a]pyridazin-5-yl }-acetoxymethyl ester, 329) 2,2-dimethyl-propionic acid 2-{ l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl- 4-ylmethyl]-5,6,7,8-tetrahydro-lH-pyrazolo[ 1 ,2-a]pyridazin-5-yl }-acetoxymedιyl ester, 330) ( l-oxo-3-ρropyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl ) -acetic acid 2-isopropyl-5-methyl-cyclohexyl ester, 331) { 3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetrahydro- 1 H-pyrazolof l,2-aJpyridazin-5-yl } -acetic acid 2-isopropyl-5-methyl-cyclohexyl ester, 332) { l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6J,8-tetralιydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl } -acetic acid 2-isopropyl-5-metiιyl-cyclohexyl ester, 333) 8-methyl-l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6,7,8- tetrahydro-lH-pyrazolof l,2-a]pyridazin-5-carboxylic acid (piperidine-l-carbonyl)-amide, 334) 3-butyl-8-methyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid (piperidine- 1 -carbonyl)-amide, 335) 8-methyl-l-oxo-3-pentyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6,7,8- tetraliydro- 1 H-pyrazolof 1 ,2-aJpyridazin-5-carboxylic acid (piperidine-l-carbonyl)-amide, 336) l-{ l-oxo-3-propyl-2-[2'-( l H-tetra7ol-5-yl)-biphenyl-4-ylmethyll-5,6J,8- tctraliydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl )-cyclohexanecarboxylic acid ethyl ester, 337) l-{ 3-hutyl-l -oxo-2-f2'-( l H-tetrazol-5-yl)-biphenyl-4-ylmethyll-5.6,7,8- tetrahydro-lH-pyrazolo[ l,2-aJpyridazin-5-yl }-cyclohexanecarboxylic acid etiiyl ester, 338) l-{ l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyIl-5,6,7.8- tctrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-yl }-cyclohexanecarboxylic acid etiiyl ester, 339) 2-{ 8-metlιyl-l-oxo-3-propyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmetlιylf- 5,6J,8-tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-ylmetiιyl }-malonic acid dietiiyl ester, 340) 2- { 3-butyl-8-methyl- 1 -oxo-2-| 2'-( 1 H-tetrazol-5-y])-biphenyl-4-ylmethyl |-5,6/7,8- tetrahydro-lH-pyrazolo[ l,2-aJpyridazin-5-ylmetiιyl )-malonic acid dietiiyl ester, 341) 2-{ 8-methyl-l-oxo-3-pentyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmetiiyl]- 5,6J,8-tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-ylmethyl }-malonic acid dietiiyl ester, 342) 5-acetyl-8-metiιyl-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyIl-5,6,7,8- tetrahydro-pyrazolof 1 ,2-aJpyridazin- 1 -one, 343) 5-acetyl-3-butyl-8-methyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6J,8- tetrahydro-pyrazolof 1 ,2-a]ρyridazin- 1 -one, 344) 5-acetyl-8-methyl-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl|-5,6,7,8- tetrahydro-pyrazolof 1,2-aJpyridazin-l-one, 345) 2-{ l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetraliydro- 1 H-pyrazolof l,2-a]pyridazin-5-yI }-3-phenyl-propionic acid ethyl ester, 346) 2-( 3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmethyll-5,6,7,8- tetrahydro-lH-pyrazolof l,2-a]pyridazin-5-yl }-3-phenyl-propionic acid ethyl ester, 347) 2-{ l-oxo-3-pentyI-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-1 H-pyrazolof l,2-aJpyridazin-5-yl}-3-phenyl-propionic acid etiiyl ester, 348) l-{ l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-yl }-cyclopentanecarboxylic acid ethyl ester, 349) l-{ 3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-lH-pyrazolo[ l,2-aJpyridazin-5-yl }-cycIopentanecarboxylic acid ethyl ester, 350) l-{ l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-lH-pyrazolof l,2-aJpyridazin-5-yl }-cyclopentanecarboxylic acid etiiyl ester, 351) 2-methyl-2-{ l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- l ,6,7,8-tetrahydro-5,8-etiιano-pyrazolo[ l,2-a]pyridazin-5-yl }-propionic acid ethyl ester, 352) 2- f 3-butyl- 1 -oxo-2-[2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 1 ,6,7,8- tetrahydro-5,8-ethano-pyrazolof l,2-a]pyridazin-5-yl }-2-meti yl-propionic acid ethyl ester, 353) 2-methyl-2-{ l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyI l- l,6J,8-tetrahydro-5,8-etiιano-pyrazolo[ l,2-a|pyridazin-5-yl }-propioιιic acid ethyl ester, 354) 8-methyl- 1 -oxo-3-propyl-2-f 2 '-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl 1-5,6.7.8- tetraliydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid dietiiylamide, 355) 3-butyl-8-methyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5.6J,8- tctraliydro- 1 H-pyrazolof l,2-aJpyridazin-5-carboxylic acid dietliylamide, 356) 8-methyl-l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl 1-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid dietiiylamide, 357) l-{ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl ]-5, 6,7,8- tctralιydro-3H-pyrazolof l,2-a]pyridazin-5-yl}-cyclopropanecarboxylic acid ediyl ester, 358) l-f l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmeUιyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl) -cyclopropanecarboxyhc acid etiiyl ester, 359) 1 - { -oxo- 1 -pentyl-2-f 2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl} -cyclopropanecarboxyhc acid ethyl ester, 360) l-{ l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclopropanecarboxyhc acid etiiyl ester, 361) l-{3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-bipheny]-4-ylmethyl]-5,6,7,8- tetraliydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl) -cyclopropanecarboxyhc acid ethyl ester, 362) l-{ l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclopropanecarboxyhc acid ethyl ester, 363) l-{3-oxo-l-propyl-2-[2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl}-cycloheptanecarboxylic acid ethyl ester, 364) l-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyI-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-aJpyridazin-5-yl}-cycloheptanecarboxylic acid ethyl ester, 365) l-{3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl}-cycloheptanecarboxylic acid etiiyl ester, 366) l-{ l-oxo-3-proρyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-1 H-pyrazolof l,2-a]pyridazin-5-yl }-cycloheptanecarboxylic acid ethyl ester, 367) l-( 3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-lH-pyrazolof l,2-a]pyridazin-5-yl}-cycloheptanecarboxylic acid etiiyl ester, 368) l-{ l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-5,6J,8- tetrahydro-lH-pyrazolo[l,2-a]pyridazin-5-yl}-cycloheptanecarboxylic acid ethyl ester, 369) 4,4-dimethyl- 1 - { 3-oxo- 1 -propyl-2-[2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl ]- 5,6,7, 8-tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl}-cyclohexanecarboxylic acid etiiyl ester, 370) 1-f l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetralιydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl } -4,4-dimetiιyl-cyclohexanecarboxylic acid ethyl estcr, 371) 4,4-dimetiιyl-l-{ 3-oxo-l-pentyl-2-(2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl |- 5.6.7,8-tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl j-cyclohexanecarboxylic acid ethyl ester, 372) 4,4-dimethyl-l-{ l-oxo-3-propyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl |- 5.6J.8-tetrahydro-lH-pyrazolo[ l,2-a|pyridazin-5-yl }-cyclohexanecarboxylic acid ethyl ester, 373) l-( 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl f-5.6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl } -4 ,4-dimetiιyl-cyclohexanecarboxylic acid ediyl ester, 374) 4,4-dimethyl- 1 - { 1 -oxo-3-pentyI-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl ]- 5, 6,7, 8-tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl }-cyclohexanecarboxylic acid ethyl ester, 375) 1 - { 6-methyl-3-oxo- 1 -propyl-2-| 2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmelhyI 1-5,8- dihydro-3H-pyrazolo[ l,2-aJpyridazin-5-yl }-cyclohexanecarboxylic acid etiiyl ester. 376) l-{ l-butyl-6-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-5.8- dihydro-3H-pyrazolof l,2-aJpyridazin-5-yl)-cyclohexanecarboxylic acid etiiyl ester, 377) 1 - { 6-methyl-3-oxo- 1 -pentyl-2-[2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5 ,8- dihydro-3H-pyrazolof l,2-aJpyridazin-5-yl }-cyclohexanecarboxylic acid ethyl ester, 378) l-{ 6-methyl-l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl}-cyclohexanecarboxylic acid ediyl ester, 379) l-{ 3-butyl-6-methyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetl yl]-5,8- dihydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl}-cyclohexanecarboxylic acid etiiyl ester, 380) l-{6-methyl-l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-1 H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid etiiyl ester. 381 ) 3,4-dimethyl-l-f 3-oxo-l-propyl-2-f2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyl l- 5,6J,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl }-cyclopent-3-enecarboxylic acid ethyl ester, 382) H l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl }-3,4-dimedιyl-cyclopent-3-enecarboxylic acid ethyl ester, 383) 3,4-dimethyl-l-{ 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ- 5,6J,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl}-cyclopent-3-enecarboxylic acid ethyl ester, 384) 3,4-dimethyI-l-{ l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll- 5, 6,7, 8 -tetrahydro- 1 H-pyrazolof l,2-aJpyridazin-5-yl}-cyclopenl-3-enecarboxylic acid ediyl ester, 385) 1 - { -butyl- 1 -oxo-2-f 2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5 , 6.7,8- tetrahydro-1 H-pyrazolof l,2-a]pyridazin-5-yI }-3,4-dimedιyl-cyclopent-3-enecarboxylic acid ethyl ester, 386) 3,4-dimethyl-l-{ l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιylJ- 5,6,7,8-tetrahydro-lH-pyrazolo[l,2-a]pyridazin-5-yl}-cyclopent-3-enecarboxylic acid ethyl ester, 387) 8-isopropyl-5-metiιyl-3-propyl-2-[2'-(l H-tetrazoI-5-yl)-biphenyl-4-ylmethyll- 5,6J,8-tetrahydro-5,8-ethano-pyrazolo[ l,2-a]pyridazin-l-one, 388) 3-butyl-8-isopropyl-5-methyI-2-f2'-(lH-tctrazol-5-yl)-bipheny!-4-ylmethyIl- 5,6J,8-tetrahydro-5,8-eti ano-pyrazolo[ l,2-a]pyridazin-l-one, 389) 8-isopropyl-5-methyl-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl |- 5,6J,8-tetrahydro-5,8-ethano-pyrazolof l,2-ajpyridazin-l-onc, 390) 5-isopropyl-8-methyl-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll- 5,6J,8-tetrahydro-5,8-ethano-pyrazolof l,2-a]pyridazin-l-one, 391) 3-butyl-5-isopropyl-8-methyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,7,8-tetrahydro-5,8-ethano-pyrazolof 1 ,2-a]pyridazin- 1 -one, 392) 5-isopropyl-8-methyl-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιylJ- 5,6,7,8-tetrahydro-5,8-ethano-pyrazolo[ l ,2-a]pyridazin-l-one, 393) l-{ 3-oxo- l-propyl-2-f2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmethyll-5,6J,8- tetrahydro-3H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid, 394) l-{ l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yI)-biphenyI-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl} -cyclohexanecarboxylic acid, 395) l-{3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid, 396) l-f l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid, 397) l-{ 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid, 398) 1 - { 1 -oxo-3-pentyl-2-[2 * -( 1 H-tetrazol-5-yl)-biρhenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid, 399) 5,8-dimethyl-3-propyl-2- { f 2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino } - 5,6,7,8-tetrahydro-5,8-ethano-pyrazolo[ 1 ,2-a]pyridazin- 1 -one. 400) 3-butyl-5,8-dimethyl-2-{ f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}- 5,6,7,8-tetrahydro-5,8-ethano-pyrazolof l,2-a]pyridazin-l-one, 401) 5,8-dimethyl-3-pentyl-2-( f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}- 5,6,7,8-tetrahydro-5,8-etiιano-pyrazolo[l,2-a]pyridazin-l-one, 402) l-{ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetralιydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid butyl ester, 403) l-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl} -cyclohexanecarboxylic acid butyl ester, 404) l-{3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl} -cyclohexanecarboxylic acid butyl ester, 405) l-( l-oxo-3-propyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6J,8- tetraliydro- 1 H-pyrazolof l,2-aJpyridazin-5-yl ) -cyclohexanecarboxylic acid butyl ester, 406) l-| 3-butyl- l-oxo-2-[2'-(lH-tetra7.ol-5-yl)-biphenyl-4-ylmethyll-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl ) -cyclohexanecarboxylic acid butyl ester, 407) l-( l-oxo-3-pcntyl-2-[2'-(lH-tctrazol-5-yl)-biphenyl-4-ylmethyl 1-5,6,7, - tetraliydro-lH-pyrazolol l,2-aJpyridazin-5-yl } -cyclohexanecarboxylic acid butyl ester, 408) 1 - f 3-oxo- 1 -propyl-2-f 2'-( 1 H-tetrazoI-5-yl)-biphenyl-4-ylmethyl]-5,6,7.8- tetralιydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid t-butyl ester, 409) l-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo| l,2-aJpyridazin-5-yl } -cyclohexanecarboxylic acid t-butyl ester, 410) l-( 3-oxo- l-pentyl-2-[2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmedιyll-5,6,7,8- tctralιydro-3H-pyrazolo[ l ,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid t-butyl ester, 41 1) 1-f l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6J,8- tctrahydro-1 H-pyrazolof l,2-aJpyridazin-5-yl ) -cyclohexanecarboxylic acid t-butyl ester, 412) l-( 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl) -cyclohexanecarboxylic acid t-butyl ester, 413) l-{ l-oxo-3-pentyl-2-|2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tctrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl) -cyclohexanecarboxylic acid t-butyl ester, 414) l-{ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl ) -cyclohexanecarboxylic acid isopropyl ester, 415) l-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid isopropyl ester, 41 ) 1 - { 3-oxo- 1 -pentyl-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl ) -cyclohexanecarboxylic acid isopropyl ester. 417) l-{ l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-1 H-pyrazolof l,2-aJpyridazin-5-yl) -cyclohexanecarboxylic acid isopropyl ester, 418) l-{ 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl ) -cyclohexanecarboxylic acid isopropyl ester, 419) l-( l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmethyl]-5,6J,8- tetrahydro- 1 H-pyrazolof 1 ,2-aJpyridazin-5-yl } -cyclohexanecarboxylic acid isopropyl ester, 420) 8-cyclohexyl-3-ρropyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ-5,6,7,8- tetrahydro-pyrazolo[ l,2-a]pyridazin-l-one, 421) 3-butyl-8-cyclohexyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 422) 8-cyclohexyl-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-pyrazolo[ l,2-aJpyridazin-l-one, 423) 5-cyclohexyl-3-propyI-2-[2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmedιyll-5,6,7.8- tctrahydro-pyrazolo[ l,2-a]pyridazin-l-one, 424) 3-butyl-5-cyclohexyl-2-f2'-( l H-tetrazol-5-yl)-biphenyl-4-ylmedιyl 1-5,6,7,8- tetraliydro-pyrazolof l,2-a]pyridazin- 1 -one, 425) 5-cyclohexyl-3-pentyl-2-f2'-(l H-tetrazoI-5-yl)-biphenyl-4-ylmethyll-5,6J.8- teiralιydro-pyrazolo[ l,2-aJpyridazin-l-one, 426) 3-propyI-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyIl-5,6,6a,7,8,9, 10,10a- octaliydro-pyrazolof 1 ,2-a|cinnolin- 1 -one, 427) 3-butyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5.6,6aJ,8,9.10, 10a- octaliydro-pyrazolof 1 ,2-alcinnolin- 1 -one, 428) 3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmcthyll-5,6,6a,7,8,9, 10, 10a- octahydro-pyrazolof 1 ,2-alcinnolin- 1 -one, 429) 7,9-methano-3-proρyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll- 5 ,6.6a,7,8,9, 10, 1 ϋa-octahydro-pyrazolof 1 ,2-alcinnolin- 1 -one, 430) 3-butyl-7,9-methano-2-I2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιylJ- 5,6,6a,7,8,9, 10, 1 Oa-octahydro-pyrazolof 1 ,2-alcinnolin- 1 -one, 431) 7,9-methano-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5 ,6,6a,7,8,9, 10, 1 Oa-octahydro-pyrazolof 1 ,2-a]cinnolin- 1 -one, 432) 8,8-dimethyl-7,9-methano-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,6a,7,8,9,10,10a-octahydro-pyrazolof l,2-a]cinnolin-l-one, 433) 3-butyl-8,8-dimetiιyl-7.9-methano-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl ]- 5,6.6a,7,8,9,10,10a-octahydro-pyrazolo[ l,2-a]cinnolin-l-one, 434) 8,8-dimethyl-7,9-methano-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmcthyl |- 5,6,6a,7,8,9,10,10a-octahydro-pyrazolof l,2-a]cinnolin-l-one, 435) l-{ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyI-4-ylmethyll-5,6J,8- tetralιydro-3H-pyrazolo[l,2-a]pyridazin-5-yl} -cyclohexanecarboxylic acid t-butyl-amide, 436) l-{ l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tctrahydro-3H-pyrazoIof l,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid t-butyl-amide, 437) l-{ 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tctrahydro-3H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid t-butyl-amide, 438) l-{ l-oxo-3-ρropyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylf-5,6J,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid t-butyl-amide, 439) l-{ 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid t-butyl-amide, 440) 1-f l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6J,8- tctrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid t-butyl-amide, 441) l-f 3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6J,8- tetralιydro-3H-pyrazolo| 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid (2-hydroxy-ethyl)- amide, 442) l-{ l-butyI-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5.6,7,8- tetrahydro-3H-pyrazolof 1 ,2-alpyridazin-5-yl ) -cyclohexanecarboxylic acid (2-hydroxy-ethyl)- amide, 443) l-{ 3-oxo- l-pentyl-2-f2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmedιyll-5.6J,8- tetrahydro-3H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid (2-hydroxy-ethyl)- amide, 444) 1-f l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tctraliydro- 1 H-pyrazolof 1 ,2-a]ρyridazin-5-yl } -cyclohexanecarboxylic acid (2-hydroxy-ethyl)- amide, 445) 1 -{ 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl ]-5,6J,8- tetralιydro-lH-pyrazolo[ l,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid (2-hydroxy-ethyl)- amide, 446) l-{ l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid (2-hydroxy-ethyl)- amide, 447) 8-[ l-(piperidine-l-carbonyl)-cyclohexyll-3-propyl-2-f 2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6J,8-tetrahydro-pyrazolo[ l,2-a]pyridazin-l-one, 448) 3-butyl-8-[ l-(piperidine-l-carbonyl)-cyclohexyl]-2-[2'-(lH-tctrazol-5-yl)- biphenyl-4-ylmethyl]-5,6J,8-tetrahydro-pyrazolo[ l,2-aJpyridazin-l-one, 449) 3-pentyl-8-[ l-(piperidine-l-carbonyl)-cyclohexyl]-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazolof l,2-a]pyridazin-l-one, 450) 5-[ l-(piperidine-l-carbonyl)-cyclohexyl]-3-propyl-2-f2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 451 ) 3-butyl-5-[ 1 -(piperidine- 1 -carbonyl)-cyclohexyl]-2-f2'-( 1 H-tetrazol-5-yl)- biphenyl-4-ylmethyll-5,6J.8-tetrahydro-pyrazolo[ l,2-a]pyridazin-l-one, 452) 3-pentyl-5-[ l-(piperidine-l-carbonyl)-cyclohexyl]-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyI]-5,6J,8-tetrahydro-pyrazolo[ l ,2-aJpyridazin-l-one, 453) l-{ 3-oxo- l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid diethylamide, 454) l-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid dietiiylamide, 455) 1-f 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid diethylamide, 456) l-{ l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6J,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl ) -cyclohexanecarboxylic acid diethylamide, 457) l-f 3-butyl-l-oxo-2-[2'-(lH-tetra7.ol-5-y])-biphenyl-4-ylmethyll-5.6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid diethylamide, 458) l-{ l-oxo-3-ρentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5.6J.8- tetraliydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid diethylamide, 459) Pentanoic acid 2-f(l-{ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmetiιyl]-5,6,7,8-tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl ) -cyclohexanecarbonyl)-amino |- eϋiyl ester, 460) Pentanoic acid 2-[(l-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolof 1 ,2-aJpyridazin-5-yl } -cyclohexanecarbonyl)-amino |- ediyl ester, 461) Pentanoic acid 2-[(l-{ 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmetiιyl]-5,6,7,8-tetrahydro-3H-pyrazolo| l,2-a]pyridazin-5-yl )-cyclohexanecarbonyl)-aminoj- ediyl ester, 462) Pentanoic acid 2-[(l-{ l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-lH-pyrazolo[ 1 ,2-a]pyridazin-5-yl (-cyclohexanecarbonyl)-amino]- ethyl ester, 463) Pentanoic acid 2-[(l-(3-butyl-l-oxo-2-(2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-l H-pyrazolof l,2-aJpyridazin-5-yl}-cyclohexanecarbonyl)-amino]- ediyl ester, 464) Pentanoic acid 2-[(l-f l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmet ιyl]-5,6,7,8-tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-yl}-cyclohexanecarbonyl)-aminol- ethyl ester, 465) 8-[ l-(moφholine-4-carbonyl)-cyclohexyl]-3-propyl-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazolof l,2-a]pyridazin-l-one, 466) 3-butyl-8-f l-(moφholine-4-carbonyl)-cyclohexyl]-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6J,8-tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 467) 8-f l-(moφholine-4-carbonyl)-cyclohexyl]-3-pentyl-2-f2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazolof l,2-a]pyridazin- 1-one, 468) 5-[l-(moφholine-4-carbonyl)-cyclohexyl]-3-propyl-2-f2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazolo[ 1 ,2-a]pyridazin- 1-one, 469) 3-butyl-5-[l-(moφholine-4-carbonyl)-cyclohexyl]-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6J.8-tetrahydro-pyrazolo[ 1 ,2-a]pyridazin- 1-one and 470) 5-[ l-(moφholine-4-carbonyl)-cyclohexyl]-3-pentyl-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6J,8-tetrahydro-pyrazolo[l,2-a]pyridazin-l-one. Pyrazole derivatives of the present invention which are represented by die general formula (I) where -Z- denotes a single bond can typically be produced by the route of reaction shown below in Scheme 1 : Scheme 1 3 4 20 21 (where R 1 and R are the same as defined above; Alk is a Q-Q alkyl group). The β-ketoester J. which can be readily produced by various methods is reacted in die usual manner with R-L (L is a leaving group such as halogen, alkyl or arylsulfonyl; R is the same as defined above) in me presence of a basic catalyst, whereby j_ is converted to 2. Examples of tlie base include sodium methoxide, sodium ethoxide, potassium t-butoxide, sodium carbonate, potassium carbonate, and metal hydrides such as sodium hydride and potassium hydride. The reaction solvent differs with the type of base used and die reaction conditioas adopted but a suitable reaction solvent can appropriately be selected from among ether based solvents such as dietiiyl ether and tetrahydrofuran, alcoholic solvents such as methanol, ethanol. propanol, isopropanol, butanol and t-butanol, amidic solvents such as dimethylformamide, diethylformamide, N-methylpyrrolidone and pyrrolidone, and dimethyl sulfoxide. The reaction temperature varies with the type of base and solvent used; if sodium ethoxide is used as a base and ethanol as a solvent, a temperature in the range from room temperature to the reflux under heating is appropriate. The case where R is a substituted biphenylmethyl group is also described in EP 0446062. It is known that compound 2_ can be converted to .3 by heating together with hydrazine. EP 0446062 shows an exemplary case for reaction with hydrazine or a mono-substituted hydrazine. When _3 is treated witii an oxidizing agent such as lead tetraacetate at low temperature, conversion from the group O O H H -N-N-C- to -N=N-C- occurs. In the presence of various dienes, the Diels-Alder reaction is performed to yield various types of compound 7a. The usual procedure for reaction merely involves providing 1-5 moles of diene per mole of mixing it with a halogenated hydrocarbon solvent such as dichloromethane or dichloroethane, and adding 1-5 moles of lead tetraacetate at a temperature in die range from -78°C to room temperature. If a halogenating agent such as N-bromosuccinimide or t-butylhypochloride is used as an oxidizing agent, a halogenated product such as 6_ is isolated; 6_ can subsequently be easily converted to 7a by treatment in the presence of a diene witii a base that is commonly used in dehydrohalogenation (see Scheme 2 below). 7a Scheme 3 7a 7t> 7c 8 9a 9b 10 As also described in J. Am. Chem. Soc, 101, 7347 (1979), 7a is subjected to hydrogenation reaction in the presence of a catalyst such as palladium-carbon or palladium hydroxide, whereby the double bond in A-B=C-D is converted to a saturated bond, producing 7b (see Scheme 3 above). In a separate step, 7_a may he brominatcd with an equimolar amount of N- broniosuccinimide by die method described in J. Org. Chem., 51, 3123 (1986); upon heating, the brominated 7a can be converted to a corresponding diene 7c. An alternative method comprises epoxidation of a double bond witii metachloroperbenzoic acid, which is followed by ring cleavage of the epoxy ring and dehydration with cone, sulfuric acid [J. Org. Chem., 50, 5604 (1985)] or addition of bromine to the double bond, and further followed by dehydrobromination witii a base |J. Heterocyclic Chem., 22, 273 (1985)]. Examples of bases that are commonly employed include sodium carbonate, potassium carbonate, sodium methoxide, sodium ethoxide, potassium t-butoxide, as well as organic amines such as triethylamine, diisopropylethylaminc, l,5-diazabicyclo|4.3.0]-5- nonene, l,8-diazabicyclo[5.4.0]-7-undecene, etc. According to yet another alternative mediod, reaction is performed using a stoichiometric amount of osmium tetroxide, or using a catalytic amount of osmium tetroxide in the presence of triethylamine N-oxide, moφholine N-oxide, etc. to form a diol, which is then treated, either at room temperature or under heating, with sulfuric acid or polyphosphoric acid to achieve conversion to diene 7c. The following method can also be used to synthesize 7a, 7b, 7c and .8: substituted or unsubstituted 1,3-dibromopropane (or 1,3-dichloropropane), 1 ,4-dibromo-2-butene (or 1,4- dichloro-2-butene), 1,4-dibromobutane (or 1,4-dichlorobutane), or 2,5-dimetiιoxy-2,5- dihydrofuran (or 2,5-dibromo-2,5-dihydrofuran) is allowed to act on 3. in an amount of 1-1.5 moles per mole of 3. using the reaction conditions commonly adopted for die alkylation reaction of amides, for example, using a base such as sodium carbonate, potassium carbonate, n-butyl lithium, phenyl lithium, lithium hydride, sodium hydride, potassium hydride, sodium methoxide, potassium methoxide, sodium ethoxide, potassium t-butoxide. etc. in an amount of 2-4 moles per mole of .3 in an ether based solvent such as dietiiyl ether, diisopropyl ether or tetrahydrofuran or in an amidic solvent such as dimet ylformamide or dietiiylformamide, at a temperature preferably in the range of 0-80°C. If a substituted or unsubstituted acrylic acid chloride or acrylic acid ester is allowed to act on 3. in the presence of tlie base described above, 3 , can be derivated to 9a or 9b via the known Michael addition reaction. Similarly, 2,2-dimethoxy-l,3-dibromopropane may be allowed to act on 3, then followed by hydrolysis to yield _K). Referring to Scheme 1, a more efficient alternative method for the synthesis of compound 4 is performing a condensation/cyclization reaction between 2 and 5_. This reaction is desirably carried out by heating under reflux using a hydrocarbon based solvent such as benzene, toluene, xylene or p-cymene, optionally in the presence of a dehydrator such as a molecular sieve, under dehydrating conditions. Compound 5_ may be synthesized by first performing the Diels-Alder reaction described above or other types of cyclization reaction using easily available JJ_ or _12 having tlie following formulas and then performing deprotection such as hydrolysis: H 3 C0 2 C-N=N-C0 2 CH 3 H 3 C0 2 C-NH-NH-C0 2 CH 3 ii 11 According to yet another alternative mediod, 20 which is produced by reacting J_ with hydrazine is converted to 2J_ by the same procedure as used in effecting → 4 conversion and, tiiereafter, a thermodynamic enolate of the type described in J. Am. Chem. Soc, 108, 3841 (1986), ibid., .109, 3017 (1987), etc. is reacted with R-L to synthesize 4. Pyrazole derivatives of the present invention that are represented by the general formula (I) where Z is -NH-, an oxygen atom or a sulfur atom may be produced by the reaction route shown below in Scheme 4: Scheme 4 15 [1] The bromide JJ which is readily produced by bromination of l_ in the usual manner can be converted to compound J4 using R-Z " Na + and a solvent such as tetrahydrofuran or dimethylformamide. R-Z ' Na + is generated from R-ZH by treatment with a base such as sodium hydride. Conversion from _14_ to (1) can be effected as in d e above-described case of conversion from 2 thru 3. to 4. While R-ZH can be synthesized by various methods, the case where Z is - NH- or an oxygen atom is described in EP 0253310, etc. An exemplary method for the case where Z is a sulfur atom is substituting R-L with NaSH. A further alternative method can be used in the case where -Z- in the general formula (I) is -NH-. First, compound J 6_ is subjected to the introduction of a nitroso group and to reduction in die usual manner and. then, alkylation is performed with R-L, thereby synthesizing 19. A dialkyl form may occasionally be generated during alkylation of .18. and, diereforc, if one wants to achieve selective synthesis of a monoalkyl form, the amino group in J i may be protected witii a t-butoxycarbonyl group, a benzyloxycarbonyl group, etc. before alkylation and deprotection are performed (see Scheme 5 below): Scheme 5 16 17 18 19 Compounds represented by the structural formula 22 in which Z in the general formula (I) is =CH- can be synthesized from \_6 and R-CHO using a suitable acid catalyst: 16 22 Examples of acids that can be used include protonic acids such as acetic acid, propionic acid, trifluoroacetic acid, p-toluene-sulfonic acid, hydrochloric acid, sulfuric acid, etc., and Lewis acids such as aluminum chloride, zinc chloride, zinc iodide, boron trifluoride etherate, etc. Examples of solvents that can be used include methanol, ethanol, propanol, tetrahydrofuran, dioxane, dimetiioxyethane, dichloromethane, dichloroethane, chloroform, etc. An appropriate reaction temperature is in the range of 0-120°C. Pharmacological Activity The pharmacological activity of die compounds of die invention is shown by the following tests. 1) In vitro angiotensin II mesenteric artery receptor binding assay According to the method (1) by Guntiier et al., a membrane fraction was prepared from mesenteric artery of male rat, 50 μm protein equivalent of it and 0.2 nM 125 I-Ang 11 as well as various concentrations of test compounds were incubated at 22°C for 90 minutes in an incubation buffer (50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl 2 , 0.25% bovine serum albumin, pH 7.2) (reaction volume; 200 μl). The incubated mixture was cooled, and die reaction was stopped by addition of ice-cooled phosphate buffer (10 mM phosphate, 140 mM NaCl, pH 7.4, hereinafter referred to as PBS), and then the reaction solution was filtered through a glass fiber filter (Whatman CF/B), die filter was washed, dried, and then the radioactivity of captured 125 I-angiotensin II which bound to die receptor was measured by a γ-countcr. Non¬ specific bound amount was obtained from the reaction in the presence of 1 μM of unlabeled angiotensin II. The test compounds were tested at the concentration of 0.01 to 1 μM, and tlie compounds that inhibited not less than 50% of total specific bound amount al 1 μM were determined as an active compound to obtain 50% inhibiting concentration (IC,.,) |see Guntiier, S., Gimbrone, M.A. and Alexander, R.W., Circ. Res., 17:278-286, 1980]. 2) In vitro adrenal cortex angiotensin II receptor binding assay According to die method by Capponi et al. (1), angiotensin II receptor binding assay was carried out by preparing a membrane fraction from an adrenal cortex of a male rat and using this as a receptor material in the same manner as that described in the above pharmacological text 1) |see Capponi, A. M. and Catt, K., J. Biol. Chem. 254:5120-5127 (1979)]. 3) Antagonism to angiotensin II constriction in an isolated rabbit thoracic aorta A rectangular strip-like sample of thoracic aorta isolated from an anaesthetized rabbit was prepared, and the sample was suspended at 2.0 g of loaded tension in a Magnus tube filled with Krebs-Henseleitoid nutrition solution which was well aerated with 95% 0**-5% C0 2 , and the constriction tension was measured using an isometric transducer. After the tension of the sample at rest became stable, accumulative administration of angiotensin II was carried out to obtain a concentration-action curve. Thereafter, the sample was washed with tlie same nutrition solution, then treated with test compound (10 6 M) for 20 minutes to obtain again a concentration-action curve of angiotensin II. The results were obtained as follows: generated maximum tension at the first accumulative administration of angiotensin II was regarded as 100%, and die 50% effective concentration (ED 50 ) was obtained in the presence or absence of die test compound, and pA, value was calculated according to die following equations: angiotensin II. The test compounds were tested at die concentration of 0.01 to 1 μM, and the compounds that inhibited not less than 50% of total specific bound amount at 1 μM were determined as an active compound to obtain 50%) inhibiting concentration (IQ-,,) |scc Guntiier, S., Gimbrone, M.A. and Alexander, R.W.. Circ. Res., .17:278-286, 1980]. 2) In vitro adrenal cortex angiotensin II receptor binding assay According to die method by Capponi et al. (1), angiotensin 11 receptor binding assay was carried out by preparing a membrane fraction from an adrenal cortex of a male rat and using tiiis as a receptor material in the same manner as that described in die above pharmacological text 1) [see Capponi, A. M. and Catt, K., J. Biol. Chem. 254:5120-5127 ( 1979)]. 3) Antagonism to angiotensin II constriction in an isolated rabhit dioracic aorta A rectangular strip-like sample of thoracic aorta isolated from an anaesthetized rabbil was prepared, and the sample was suspended al 2.0 g of loaded tension in a Magnus tube filled witii Krebs-Henseleitoid nutrition solution which was well aerated with 95% 0 2 -5%ι C0 2 , and tlie constriction tension was measured using an isometric transducer. Alter the tension of die sample at rest became stable, accumulative administration of angiotensin II was carried out to obtain a concentration-action curve. Thereafter, the sample was washed with die same nutrition solution, then treated with test compound (10 "6 M) for 20 minutes to obtain again a concentration-action curve of angiotensin II. The results were obtained as follows: generated maximum tension at the first accumulative administration of angiotensin II was regarded as 100%, and the 50% effective concentration (ED, 0 ) was obtained in the presence or absence of d e test compound, and pA 2 value was calculated according to die following equations: pA 2 =-logK B K B =C/( (A'/A)-l ) C; concentration of the test compound (M) A'; ED 50 in the presence of test compound (M) A; ED 50 in the absence of die test compound (M) 4) Antagonism to blood pressure increasing by angiotensin II in a spine destroyed rat A Wistar rat anaesthetized with pentobarbital was fixed in a dorsal position, and a cannula for measuring blood pressure was inserted into the sinister arteria carotis communis, and a cannula for administration of the test compound into the dexter external jugular vein and a cannula for administration of angiotensin II into the sinister external jugular vein. The ambilateral nervus vagus was cut, and artificial respiration was carried out. A thin metal bar was inserted into the spinal column through the sinister orbita to destroy the spine. Blood pressure was recorded on polygraph via pressure transducer from an arterial cannula. After blood pressure was stable for more than 30 min., 3 μg/kg of angiotensin II was administered intravenously four times every 15 min., and every 5 min. before the administration of angiotensin II from the second administration onward, a solvent, a lower dose of die test compound, and a higher dose of the test compound were administered intravenously in this order to observe the blood pressure increasing response by angiotensin II. ED 5n values were calculated from die inliibiting rate when the first blood pressure increase by angiotensin II was regarded as 100%. 5) Antagonism Against Hypertensive Reaction By Angiotensin II in Anaesthetized Rats (Administered Drugs into die Duodenum) Wistar rats that had been fasted from the previous day were anesthetized with pentobarbital sodium (50 mg/kg, i.p.) while a tracheotomy tube was inserted into each rat. Three cannulas were inserted to each animal; two of them were inserted into tlie right femoral artery, one for measuring the blood pressure and anotiier for injection of die anestiietic and the third one for administration of angiotensin II was inserted into tlie left femoral vein. Furthermore, the abdomen of each animal was cut along die midline and a cannula for administration of test drugs was inserted into die duodenum perorally and the pylorus was ligated so that the cannula would not slip out of the duodenum. A cannula for excretion of gastric juice was also inserted into the stomach of each animal perorally. For the maintenance of anesthesia, injection of pentobarbital sodium (20 mg/kg/hr) was started just after the surgical opration and continued until the end of the experiment. After the blood pressure of each animal was stabilized for 30 min, angiotensin II (0.3 μg/kg) was administered at 15-min intervals; after die reaction leveled off, a test compound was administered into the duodenum at a dose of 5 ml/kg. At 5, 15, 25, 35, 45 and 60 min after the administration of the test compound, angiotensin II was administered; after 60 min, the administration of angiotensin II was continued at 30-min intervals until after 5h. With die hypertensive reaction by angiotensin II just before tlie administration of test drug being taken as 100%), the percentage of maximum inhibition of die hypertensive reaction by angiotensin II after drug administration was determined and die value of ED 5n for each test drug was calculated. The results of tests 1), 3), 4) and 5) that were conducted on representative compounds within tlie scope of the present invention are shown in Tables 1 and 2 below. TABLE 1 TABLE 2 The pyrazole derivatives or pharmacologically acceptable esters or salts thereof of tlie present invention can be formulated, by a conventional method, into a dosage unit form such as tablets, capsules, pills, powders, granules, powder packet, cachets, sterile parenteral solutions or suspensions, eyedrops, solutions or suspensions, elixirs, suppositories, aerosols and emulsions which contains them in a predetermined amount. For oral administration, a solid or fluid unit dosage form can be prepared. For preparing solid composition, the active compound is mixed witii an excipient or a carrier such as magnesium stearate, dicalcium phosphate, magnesium aluminum silicate, calcium sulphate, starch, lactose, acacia, methyl cellulose and die like. A capsule agent is prepared by mixing the compound of the present invention widi an inert pharmaceutical excipient, filling the mixture into a hard gelatin capsule having a suitable size. A soft gelatin capsule is prepared by machine capsulation of slurry composed of die compound, suitable vegetable oil, light petrolatum or other inert oil. For preparing a fluid composition, the compound of the present invention is dissolved in an aqueous vehicle together with sugar, aromatic flavor and preservative to obtain a syrup. Elixirs are prepared using an alcoholic vehicle such as ethanol, a sweetener such as sugar and saccharin as well as a flavor. Suspensions are prepared using a suspending agent such as acacia, tragacanth or methyl cellulose and an aqueous vehicle. For parenteral administration, a fluid unit dosage form is prepared using die compound of the present invention and a sterile vehicle. Depending upon a vehicle such as water, Ringer's solution, isotonic sodium chloride solution and the concentration to be used, the compound is suspended or dissolved in the vehicle. For preparing solutions, the compound is dissolved in water for injection, and this is sterile filtered, filled into a vial or an ampoule, and sealed. Advantageously, an adjuvant such as local anaesthetic, preservative and buffer is dissolved in vehicle. Alternatively, a lyophilized powder having good shelf stability can be prepared. In the case of this formulation, the powder is reconstituted upon use. Parenteral suspensions can be similarly prepared using the compound of the present invention. In the case of this foπnulation, the compound of die present invention can be sterilized by exposure to etiiylene oxide before being suspended in a sterile vehicle. Advantageously, a surfactant or a wetting agent is added to facilitate dispersion of the compound. Alternatively, the compound of die present invention can be formulated into a local dosage form in combination with a suitable carrier for local administration. Examples of a carrier to be used are cream, ointment, lotion, paste, jelly, spray, aerosol and die like. Further, when other form can not be administered, suppositories can be prepared. Examples of such a base are cacao butter, polyethylene glycol, polyetiiylene sorbitan monostearate and die like. The pyrazole derivatives or pharmacologically acceptable esters or salts thereof are administered orally, parenterally by insufflation, rectally, locally. Parenteral administration includes subcutaneous, intravenous, intramuscular, intranasal administration or injection. Dose to be administered to an adult is in a range of 1 to 50 mg/day. The exact dose can be selected from die above range, taking die age of patient, weight, condition and route of administration into consideration. The frequency of administration is usually one to four times a day. Additionally, no toxicity of die compound of die present invention or pharmacologically acceptable esters or salts thereof was observed in die above-described dose range. Advantages of the Invention The present invention provides novel pyrazole derivatives that can be used as pharmaceutical compositions agents for preventing or treating hypertension, congestive heart failure, renal failure, glaucoma and hyperuricemia. The pharmaceutical compositions of tlie present invention that contain those novel compounds are characterized by having high activity, being capable of rapid manifestation of the intended action upon intravenous injection, exhibiting efficient absoφtion by the body upon oral administration, having low toxicity and working effectively for a prolonged time. DESCRIPTION OF THE PREFERRED EMBODIMENTS Examples The following Examples further illustrate the present invention in detail but are not to be construed to limit die scope thereof. EXAMPLE 1 Preparation of 3-butyl-5,8-diethyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyll 5,8-dihydro-5,8-etiιano-pyrazolof 1.2-a]-pyridazin-l-onc (compound No. 35) Etiiyl 3-oxoheptanoate (1.72 g) was dissolved in anhydrous ethanol to make a 25-ml solution. Sodium hydride (0.60 g) was added to die solution and tlie mixture was stirred at room temperature for 20 min. To die resulting suspension, N-triphenylmethyl-5-[2-(4'- bromomethylbiphenylyl)]tetrazole (6.68 g) was added and die mixture was stirred first at room temperature for 1 h, then under heating at reflux for 3 h and finally at room temperature for 4 h. Subsequently, the reaction solution was concentrated under vacuum and die resulting residue was dissolved in dichloromethane (100 ml), washed with a saturated NaCl solution, and dried witii anhydrous magnesium sulfate. After filtration, the filtrate was concentrated under vacuum and the resulting residue was subjected to silica gel column chromatography. Fractions eluted witii a solvent system of hexane/acetone (4/1) were subjected again to silica gel column chromatography (solvent:chloroform), giving ethyl 2-f2'-(N-triρhenylmethyl-tetrazol-5-yl)- biphenyl-4-ylmethyl]-3-oxo-heptanoate in an amount of 4.00 g (yield: 62%). The compound (1.38 g) was dissolved in edianol (10 ml). To the solution, a hydrazine monohydrate (105 mg) and acetic acid (0.13 ml) were added and die mixture was heated under reflux for 2 h. After cooling the reaction solution down to room temperature, the solvent was distilled off under vacuum and the resulting residue was fractionally purified by silica gel column chromatography (solvent system :methanol/chloroform = 5/95), giving 3-butyl-2-f2'-(N- triphenylmethyl-tetrazol-5-yl)-biphenyl-4-ylmethyl]-pyrazolo-l-one in an amount of 1.17 g (yield: 90%). The pyrazole derivative (300 mg) was dissolved in dichloromethane (5 ml) and 1 ,4- diethylcyclohexa- 1 ,3-diene (167 mg; purity = 60%) was added to the solution. The resulting mixture was cooled down to -78°C. Lead tetraacetate (477 mg) was added to die reaction mixture and die reaction temperature was raised slowly up to room temperature under stirring over 3 h or more. Then, ethyl acetate (20 ml) was added and die resulting precipitate was filtered off. The filtrate was washed first witii a saturated aqueous solution of sodium hydrogen carbonate, then witii a saturated NaCl solution, and the organic layer was dried witii anhydrous sodium sulfate. After filtration, die filtrate was concentrated under vacuum and die resulting residue was washed with hexane to remove the unreacted diene. The hexane-insoluble portion was dried under vacuum to give a Diels-Alder adduct (405 mg). The adduct could also be produced by the following alternative method. The pyrazole derivative (see above; 300 mg) was dissolved in acetone (2 ml) and t-butyl hypochloride (0.07 ml) was added to die resulting solution as it was cooled at -78°C. The reaction solution was stirred in a nitrogen atmosphere first at -78°C for 1 h, then at -30°C for 1 h; thereafter, the reaction temperature was reverted to room temperature. The solvent was distilled off under vacuum and die residue was fractionally purified by silica gel column chromatography (solvent system diexane/acetone = 4/1), giving 3-butyl-2-chloro-2-f2'-(N-triphenylmethyl-tetrazol-5-yl)- biphenyl-4-ylmethyl]pyrazolo-l-one in an amount of 180 mg (yield: 83%). This chloride (158 mg) was dissolved in dry dietiiyl ether (5 ml); to the resulting solution, l,4-dietiιylcyclohexa-l,3-diene (82 mg) and triediylamine (29 mg) were added and the mixture was heated at reflux for 14 h. Subsequently, die solvent was distilled off under vacuum and the residue was fractionally purified by silica gel column chromatography (solvent:chloroform), giving the above-mentioned Diels-Alder adduct in an amount of 138 mg (yield: 77%). The Diels-Alder adduct (405 mg) was dissolved in acetone (5 ml); to die resulting solution, 2 N HC1 (1 ml) was added and the mixture was heated under stirring at 50°C for 10 min. After cooling to room temperature, the reaction solution was neutralized witii a dilute aqueous solution of sodium hydroxide and die solvent was distilled off under vacuum. Etiiyl acetate (100 ml) was added to die resulting residue and die mixture was dried witii anhydrous sodium sulfate. After filtration, the filtrate was concentrated under vacuum and the residue was fractionally purified by silica gel column chromatography (solvent system :methanol/chloroform = 4/96), producing the titled compound in an amount of 17.2 mg (yield: 78%). This compound gave the following NMR spectrum: Η NMR (CDC1 3 ) δ ppm: 0.89 (3H, t, J = 6.8 Hz), 1.08 (3H, t, J = 6.8 Hz), 1.15 (3H, l, J = 6.8 Hz), 1.30-1.48 (4H, m), 1.53-1.76 (3H, m), 1.98-2.18 (2H, m), 2.25-2.36 (2H, m), 2.51 - 2.61 (3H, m), 3.43 (2H, s), 6.32 (4H, t, J = 9.2 Hz), 7.39-7.56 (3H, m), 7.87 (1H, d, J = 7.3 Hz). EXAMPLE 2 Preparation of 3-butyl-6J-dimethyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,8-dihydro-pyrazolo[ l,2-a]pyridazin-l-one (compound No. 14) The titled compound was prepared from 2,3-dimethyl-l,3-butadiene by the same method as used in Example 1. This compound had die following NMR spectrum: Η NMR (CDClj) δ ppm: 0.89 (3H, t, J = 7.3 Hz), 1.25-1.46 (4H, m), 1.75 (6H, s), 2.46 (2H, I, J = 6.8 Hz), 3.49 (2H, s), 3.90 (2H, br s), 3.99 (2H, br s), 7.00 (4H, t, J = 6.8 Hz), 7.27-7.53 (3H, m), 7.85 (1H, d, J = 4.9 Hz). EXAMPLE 3 Preparation of l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,8-dihydro-3H-pyrazolof l,2-a]-pyridazin-5-carboxylic acid ediyl ester (compound No. 98) and 3-butyl-8-metiιyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,8-dihydro-lH-pyrazolof l,2-a]pyridazin-5-carboxylic acid etiiyl ester (compound No. 101) Starting from 3-butyl-2-[2'-(N-tripheιιylmethyl-tetrazol-5-yl)-biphenyl-4-ylmethyllpyra/,olo- l-onc (300 mg) and etiiyl 2,4-hexadienoate ( 103 mg), reaction was carried out in die same manner as in Example 1 , giving a Diels-Alder adduct in an amount of 268 mg (yield: 73% ) as a mixlurc of two regio-isomers. The adduct was deprotected as in Example 1 and die resulting reaction mixture was subjected to repeated fractional purification by silica gel column chromatography (solvent system:methanol/chlorofoπιι = 1/99), producing the titled compound 98 (25 mg; yield = 14%) and its regio-isomer 101 (68 mg; yield = 37%-). These compounds had the following NMR spectra: Compound No. 98 'H NMR (CDC1*,) δ ppm: 0.86 (1.5H, t, J = 7.3 Hz), 0.90 ( 1.5H, t, J = 7.3 Hz), 1.09 ( 1.5H, d, J = 6.2 Hz), 1.17 (1.5H, t, J = 7.3 Hz), 1.22 (1.5H, t, J = 7.3 Hz), 1.34 (1.5H, d, J = 6.2 Hz), 1.30- 1.52 (4H, m), 2.33-2.64 (2H, m), 3.51 (1H, d, J = 10.8 Hz), 3.59 (1H, d, J = 10.8 Hz), 4.07-4.20 (2H, m), 4.44 (1H, m), 4.99 (0.5 H, br s), 5.20 (0.5 H, br s), 5.96-6.14 (2H, m), 6.96-7.1 1 (4H, m), 7.39-7.57 (3H, m), 7.91 (1H, m). Compound No. 101 Η NMR (CDC1*,) δ ppm: 0.89 (3H, m), 1.24 (3H, t, J = 6.8 Hz), 1.30-1.40 (4H, m), 1.53 (3H, d, J = 6.8 Hz), 2.20-2.60 (2H, ), 3.62 (2H, m), 4.18 (2H, m), 4.60 (1H, m), 4.94 ( 1H, m), 6.00-6.09 (2H, m), 7.01-7.09 (4H, m), 7.40-7.58 (3H, m), 7.94 (1H, br s). EXAMPLE 4 Preparation of l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ- 3H,8H-5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid mediyl ester (compound No. 1 16) and 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-lH,8H-5,8-edιano-pyrazolof l,2-a]pyridazin-5-carboxylic acid mediyl ester (compound No. 1 19) Starting from methyl 1,3-cyclohexadiene-l-carboxylate. the procedure of Example 1 was repeated, giving 1-butyl -3-oxo-2-[2'-(N-triphenylmethyl-tetrazol-5-yl)biphenyl-4-ylmethyl]- 3H,8H-5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid mediyl ester and a regio-isomer thereof in respective yields of 34% and 58%. These two Diels-Alder adducts were deprotected as in Example 1, producing the titled compound 1 16 (yield: 54%) and its regio-isomer 1 19 (yield: 52%). These compounds had the following NMR spectra: Compound 1 16 Η NMR (CDCl,) δ ppm: 0.89 (3H, l, J = 7.3 Hz), 1.21 - 1.48 (6H, m), 1.67 (2H, m), 2.20-2.60 (2H. m), 3.41 (2H. br s). 3.78 (3H. s). 4.61 (1 H, br s), 6.28 (1 H, dd, .1 = 5.9. 8.4 H ). 6.86 ( 1 H, d, J = 8.4 Hz). 6.96 (4H, t, J = 6.8 Hz), 7.38-7.54 (3H. m), 7.88 ( 1 H, br s). Compound 1 1 'H NMR (CDC1 δ ppm: 0.85 (3H, l, J = 7.3 Hz), 1.29 (4H, m), 1.65 (2H, in), 2.06- 2.55 (4H. m), 3.37 ( 1H, d, J = 15.3 Hz), 3.47 ( 1 H, d, J = 15.3 Hz), 3.90 (3H, s), 5.10 ( 1 H. br s), 6.41 ( 1H, dd, J = 5.9, 8.4 Hz), 6.63 ( 1 H, d, J = 8.4 Hz), 7.01 (4H, t. J = 6.8 Hz), 7.39-7.58 (3H, m), 7.89 ( 1H, d, J = 7.3 Hz). EXAMPLE 5 Preparation of l -butyl-8-methyl-3-oxo-2-|2'-(l H-tetrazol-5-yl)-biphenyl-4- ylmethyI]-5,8-dihydro-3H-pyrazolo| l ,2-a|pyridazin-5-carboxylic acid (compound No. 62) and 3-butyl-8-metiιyl- l-oxo-2-[2 , -( l H-tetrazol-5-yl)-biphenyl-4- ylmethyll-5,8-dihydro- lH-pyrazolo| l ,2-aJpyridazin-5-carboxylic acid (compound No. 65) The mixture of compound Nos. 98 and 101 which were prepared in Example 3 (65 mg) was dissolved in methanol (2 ml), followed by addition of an aqueous solution of 2 N NaOH (0.64 ml). The reaction mixture was stirred in a nitrogen atmosphere at 60°C for 2 h and tiiereaftcr cooled down to room temperature. Subsequently, water (8 ml) was added and die resulting precipitate was filtered off. The pH of the filtrate was adjusted to ca. 2.0 witii 2 N HCl and the resulting white precipitate was recovered by filtration. The precipitate thus obtained was dried by heating at 60°C under vacuum, producing a mixture of the titled compounds in an amount ol " 61 mg (yield: 99%>). The mixture had die following NMR spectrum: Η NMR (CD 3 OD) δ ppm: 0.87 ( 1.5 H, t, J = 7.3 Hz), 0.90 ( 1.5 H, t, J = 7.3 Hz), 1.30 (3H, d, J = 6.2 Hz), 1.1 1- 1.46 (4H, m), 2.29-2.80 (2H, m), 3.68 (2H, m), 4.60-4.80 ( 1 H, ), 5.27 (1H, m). 6.15 (2H, m), 7.03 (2H, d, J = 8.4 Hz), 7.19 (2H, d, J = 8.4 Hz), 7.50-7.68 (4H. m). EXAMPLE 6 Preparation of 3-butyl-8-hydroxymetiιyl-2-f2'-( lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6J,8-tetrahydro-5.8-ethano-pyrazolo[ l ,2-a]pyridazin-l-one (compound No. 221) Starting from 4-hydroxymethyl- l ,3-cyclohexadiene, die procedure of Example 1 was repeated, giving a Diels-Alder adduct in a yield of 86%). The adduct ( 100 mg) was dissolved in a solvent system composed of metiianol (20 ml) and ethyl acetate ( 10 ml); after adding 20% palladium hydroxide/carbon (25 mg), die reaction mixture was catalytically reduced under atmospheric pressure condition for 3 h. After filtering off the catalyst, the filtrate was concentrated under vacuum and die resulting residue was fractionally purified by silica gel column chromatography (solvent system :methanol/chloroform = 3/97), producing the titled compound in an amount of 44 mg (yield: 67%)). This compound had die following NMR spectrum: Η NMR (CDC1 3 ) δ ppm: 0.87 (3H, t, J = 6.8 Hz), 1.26- 1.42 (4H, m), 1.61 -2.09 (8H, m). 2.43 (2H, t, J = 7.0 Hz), 3.53 (2H, s), 3.79 (2H, s), 4.32 ( 1 H, br s), 6.97 (2H, d, J = 7.8 Hz), 7.01 (2H, d, J = 7.8 Hz), 7.39-7.57 (3H, m), 7.82 (1H, d, J = 7.3 Hz). EXAMPLE 7 Preparation of ( l-butyl-3-oxo-2-f2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmethyll- 3,6,7,8-tetrahydro-5,8-ethano-pyrazolol 1 ,2-aJpyridazin-5-ylmethoxy (-acetic acid methyl ester (compound No. 25 1 ) l-Hydroxymethyl- l ,3-cyclohexadiene (3.0 g) was dissolved in dry dimethylformamide ( 15 ml); tiien, sodium hydride (2.18 g) was added to tlie resulting solution under cooling witii ice. After stirring for 1 h, methyl bromoacetate (8.26 g) was added and die mixture was then stirred at room temperature for 38 h. The reaction solution was diluted with water (100 ml) and extracted twice witii ethyl acetate (50 ml). The organic layers were combined and washed with a saturated NaCl solution, followed by drying with anhydrous magnesium sulfate. After filtration, tlie filtrate was concentrated under vacuum and the resulting residue was fractionally purified by silica gel column chromatography (solventxhlorofoπii), producing d e target dicne in an amount of 1.89 g (yield: 30%>). Starting from this diene, the procedures of Examples 1 and 6 were repealed to produce die titled compound. It had the following NMR spectrum: 'H NMR (CDC1 δ ppm: 0.91 (3H, I, J = 6.8 Hz), 1.25- 1.64 (4H, m). 1.85-2.04 (8H, m). 2.46 (2H, I. J = 6.8 Hz). 3.53 (2H. br s). 3.72 (3H, s). 4.20 ( IH, m). 4.30 (2H. m). 4.65 (2H. s), 7.04 (4H, in), 7.42-7.58 (3H, m), 7.99 ( l H. br s). EXAMPLE 8 Preparation of f l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmetiιyl]-5,6,7,8-tetrahydro-3H-pyrazolo[ 1 ,2-a]-pyridazin-5-yl } -acetonitrile (compound No. 242) and f 3-butyl-8-methyl-l-oxo-2-[2'-( lH-tetrazol-5-yl)- biphenyl-4-ylmetiιyl]-5,6J,8-tetralιydro- lH-pyrazolo[ l,2-aJρyridazin-5-yl (- acetonitrile (compound No. 254) Sorbyl bromide was synthesized by a documented known method (J. Am. Chem. Soc, 77, 2461 (1955)]. A portion (1.27 g, 7.89 mmol) of this bromide was dissolved in dimediylformamide (10 ml); to die solution, 95% sodium cyanide (420 mg, 8.14 mmol) was added and die mixture was stirred at room temperature for 18 h. The reaction solution was diluted by addition of diethyl ether and water. The separating ether layer was washed with a saturated NaCl solution and dried witii anhydrous sodium sulfate. The solvent was distilled off under vacuum, giving hepta-3,5-dienenitrile as a brown oil in an amount of 556 mg (yield: 56%;). This compound had die following NMR spectrum: Η NMR (CDC1 3 ) δ ppm: 1.77 (3H, d. J = 6 Hz), 3.14 (2H, d, J = 5 Hz), 5.3-5.5 (IH, m), 5.65-5.85 (IH, m), 5.95-6.15 (IH, m), 6.2-6.4 (IH, m). This compound was treated as in Example 6 to produce die titled compounds, which had die following NMR spectrum: Compound No. 242 Η NMR (CDCl,) δ ppm: 0.90 (3H, t, J = 7Hz), 1.22 (3H, d, J = 6 Hz), 1.2-1.6 (2H, 111), 1.7-2.2 (2H, m), 2.2-2.4 (2H, m), 2.4-2.7 (2H, m), 3.19 (IH, dd, J = 16 Hz. 3 Hz), 3.50 (2H, s), 3.67 (IH, dd, J = 16 Hz, 7 Hz), 3.9-4.05 (IH, ), 4.05-4.25 (IH, m), 6.9-7.15 (4H, br s), 7.3-7.6 (3H, m), 7.85-8.0 (IH, m). Compound No. 254 -U NMR (CDC1 3 ) δ ppm: 0.91 (3H, t, J - 7 Hz), 1.24 (3H, d, J = 6 Hz), 1.2-1.6 (2H, m), 1.6-2.2 (4H, m). 2.2-2.45 (2H, m), 2.45-2.7 (2H, m), 3.1 (I H, dd, J = 16 H/„ 3 Hz), 3.53 (2H, s), 3.71 (IH, dd, J = 16 Hz. 7 Hz), 3.9 -4.1 (IH, m), 4.1 -4.3 (IH. m), 6.9-7.2 (4H, m), 7.3-7.6 (3H, m), 7.9-8.0 (I H, m). EXAMPLE 9 Preparation of {l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyll-5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]-pyridazin-5-yl >-acctic acid (compound No. 182) {l-Butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl}-acetonitrile (compound No. 242; 105 mg, 0.218 mmol) was dissolved in an aqueous solution of 5 N potassium hydroxide (1 ml) and the solution was stirred under heating at reflux for 2 h. The reaction solution was washed with diethyl etiicr and the aqueous layer was rendered acidic with cone, hydrochloric acid, followed by extraction with ethyl acetate. The ethyl acetate layer was washed with a saturated aqueous NaCl solution and dried with anhydrous sodium sulfate. Thereafter, the solvent was distilled off under vacuum, producing the titled compound as a pale brown oil in an amount of 97 mg (yield: 89.0%>). This compound had the following NMR spectrum: -H NMR (CDCI3) δ ppm: 0.86 (3H, t, J = 7 Hz), 1.04 (3H, d, J = 6 Hz), 1.2-1.6 (2H, m), 1.6-2.1 (4H, m), 2.1-2.4 (2H, m), 2.4-2.7 (4H, m), 3.48, 3.63 (each IH, d, J = 17 Hz), 4.1 - 4.3 (IH, m), 4.8-5.0 (IH, ), 6.8-7.2 (4H, m), 7.3-7.4 (3H, m), 7.8-8.0 (IH, m). EXAMPLE 10 Preparation of {l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphcny]-4- ylmethy]]-5,6J,8-tetrahydro-3H-pyrazolori,2-a]pyridazin-5-yl>-acctic acid ethyl ester (compound No. 191) f l -Butyl-8-methyl-3-oxo-2-[2'-( l H-tetrazol-5-yl)-biphenyl-4-ylmetiιyl ]-5,6J. - tctrahydro-3H-pyrazolo[ l ,2-a]pyridazin-5-yl ( -acetic acid (compound No. 182; 74 mg. 0.148 mmol) was dissolved in ethanol ( 1 ml). Cone, sulfuric acid (0. 1 ml) was added lo the resulting solution and the mixture was stirred at room temperature for 12 h. Edianol was distilled off under vacuum and the residue was neutralized with a saturated aqueous solution of sodium hydrogen carbonate, followed by extraction witii ethyl acetate. The ethyl acetate layer was washed with a saturated aqueous NaCl solution and dried with anhydrous sodium sulfate. The solvent was distilled off under vacuum and the remainder was purified by preparative silica gel TLC (developing solvent systcm hloroform/methanol = 10: 1 ), producing die titled compound as a colorless oil in an amount of 17 mg (21.8% ). This compound had the following NMR spectrum: Η NMR (CDCl,) δ ppm: 0.90 (3H, t, J = 8 Hz), 1.01 (3H, d, J = 6Hz), 1.22 (3H, 1. J = 7 Hz), 1.1-1.9 (6H, m), 2.0-2.4 (2H, m), 2.4-2.7 (4H, m), 3.4-3.6 (2H, m), 4.09 (2H, q. J = 7 Hz), 4.0-4.3 (IH, m), 4.7-4.9 ( IH, m). 6.9- 7.2 (4H. br s), 7.3-7.6 (3H, 111), 7.8-8.0 ( I H. m). EXAMPLE 1 1 Preparation of 3-f l-butyI-8-methyl-3-oxo-2-|2'-(l H-tetrazol-5-yl)-biphenyl-4- ylmetiιyl]-5,6,7.8-tetrahydro-3H-pyrazolo| l,2-a]pyridazin-5-yl (-propionic acid etiiyl ester (compound No. 194) and 3-{ 3-butyl-8-methyl-l-oxo-2-[2'-(lH- tetrazol-5-yl)-biphenyl-4-ylmetlιyl]-5,6,7,8-tetrahydro- lH-pyrazolo[ l,2- aJpyridazin-5-yl (-propionic acid etiiyl ester (compound No. 257) Trans-4-trans-6-octadienic acid was syntiiesized by a documented known method [J. A . Chem. Soc, 77, 2461 (1955)1. A portion (538 mg. 3.84 mmol) of this compound was dissolved in methylene chloride (2 ml) and oxalyl chloride (730 mg, 5.75 mmol) was added to the solution. After stirring at room temperature for 2 h, die solvent and excess reagents were distilled off under vacuum. The remainder was dissolved in metiiylene chloride and triethylamine (780 mg, 7.71 mmol) and edianol (350 mg, 7.60 mmol) were added, followed by stirring at room temperature for 14 h. The reaction solution was diluted witii n-pentane and washed successively witii purified water, a saturated aqueous NaCl solution, a saturated aqueous solution of sodium hydrogen carbonate and a saturated aqueous NaCl solution. The separating n-pentane layer was dried witii anhydrous sodium sulfate and die solvent was distilled off under vacuum, producing ethyl trans-4-trans-6-octadιenale as a colorless oil in an amount of 527 g (yield: 81.6%>). This compound had the following NMR spectrum: Η NMR (CDCl,) δ ppm: 1.25 (3H. 1. .1 = 7 Hz). 1.73 (3H. d. J = 6 H/). 2.25-2.55 (4H, m). 4.13 (2H. q, J = 7 Hz), 5.3-5.8 (2H, m). 5.9-6.2 (2H, m). This compound was treated as in Example 6, yielding the tilled compounds as colorless oil. They had die following NMR spectra: Compound No. 200 Η NMR (CDCI 3 ) δ ppm: 0.89 (3H, t, J = 7 Hz), 1.1- 1.3 (6H, m), 1.2- 1.5 (4H, m). 1.6- 2.1 (4H, m), 2.1-2.6 (6H, m), 3.41, 3.49 (each IH, d, J = 16 Hz), 3.9-4.2 (2H, m). 4.10 (2H, q. J = 7 Hz), 6.85-7.1 (br s, 4H), 7.3-7.6 (3H, m), 7.84 ( IH, d, J = 8 Hz). Compound No. 257 Η NMR (CDCI 3 ) δ ppm: 0.89 (3H, I, J = 7 Hz), 1.25 (3H, l, J = 7 Hz). 1.1-1.55 (4H. m), 1.63 (3H, d, J = 6 Hz), 1.6-2.1 (4H, m). 2.1-2.7 (6H, m), 3.4-3.6 (2H, br s). 3.7-3.9 ( I H. m). 3.9-4.2 ( IH, m), 4.13 (2H, q, J = 7 Hz). 6.9-7.15 (4H, m). 7.3-7.65 (3H, 111). 7.8-8.0 ( I H, 111). EXAMPLE 12 Preparation of 3-butyl-8-hydroxymetiιyl-5-methyl-2-|2'-(lH-tetrazol-5-yl)- biphenyl*4-ylmethyl]-5,6,7,8-tetrahydro-pyrazolo[ 1 ,2-aJpyridazin- 1 -one (compound No. 203) Starting from 3-butyl-2-f2'-(N-triphenylmethyl-tetrazol-5-yl)-biphenyl-4- ylmethyljpyrazolo-l-one and 2,4-hexadien-l-ol, the procedure of Example 6 was repeated lo yield the titled compound, which had die following NMR spectrum: Η NMR (CDCI 3 ) δ ppm: 0.92 (3H. t, J = 7 Hz), 1.05 (3H, d, J = 6.5 Hz), 1.3-1.6 (3H. m). 1.65-1.9 (3H, m), 2.10 (IH, m), 2.30 (IH, m), 2.56 (IH, m), 3.5-3.75 (4H, m), 4.01 ( IH. dd. J = 13 Hz, 8 Hz), 7.08 (2H, d, J = 8 Hz), 7.15 (2H, d, J = 8 Hz), 7.4-7.6 (3H, m), 8.02 ( IH, d. J = 8 Hz). EXAMPLE 13 Preparation of 2-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyIl- 5,8-dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-benzoic acid mediyl ester (compound No. 265) Methyl 2-methylhenzoate (15 g) was dissolved in a carbon tetrachloride solution (150 ml). N-Bromosuccinimide (17.78 g) and benzoyl peroxide (75 mg) were added to the solution and die mixture was refluxed under heating for 4 h. The reaction solution was cooled lo roo temperature and die resulting precipitate was filtered off. The filtrate was concentrated under vacuum to give methyl 2-bromomethylbenzoate (23.26 g; yield = 85%>). The bromide (20 g) was dissolved in benzene (80 ml) and triphenylphosphine ( 18.3 g) was added to die solution, which was refluxed under heating for 1 h. The reaction solution was cooled to room temperature and die resulting white crystal was recovered by filtration. The crystal was washed witii benzene and dried under vacuum at 70°C for 4 h to give a phosphonium salt (25.6 g). The phosphonium salt (17.5 g) was dissolved in dry tetrahydrofuran (50 ml) and potassium t- butoxide (4.04 g) was added under cooling with ice in a nitrogen atmosphere. The reaction solution was stirred at 0°C for 2 h in a nitrogen atmosphere; the, acrolein (2g) was added and the mixture was further stirred for 2 h. Water (100 ml) was added to die reaction mixture, followed by two extractions witii diethyl ether (50 ml). The organic layer was washed witii a saturated aqueous solution of sodium chloride and dried witii anhydrous magnesium sulfate. After filtration, die filtrate was concentrated under vacuum and the resulting residue was fractionally purified by silica gel column chromatography (solvent systeπr.ethyl acetate/hexane = 4/96), yielding 4-(2-carbometiιoxyphenyl)-l ,3-butadiene as a mixture with methyl 2- methylbenzoate (4.2 g; diene:ester = 3:7). Starting witii the diene, tlie procedure of Example 1 was repeated to prepare the titled compound. It had the following NMR spectrum: Η NMR (CDCl,) δ ppm: 0.89 (3H. t. J = 7.3 Hz), 1.23 (2H, m), 1.49 (2H, m), 2.53 (2H, m), 3.44 (2H, s), 3.84 (3H, s), 3.94 (2H, m), 4.34 (IH. d, J = 1 1.6 Hz), 5.89 (IH, m), 6.25 (IH, dd, J = 6.2, 10.3 Hz), 6.67 (IH, d. J = 8.4 Hz), 6.87 (2H, d, J = 7.8 Hz), 6.92 (2H, d, J = 7.8 Hz), 7.09-7.86 (7H, m). EXAMPLE 14 Preparation of 3-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl |- 5,8-dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-benzoic acid mediyl ester (compound No. 268) Starting with methyl 3-methylbenzoate ( 10 g), the procedure of Example 13 was repeated to prepare a phosphonium salt ( 19.6 g). The phosphonium salt (12.84 g) and acrolein (4.40 g) were subjected to a Wittig reaction by the same method as in Example 13, yielding 4- (3-carbomethoxyphenyl)- l ,3-butadiene as a mixture with methyl 3-medιylbenzoate (2.84 g; diene:ester = 5: 1 ). Starting with the diene, the procedure of Example 1 was repeated to prepare die titled compound. It had the following NRM spectrum: 'H NMR (CDC1 3 ) δ ppm: 0.90 (3H, t, J = 7.3 Hz), 1.19-1.49 (4H, m), 2.45-2.63 (2H. 111), 3.42 (IH, d, J = 10.1 Hz), 3.52 ( IH, d, J = 10.1 Hz), 3.75 (3H, s), 3.93 (2H, m), 4.31 (IH, d, J = 1 1.6 Hz), 5.71 (IH, br s), 6.03 (IH, br s), 6.88 (2H, d, J = 7.8 Hz), 6.94 (2H, d, J = 7.8 Hz), 7.31-7.95 (8H, m). EXAMPLE 15 Preparation of l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolo[ l ,2-a]pyridazin-5-carboxylic acid 2- ethoxycarbonylphenyl ester (compound No. 122) Etiiyl salicylate (1.66 g) was dissolved in anhydrous tetrahydrofuran to make a 10 ml solution. To the solution, potassium t-butoxide (1.12 g) was added under cooling witii ice and die mixture was stirred for 20 min. In a separate step, sorbic acid (1.12 g) was reacted witii oxalyl chloride (0.70 g) in tetrahydrofuran (5 ml) first at room temperature for 30 min, tiien al 40°C for 30 min, thereby preparing a solution of sorbic acid chloride. The solution was added dropwise to die previously prepared solution and die mixture was stirred under cooling witii ice for 10 min, then at room temperature for 3 h. Water was added to the reaction solution and the mixture was subjected to extraction with methylene chloride. The metiiylene chloride layer was dried with anhydrous sodium sulfate. After filtration, tlie filtrate was concentrated under vacuum and die resulting precipitate was fractionally purified by silica gel column chromatography (solvent system: ediyl acetate/hexane = 1/6), producing 2-hexa-2,4- dienoyloxybenzoic acid etiiyl ester (0.90 g; yield = 35%). Starting with tiiis diene and 3-butyl-2-[2'-(N-triphenylmethyl-tclrazol-5-yl)-biphenyl-4- ylmethyl]pyrazolo-l-one, tlie procedure of Example 6 was repeated to prepare die titled compound. It had the following NMR spectrum: Η NMR (CDC1 3 ) δ ppm: 0.92 (3H, t, J = 7 Hz), 1.34 (3H, d, J = 7Hz). 1.35 (3H, t. J = 7Hz), 1.2-1.6 (4H, m), 1.9- 2.1 (6H, m), 3.52 (IH, d, J = 16 Hz), 3.58 ( IH, d, J = 16 Hz), 4.19 ( IH, m), 4.30 (2H, q, J = 7 Hz), 4.55 (IH, dd, J = 10, 6 Hz), 6.99 (2H, d, J = 8 Hz), 7.09 (2H. d, J = 8 Hz), 7.2-7.6 (6H, m), 7.94 (2H, m). EXAMPLE 16 Preparation of l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,7,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid methyl ester (compound No. 271) and 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmetiιyl]-5,6,7,8-tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid mediyl ester (compound No. 313) Starting with 1,3-butadiene-l-carboxylic acid mediyl ester, the procedure of Example 6 was repeated to yield the titled compounds. They had die following NMR spectra: Compound No. 271 Η NMR (CDCl,) δ ppm: 0.88 (3H, t, J = 7 Hz), 1.2-1.55 (4H, m), 1.6-2.2 (4H, m), 2.3-2.6 (2H, m). 3.09 (IH, dt, J = 11 Hz, 3Hz), 3.55 (2H, s), 3.64 (3H, s), 3.83 (IH, d, J = 1 1 Hz), 4.97 (IH, d, J = 4 Hz), 7.01, 7.09 (each 2H, d, J = 8 Hz), 7.35-7.6 (3H. m), 7.88 (IH, br s). Compound No. 313 Η NMR (CDCl,) δ ppm: 0.88 (3H, t, J = 7 Hz), 1.2-1.5 (4H, m), 1.55-1.8 (IH, m), 1.8-2.0 (IH, m), 2.0-2.3 (2H, m), 2.4-2.6 (2H, m), 3.11 (IH, dt, J = 13 Hz, 4 Hz), 3.54 (2H, s). 3.63 (3H, s), 4.21 (IH, dd, J = 13 Hz, 4 Hz), 4.55 (IH, dd, J = 5 Hz, 2 Hz), 7.01, 7.08 (each 2H, d, J = 8 Hz), 7.35-7.65 (3H, m). 7.88 (IH, d, J = 8 Hz). EXAMPLE 17 Preparation of f l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,7,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl}-acetic acid ethyl ester (compound No. 197) and {3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-lH-pyrazolo[ l,2-alpyridazin-5-yl}acctic acid ethyl ester (compound No. 310) Ethyl 3,5-hexadienate was synthesized by a documented known method [J. Am. Chem. Soc, 98, 6317 (1976)]. Starting with this compound, the procedure of Example 6 was repeated to yield the titled compounds. They had the following NMR spectra: Compound No. 197 -H NMR (CDC1 3 ) δ ppm: 0.88 (3H, t, J = 7 Hz), 1.21 (3H, t, J = 7 Hz), 1.1-1.6 (4H, m), 1.7-2.25 (4H, m), 2.25-2.8 (4H, m), 3.01 (IH, t, J = 11 Hz), 3.46 (2H, br s), 3.79 (IH, d, J = 11 Hz), 4.08 (2H, q, J = 7 Hz), 4.76 (IH, br s), 6.8-7.2 (4H, br s), 7.3-7.65 (3H, m), 7.85 (IH, d, J = 7 Hz). Compound No. 310 l H NMR (CDCI3) δ ppm: 0.89 (3H, t, J = 7 Hz), 1.21 (3H, t, J = 7 Hz), 1.1-1.6 (4H, m), 1.7-2.2 (4H, m), 2.3-2.7 (4H, m), 3.06 (IH, t, J = 11 Hz), 3.51 (2H, br s), 3.81 (IH, d, J = 11 Hz), 4.09 (2H, q, J = 7 Hz), 4.76 (IH, br s), 6.8-7.2 (4H, br s), 7.35-7.65 (3H, m), 7.87 (IH, d, J = 6 Hz). EXAMPLE 18 Preparation of l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 1 - (2,2-dimethyl-propionyloxy)-ethyl ester (compound No. 274) and 3-butyl-8- methyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro- lH-pyrazolof 1 ,2-a]-pyridazin-5-carboxylic acid l-(2,2-dimethyl-propionyloxy)- ethyl ester (compound No. 316) Sorbic acid (560 mg) was reacted witii 2,2-dimethyl-propionic acid 1-iodoethyl ester by the method described in Japanese Patent Public Disclosure No. Hei 1-249778, giving hexa-2,4- dicnic acid l -(2,2-dimethyl-propionyloxy)-ethyl ester (704 mg; yield = 59% ). Starting with this diene and 3-butyl-2-f2'-(N-triphenylmetiιyl-tetrazol-5-yl)-biphenyl-4- ylmethyl]pyrazolo- l-one, the procedure of Example 6 was repeated to yield the titled compounds as a mixture of diastereomers. These compounds had die following NMR spectra: Compound No. 274 Η NMR (CDC1 3 ) δ ppm: 0.89 (3H, t, J = 7 Hz), 1.15, 1.19 (9H, two s). 1.30 (3H, t, J = 7 Hz), 1.38 (3H, d, J = 7 Hz), 1.46 (3H, d, J = 7 Hz), 1.2- 1.6 (10H, m), 3.48 (2H, m), 4.10 (IH, m), 4.40 (IH, t, J = 7 Hz), 6.81 (IH, m), 6.9-7.1 (4H, m), 7.35-7.6 (3H, m). 7.88 ( I H, m). Compound No. 316 'H NMR (CDCI 3 ) 8 ppm: 0.90 (3H, t, J = 7 Hz), 1.15, 1.18 (9H, two s), 1.40 (3H, m), 1.60 (3H, m), 1.3-2.6 ( 10 H, m), 3.55 (2H, s), 3.90 (IH, ), 4.50 (IH, m). 6.79 ( I H, m), 7.05 (2H, d, J = 8 Hz), 7.16 (2H, d, J = 8 Hz), 7.4-7.6 (3H, m), 8.00 ( IH, dd, J = 8. 1 Hz). EXAMPLE 19 Preparation of l-butyl-8-methyl-3-oxo-2-f2'-(l H-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolof l ,2-a]pyridazin-5-carboxylic acid t- butylamide (compound No. 167) and 3-butyl-8-methyl-l-oxo-2-[2'-(lH-tetrazol- 5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro- l H-pyrazolof l ,2-a]pyridazin-5- carboxylic acid t-butyl amide (compound No. 322) Sorbic acid (1.12 g) was reacted with oxalyl chloride (0.70 g) in methylene chloride (10 ml) first at room temperature for 30 min, then under reflux for 1 h to prepare a solution of sorbic acid chloride in methylene chloride. The solution was added dropwise to a solution of 1- butylamide (1.46 g) in methylene chloride (20 ml) under cooling with ice and die mixture was stirred at room temperature for 2 h. The reaction solution was filtered and die filtrate was concentrated under vacuum. The resulting residue was fractionally purified by silica gel column chromatography (solvent system:ethyl acetate/hexane = 1/6 - 1/4), producing sorbic acid t- butylamide (990 mg; yield = 59%). Starting with this diene and 3-butyl-2-[2'-(N-triphenylmetiιyl-tetrazol-5-yl)-biphenyl-4- ylmethyl]pyrazolo-l-one, the procedure of Example 6 was repeated to prepare the titled compounds. They had die following NMR spectra: Compound No. 167 Η NMR (CDCl,) δ ppm: 0.89 (3H, t, .1 = 7 Hz), 1.25 (9H, s), 1.2-2.6 ( 13 H, m), 3.47 (IH, d, J = 6 Hz), 3.53 (IH, d, J = 16 Hz), 4.13 (IH, m), 4.49 (IH, t, J = 5 Hz), 6.96 ( I H, d, J = 8 Hz), 7.00 ( IH, d, J = 8 Hz), 7.23 (IH, s), 7.35-7.6 (3H, m), 7.89 (IH, dd, J = 8, 1 Hz). Compound No. 322 Η NMR (CDCl,) δ ppm: 0.88 (3H, t, J = 7 Hz), 1.22 (9H, s), 1.56 (3H, d, J = 7 Hz), 1.2-2.5 ( 10H, m), 3.44 (2H, s), 3.95 (IH, m), 4.32 (IH, m), 5.26 (I H, s), 6.99 (2H, d, J = 8 Hz), 7.04 (2H, d, J = 8 Hz), 7.3-7.6 (3H, m), 7.87 (IH, d, J = 8, 1 Hz). EXAMPLE 20 Preparation of piperidine-1-carboxylic acid f l-butyl-8-methyl-3-oxo-2-[2'-( lH- tetrazol-5-yl)-biphenyI-4-ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolol l,2- aJpyridazin-5-carbonyl (-amide (compound No. 277) and 3-butyl-8-methyl- l -oxo- 2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιy]l-5,6,7,8-tetralιydro-lH-pyrazolo| l ,2- a]pyridazin-5-carboxylic acid (piperidinc-l-carbonyl)-amide (compound No. 334) A hexane solution of n-butyl lithium ( 1.6 M, 6.5 ml) was added dropwise to a tetrahydrofuran solution (20 ml) of 1-piperidinecarboxamide (1.28 g) under cooling witii ice, and die mixture was stirred at die same temperature for 1 h. A tetrahydrofuran solution (3 ml) of ethyl sorbate (1.28 g) was added dropwise to die resulting solution and die mixture was stirred at room temperature for 3 h. A saturated aqueous solution of ammonium chloride was added to the reaction solution and die mixture was diluted with water. Thereafter, the dilution was subjected to extraction with methylene chloride and dried with anhydrous sodium sulfate. After filtration, die filtrate was concentrated under vacuum and die resulting residue was fractionally purified by silica gel column chromatography (solvent system:ethyl acetate/hexane = 1/3 or ethyl acetate alone) to produce piperidine-1-carboxylic acid hexa-2,4-dienoylamide (819 mg; yield = 37%). Starting with this diene and 3-butyl-2-(2'-(N-triphenyl-methyl-tetrazol-5-yl)-biphenyl-4- ylmethyl]pyrazolo-l-one, the procedure of Example 6 was repeated to yield the titled compounds. They had die following NMR spectra: Compound No. 277 - NMR (CDCl,) δ ppm: 0.92 (3H, I, J = 7 Hz), 1.1 1 , 1.27 (3H, two d, J = 8 Hz), 1.3- 2.7 (m), 3.2-3.8 (m), 4.19 (m). 4.4-4.6 (m), 5.09 (d, J = 5 Hz). 6.8-7.15 (4H, m), 7.3-7.6 (3H, m), 7.91 (IH, m). Compound No. 334 'H NMR (CDCl,) δ ppm: 0.85 (3H, t, J = 7 Hz), 1.2-2.5 (m), 3.3-3.6 (m), 4.02 ( IH, m), 5.06 (IH. m), 6.88 (2H, d, J = 8 Hz), 7.04 (2H, d, J = 8 Hz), 7.3-7.6 (3H, m), 7.84 (IH, d, J = 8 Hz). EXAMPLE 21 Preparation of 2,2-dimetiιyl-propionic acid 2-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5- yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5- yl (acetoxymetiιyl ester (compound No. 280) and 2,2-dimetiιyl-propionic acid 2- { 3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro- lH-pyrazolo[ l,2-aJpyridazin-5-yl )-acetoxymethyl ester (compound No. 328) 3,5-hexadienic acid was synthesized by a documented known method [J. Org. Chem., 47, 1789 (1982)] and reacted with 2,2-dimethylpropionic acid iodomethyl ester in accordance witii the method described in Japanese Patent Public Disclosure No. Hei 1-249778, thereby yielding hexa-3,5-dienic acid 2,2-dimethyl-piOpionyloxymethyl ester. This compound had die following NMR spectrum: 'H NMR (CDC1 3 ) δ ppm: 1.28 (9H, s), 3.23 (2H, d, J = 7 Hz), 5.14 (IH, d, J = 10 Hz), 5.24 (IH, d, J = 17 Hz), 5.7-5.9 (2H, m), 5.83 (2H, s), 6.15-6.5 (2H, m). Starting with this diene, the procedure of Example 6 was repeated to yield die titled compounds. They had die following NMR spectra: Compound No. 280 Η NMR (CDCI 3 ) δ ppm: 0.90 (3H, t, J = 7 Hz), 1.17 (9H, s), 1.15-1.6 (4H, m), 1.7-2.2 (4H, m), 2.3-2.55 (2H, m), 2.58 (IH, dd, J = 15 Hz, 9Hz), 2.71 (IH, dd, J = 15 Hz, 5 Hz), 3.00 (IH, t, J = 11 Hz), 3.49 (2H, s), 3.76 (IH, d, J = 11 Hz), 4.7-4.9 (IH, m), 5.65-5.73 (2H, br s), 7.00, 7.06 (each 2H, d, J = 8 Hz), 7.3-7.6 (3H, m), 7.92 (IH, d, J = 8 Hz). Compound No. 328 Η NMR (CDCI 3 ) δ ppm: 0.90 (3H, t, J = 7 Hz), 1.17 (9H, s), 1.2-1.5 (4H, m), 1.75-2.4 (4H, m), 2.3-2.5 (2H, m), 2.58 (IH, dd, J = 15 Hz, 9 Hz). 2.71 (IH, dd, J = 15 Hz, 7 Hz). 3.01 ( IH, dt, J = 1 1 Hz, 3 Hz), 3.50 (2H, s), 4.78 (IH, d, J = 1 1 Hz), 4.7-4.85 (IH, m), 5.67, 5.70 (each IH, d, J = 5 Hz), 7.03, 7.10 (each 2H, d, J = 8 Hz), 7.35-7.6 (3H, m), 7.95 (IH, d, J = 7 Hz). EXAMPLE 22 Preparation of f l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl |- 5,6,7,8-tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl } -acetic acid 2-isopropyl-5- methyl-cyclohexyl ester (compound No. 283) and ( 3-butyl-l-oxo-2-f2'-(lH- tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6J,8-tetrahydro- lH-pyrazolo[ l,2- a]pyridazin-5-yl)-acetic acid 2-isopropyl-5-metiιyl-cyclohexyl ester (compound No. 331) 3,5-hexadienic acid (580 mg, 5.17 mmol)was dissolved in ethyl acetate (5 ml). To the resulting solution, dicyclohexylcarbodiimide (1.28 g, 6.20 mmol) and L-(-)-menthol were added and the mixture was stirred at room temperature for 2 h. The reaction mixture was filtered to remove the insoluble matter and d e filtrate was diluted witii etiiyl acetate. After washing witii a saturated aqueous solution of sodium hydrogencarbonate and a saturated aqueous solution of sodium chloride, die dilution was dried with anhydrous sodium sulfate. The solvent was distilled off under vacuum and die remainder was purified by silica gel column chromatography (solvent system:hexane/ethyl acetate = 50/1) to give hexa-3,5-dienic acid 2-isopropyl-5-metiιyl- cyclohexyl ester (343 mg) as a colorless oil. It had the following NMR spectrum: 'H NMR (CDCl,) δ ppm: 0.75 (3H, d, J = 7 Hz), 0.8-1.2 (8H, m), 1.25-1.6 (3H, in), 1.6-1.75 (2H, m), 1.75-1.94 (IH, m), 1.94-2.05 (IH, m), 3.10 (2H, d, J = 8 Hz), 4.69 ( IH, dt. J = 10 Hz, 4 Hz), 5.06 (IH, d, J = 1 1 Hz), 5.16 (IH, d, J = 16 Hz), 5.7-5.9 (IH, m), 6.14 (IH, dd, J = 15 Hz, 1 1 Hz), 6.25-6.5 (IH, m). Starting with this diene, the procedure of Example 6 was repeated to yield die titled compounds. They had the following NMR spectra: Compound No. 283 'H NMR (CDC1 3 ) δ ppm: 0.71 (3H, d, J = 7 Hz), 0.7-1.2 (11H, m), 1.2-1.55 (7H, m). 1.55- 1.75 (2H, m), 1.75-2.2 (6H, m), 2.3-2.55 (2H, m), 2.55 (IH, dd, J -= 15 Hz, 1 1 Hz), 2.65 (IH, dd, J = 15 Hz, 5 Hz), 2.99 (IH, t, J = 1 1 Hz), 3.3-3.6 (2H, br s), 3.79 (IH, d, J = 1 1 Hz), 4.65 (IH, dt, J = 1 1 Hz, 4 Hz), 4.75-4.9 (IH, m), 6.9-7.2 (4H, m), 7.35-7.6 (3H, m), 7.85-8.05 (IH, br s). Compound No. 331 1H NMR (CDC1 3 ) δ ppm: 0.73 (3H, d, J = 7 Hz), 0.75-1.15 (11H, m), 1.15-1.55 (7H, m), 1.55-1.75 (2H, m), 1.75-2.2 (6H, m), 2.3-2.55 (2H, m), 2.53 (IH, dd, J = 15 Hz, 1 1 Hz), 2.65 (IH, dd, J *•* -* 15 Hz, 4 Hz), 3.01 (IH, t, J = 11 Hz), 3.3-3.6 (2H, m), 3.78 (IH, d, J = 1 1 Hz), 4.67 (IH, dt, J = 11 Hz, 4 Hz), 4.7-4.9 (IH, m), 6.98, 7.02 (each 2H, d, J = 8 Hz), 7.3-7.6 (3H, m), 7.86 (IH, d, J -= 8 Hz). EXAMPLE 23 Preparation of 8-acetyl-3-butyl-5-methyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylrnethy]]-5,6,7,8-tetrahydro-3H-pyrazolo[ 1 ,2-a]-pyridazin- 1 -one (compound No. Starting w t , - epta en- -one, the procedures o xamples 1 and 6 were repeated to yield the titled compound. It had the following NMR spectrum: 1H NMR (CDCI3) δ ppm: 0.87 (3H, t, J = 6.9 Hz), 1.05 (3H, d, J = 7.0 Hz), 1.26-1.46 (6H, m), 1.97 (3H, s), 2.20-2.31 (2H, m), 2.55-2.72 (2H, m), 3.50-3.68 (2H, m), 4.10-4.15 (IH, m), 4.93-4.98 (IH, m), 6.98-7.07 (4H, m), 7.39-7.57 (3H, m), 7.84 (IH, d, J = 1.1 Hz). EXAMPLE 24 Preparation of 2-{l-butyl-8-mcthyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl)-5,6,7,8-tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-ylmethyl}-malonic acid dietiiyl ester (compound No. 289) and 2-{3-butyl-8-methyl-l-oxo-2-f2'-(lH- tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6,7,8-tetrahydro-3H-pyrazolo[l,2- a]pyridazin-5-ylmethyl}-malonic acid dietiiyl ester (compound No. 340) Sodium hydride (60% in mineral oil, 0.75 g) was added to an anhydrous tetrahydrofuran solution (40 ml) of dietiiyl malonate (3.0 g) under cooling witii ice and die mixture was stirred for 10 min. To the suspension, 2E,4E-hexadienylbromide (2.0 g) was added and the mixture was stirred at room temperature for 2.5 h. A saturated aqueous solution of ammonium chloride was added to die mixture under cooling witii ice and die resulting mixture was subjected to extraction with ethyl acetate. The organic layer was washed with water and a saturated aqueous solution of sodium chloride, followed by drying with anhydrous sodium sulfate. The solvent was distilled off under vacuum and die resulting residue was purified by silica gel column chromatography (solvent system:ethyl acetate/hexane = 1/25), giving dietiiyl 2E.4E- hexadienylmalonate (1.49 g, 50%) as a colorless oil. This compound had tlie following NMR spectrum: Η NMR (CDCl,) δ ppm: 1.26 (6H, t, J = 7.2 Hz), 1.72 (3H, d, J = 7.0 Hz), 2.64 (2H, dd, J = 1.1, 1.1 Hz), 3.38 (IH, I, J = 7.4 Hz), 4.20 (4H, q, J = 7.2 Hz), 5.40-5.68 (2H, m), 5.93- 6.14 (2H, m). Starting with this diene, the procedures of Examples 1 and 6 were repeated to yield the titled compounds. They had the following NMR spectrum: Compound No. 289 NMR (CDCl,) δ ppm: 0.92 (3H, t, J = 7.2 Hz), 1.19 (3H, d, J = 7.0 Hz), 1.25 (6H, t. J = 7.2 Hz), 1.33-1.49 (4H, m), 1.78-2.09 (4H, m), 2.24-2.43 (2H, m), 2.50-2.63 (IH, m), 2.71-2.84 (IH, m), 3.44-3.64 (2H, m), 3.83-3.88 (IH, m), 4.00-4.06 (2H, m), 4.09-4.27 (4H, m), 6.97-7.12 (4H, m), 7.40-7.56 (3H, m), 7.92-7.99 (IH, m). Compound No. 340 'H NMR (CDCl,) δ ppm: 0.88 (3H, t, J = 6.9 Hz), 1.23-1.42 (10H, m), 1.62 (3H, d, J = 6.5 Hz), 1.68-2.19 (6H, m), 2.33-2.56 (2H, m), 3.24 (IH, dd, J = 5.0, 9.9 Hz), 3.37-3.50 (2H, m), 3.77-3.85 (IH, m), 4.00-4.10 (IH, m), 4.15-4.27 (4H, m), 6.96-7.05 (4H, m), 7.39-7.56 (3H, m), 7.84 (IH, d, J = 7.3 Hz). EXAMPLE 25 Preparation of 2-{ l-butyI-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl |- 5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl}-3-phenyl-propionic acid ediyl ester (compound No. 292) Diisopropylamine (7.95 g, 0.0786 mol) was dissolved in anhydrous tetrahydrofuran ( 1(H ) ml) and d e mixture was stirred under cooling witii ice in a nitrogen stream while a 1.6 M hcxane solution of n-butyl lithium as diluted with hexanc (40 ml) was added dropwise. The reaction temperature was lowered to -78°C and hexamediylphosphoric amide (16.6 g, 0.0877 mol) was added dropwise, followed by stirring for 10 min. Thereafter, ethyl sorbate (10.0 g, 0.0713 mmol) was added dropwise, followed by stirring for 1 h. Benzyl bromide (13.4 g, 0.0783 mol) was added dropwise. Following stirring for 20 min, a saturated aqueous solution of ammonium chloride was added to quench tlie reaction. The reaction solution was subjected to extraction with dietiiyl ether and the separating ether layer was washed with a saturated aqueous solution of sodium chloride and dried with anhydrous sodium sulfate. The solvent was distilled off under vacuum and the remainder was distilled under vacuum to give 2- bcnzyl-hexa-3.5-dienic acid ediyl ester (12.5 g, 78.3%; b.p. 130-133°C/5 mmHg) as a pale yellow liquid substance. It had die following NMR spectrum: 'H NMR (CDCl,) δ ppm: 1.15 (3H, t, J = 7 Hz), 2.85 (IH, dd, J = 13 Hz), 3.08 (IH, dd, J = 13 Hz, 8 Hz), 3.33 (IH, q, J = 8 Hz), 4.09 (2H, q, J = 17 Hz), 5.05 (IH, d, J = 10 Hz), 5.14 (IH, d, J = 17 Hz), 5.73 (IH, dd, J = 15 Hz, 8 Hz), 6.08 (IH, dd, J = 15 Hz, 10 Hz), 6.29 ( IH, dt, J = 17 Hz, 10 Hz). 7.05-7.35 (5H, m). Starting with this diene, the procedure of Example 6 was repeated to prepare die tided compound. It had the following NMR spectra: 'H NMR (CDCl,) δ ppm: 0.75-0.95 (6H, m), 1.15-1.5 (4H, m), 1.55-1.95 (2H, m), 1.95-2.25 (2H. m), 2.25-2.55 (2H, m), 2.71 (IH, dd, J = 14 Hz, 4 Hz), 2.86, 2.95 (each IH, d, J = 14 Hz), 3.1-3.3 (IH, m), 3.40, 3.49 (each IH, d, J = 15 Hz), 3.6-3.9 (3H, m), 4.6-4.75 (IH, m), 6.95, 7.00 (each 2H, d, J = 9 Hz), 7.0-7.55 (8H, m), 7.77 (IH, d, J = 8 Hz). EXAMPLE 26 Preparation of 2-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]- 5,6J,8-tetrahydro-3H-pyrazolof l,2-a]-pyridazin-5-yl}-2-methylpropionic acid ethyl ester (compound No. 295) and 2-{ 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl}-2- methylpropionic acid etiiyl ester (compound No. 319) A 1.6 M n-butyl litiiium solution (69 ml) in hexane was added lo a dry tetraliydroluran solution (200 ml) of diisopropylamine (1 1.13 g) in a nitrogen atmosphere. The resulting reaction solution was cooled lo -78°C, hexamethyl phosphorylamide (HMPA, 23.3 g) was added and the mixture was stirred for 30 min to prepare a lithium diisopropylamide (LDA) - HMPA solution. Ethyl sorbate (14 g) was added dropwise to die LDA - HMPA solution at -78°C and, following stirring for 1.5 h, methyl iodide (21.3 g) was added dropwise. The reaction temperature was raised to room temperature. After stirring for 1.5 h, the reaction solution was poured into a liquid mixture of acetic acid (18.0 g) and water (360 ml) under vigorous agitation. Following tiiree extractions with pentane (200 ml), the organic layer was washed successively with water, 1 N sodium hydrogencarbonate and a saturated aqueous solution of sodium chloride (each 200 ml) and then dried witii anhydrous magnesium sulfate. After filtration, the filtrate was concentrated under vacuum to give 2-methyl-3,5-hexadienic acid etiiyl ester (1 1.5 g). This ester (15.4 g) was reacted again witii LDA-HMPA, then witii methyl iodide, thereby giving a crude product. The product was purified by distillation under vacuum to give 2,2'-dimethyl-3.5- hexadienic acid ethyl ester (14.26 g; b.p. 76°C/5 mmHg). Starting with this diene, the procedure of Example 1 was repeated to produce 2-f 1- butyl-3-oxo-2-f2'-(triphenylmethyl-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-3H- pyrazolof l,2-a]pyridazin-5-yl(-2-methylpropionic acid ediyl ester and a regio-isomer thereof in respective yields of 50%) and 18%). These two Diels-Alder adducts were reduced and deprotected by die same procedure as in Example 6, giving tided compound No. 295 (yield, 75%) and its regio-isomer compound No. 319 (yield, 53%)). These compounds had die following NMR spectra: Compound 295 Η NMR (CDCl,) δ ppm: 0.88 (3H, t, J = 7.3 Hz), 1.14 (3H, t, J = 7.3 Hz), 1.18-1.46 (4H, m), 1.68-2.17 (4H, m), 2.32-2.50 (2H, m), 2.76 (IH, dd, J = 7.8, 10.8 Hz), 3.50 (2H, br s), 3.72 (IH, br d, J = 10.8 Hz), 4.1 1 (2H, q, J = 7.3 Hz), 4.74 (IH, d, J = 5.9 Hz), 6.97 (4H, br s), 7.37-7.55 (3H, m), 7.78 (IH, d, J = 6.8 Hz). Compound 319 Η NMR (CDCl,) δ ppm: 0.89 (3H, t, J = 7.3 Hz), 1.05 (3H, t, J = 7.3 Hz), 1.08-1.45 (4H, m), 1.75-2.20 (4H, m), 2.36-2.49 (2H, m), 2.75 (IH, dd, J = 7.8, 10.8 Hz), 3.57 (2H, br s), 3.72 (IH, br d, J = 10.8 Hz), 4.09 (2H, q, J = 7.3 Hz), 4.74 (IH, d, J = 5.9 Hz), 7.00 (4H, br s). 7.38-7.56 (3H, m), 7.86 (IH, br s). EXAMPLE 27 Preparation of 2-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl)-2-ethyl-butyric acid etiiyl ester (compound No. 298) and 2-{ 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)- biphenyl* -ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl ) -2- etliyl-butyric acid ediyl esier (compound No. 325) Etiiyl sorbate ( 14.0 g) was treated first witii LDA-HMPA. then witii etiiyl iodide by the same procedure as in Example 26, yielding 2,2'-dietlιyl-3,5-hexadienic acid etiiyl ester (7.0 g; b.p. 83°C/5 mmHg). Starting with this diene, the procedures of Examples 1 and 6 were repeated to produce titled compound No. 298 and its regio-isomer compound No. 325. These compounds had the following NMR spectra: Compound No. 298 'H NMR (CDCl,) δ ppm: 0.68 (3H, t, J = 7.3 Hz), 0.86 (6H, t, J = 7.3 Hz), 1.15 (3H, t, J = 7.3 Hz), 1.21-1.84 (12H, m), 2.38-2.53 (2H, m), 2.85 (IH, m), 3.51-3.65 (3H, m), 4.16 (2H, m). 4.62 ( IH, br d), 7.01-7.13 (4H, m), 7.41-7.65 (3H, m), 7.91 (br s). Compound No. 325 'H NMR (CDCl,) δ ppm: 0.78 (3H, I, J = 7.3 Hz), 0.92 (6H, t, J = 7.3 Hz). 1.17 (3H. t. J = 7.3 Hz), 1.23-2.20 (12H, m), 2.30-2.52 (2H, m), 2.71 (IH, dd, J = 7.8, 10.8 Hz), 3.60 (2H, br s), 3.70 (IH, m), 4.20 (2H, m), 4.62 (IH, d, J = 5.9 Hz), 7.00-7.14 (4H, m). 7.40-7.58 (3H, m). 7.93 ( IH, br s). EXAMPLE 28 Preparation of l-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]- 5,6,7,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl( -cyclohexanecarboxylic acid etiiyl ester (compound No. 301) and l-{3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5 , 6,7, 8-tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-yl ) - cyclohexanecarboxylic acid ethyl ester (compound No. 337) Diisopropylamine (7.95 g, 0.0786 mol) was dissolved in anhydrous tetrahydroluran ( 1(K) ml) and die solution was stirred under cooling witii ice in a nitrogen stream. To the stirred solution, a 1.6 M n-butyl lithium solution in hexane as diluted with liexane (40 ml) was added dropwise. The reaction temperature was lowered to -78°C and hexamethyl phosphorylamidc ( 16.6 g, 0.0877 mol) was added dropwise and the mixture was stirred for 10 min. Thereafter, ethyl sorbate (10.0 g, 0.071 mmol) was added dropwise and the mixture was stirred for I h. Then 1 ,5-dibromopentane ( 18.1 g, 0.0787 mol) was added dropwise and, following stirring for 30 min, the reaction temperature was raised to -15°C. Alter stirring at -15°C for 1.5 h, the mixture was further stirred at 0°C for 30 min. A saturated solution of ammonium chloride was added to die reaction solution to quench die reaction, followed by extraction with diethyl etiier. The separating etiier layer was washed with a saturated aqueous solution of sodium chloride and dried with anhydrous sodium sulfate. The solvent was distilled off under vacuum, giving 2-(5- bromopentyl)-hexa-3,5-dienic acid etiiyl ester. Di isopropyl amine (7.95 g, 0.0786 mol) was dissolved in anhydrous tetrahydrofuran ( 1(X) ml) and d e solution was stirred under cooling with ice in a nitrogen stream. To the stirred solution, a 1.6 M n-butyl lithium solution in hexane as diluted witii hexane (40 ml) was added dropwise. The reaction temperature was lowered to -78°C and hexamethyl phosphorylamidc (16.6 g, 0.0877 mol) was added dropwise and the mixture was stirred for 10 min. Thereafter, the previously prepared 2-(5-bromopentyl)-hexa-3,5-dienic acid ethyl ester was dissolved in anhydrous tetrahydrofuran and die resulting solution was added dropwise to the mixture. Following stirring for 30 min, the reaction temperature was raised to -15°C and die mixture was stirred for 1.5 h at that temperature, then at 0°C for 30 min. A saturated solution of ammonium chloride was added to the reaction solution lo quench the reaction, followed by extraction with diethyl etiier. The separating etiier layer was washed with a saturated aqueous solution of sodium chloride and dried witii anhydrous sodium sulfate. The solvent was distilled off under vacuum and the remainder was distilled under vacuum to give l-buta-l,3-dienyl- cyclohexanecarboxylic acid etiiyl ester (3.1 g, 20.8%; b.p. 100°C/8 mmHg) as a pale yellow liquid substance. It had die following NMR spectrum: 'H NMR (CDCl,) δ ppm: 1.25 (3H, t, J = 7 Hz), 1.2- 1.7 (8H, m), 2.0-2.2 (2H, m), 4.14 (2H, q, J = 7 Hz), 5.05 (IH, d, J = 10 Hz), 5.16 (IH, d, J = 17 Hz), 5.65 (IH, d, J = 15 Hz), 6.10 (IH, dd, J = 15 Hz, 10 Hz), 6.30 (IH, dt, J = 17 Hz, 10 Hz). Starting with this diene, the procedure of Example 6 was repeated to yield d e titled compounds. They had die following NMR spectra: Compound No. 301 'H NMR (CDC1 3 ) δ ppm: 0.89 (3H, t, J = 7 Hz), 1.21 (3H, t, J = 7 Hz), 0.95-1.8 (12H, m), 1.95-2.3 (6H, m), 2.3-2.6 (2H, m), 2.67 (IH, t, J = 10 Hz), 3.51, 3.59 (each IH, cl, J = 16 Hz), 3.71 (IH, d. J = 10 Hz), 3.9-4.3 (2H, m), 4.47 (IH. d, J = 6 Hz), 7.01, 7.07 (each 2H, d. J = 9 Hz), 7.35-7.65 (3H, m), 7.89 (IH, d, J = 6 Hz). Compound No. 337 Η NMR (CDCI 3 ) δ ppm: 0.90 (3H, t, J = 7 Hz), 0.95- 1.85 (15H, m), 2.0-2.7 (8H, m). 2.67 (IH, t, J = 1 1 Hz), 3.4-3.85 (3H, m), 3.9-4.3 (2H, m). 4.48 (IH, d, J = 6 Hz), 7.04, 7.1 1 (each 2H, d, J = 8 Hz), 7.35-7.65 (3H, m), 7.96 (IH, d. J = 8 Hz). EXAMPLE 29 Preparation of 1-f l-buty]-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl)- 5,6J,8-tetrahydro-3H-pyrazolo[ l ,2-a]pyridazin-5-yl )-cyclopentanecarboxylic acid ethyl esier (compound No. 304) Starting with 1 ,4-dibromobutane, the procedure of Example 28 was repeated to form 2- (4-bromobutyl)-hexa-3,5-dienic acid ethyl ester as an intermediate, from which l-buta-1 ,3- dienyl-cyclopentanecarboxylic acid ethyl ester (b.p. 90-93°C/5 mmHg) was prepared. This compound had die following NMR spectrum: Η NMR (CDCl,) δ ppm: 1.25 (3H, t, J = 7 Hz), 1.5-1.85 (6H, m), 2.1-2.3 (2H, m), 4.14 (2H, q, J = 7 Hz), 5.04 (IH, d, J = 10 Hz), 5.16 (IH, d, J = 17 Hz), 5.86 (IH, d, J = 16 Hz), 6.1 1 (IH, dd, J = 16 Hz, 5 Hz), 6.32 (IH, dt, J = 17 Hz, 10 Hz). Starting with this diene, the procedure of Example 6 was repeated to yield die titled compound. It had die following NRM spectrum: 'H NMR (CDCl,) δ ppm: 0.91 (3H, t, J = 8 Hz), 1.22 (3H, t, J = 7 Hz), 1.2-2.3 (16H, 111), 2.3-2.6 (2H, m), 2.75 (IH, t, J = 9 Hz), 3.5-3.7 (2H, m), 3.7-3.9 (IH, m), 3.9-4.25 (2H, m), 4.87 (IH, d, J = 6 Hz). 7.07, 7.14 (each 2H, d, J = 8 Hz), 7.3-7.65 (3H, m), 8.00 (IH, d, J = 7 Hz). EXAMPLE 30 Preparation of 2-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 3,6,7,8-tetrahydro-5,8-ethano-pyrazolo( 1 ,2-a]pyridazin-5-yl } -2-methyl-ρropionic acid ethyl ester (compound No. 307) and 2-{ 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5- yl)-biphenyl-4-ylmethyl]-3,6,7,8-tetrahydro-5,8-ethano-pyrazolof l,2-a]pyridazin- 5-yl }-2-methyl-propionic acid etiiyl ester (compound No. 352) 2-cyclohexen-l-one (10 g) was dissolved in toluene (50 ml). To tlie resulting solution, carboethoxymethylene triphenyl phosphoran (36.24 g) was added and d e mixture was refluxed under heating for 48 h. the reaction mixture was cooled to room temperature and hexane (100 ml) was added, witii tlie resulting precipitate being then filtered off. The filtrate was distilled under vacuum (ca. 10 mmHg) at 100°C, thereby distilling off the solvent. The residue which was a brown oil was fractionally purified by silica gel column chromatography (solvent system:ethyl acetate/hexane = 5/95) to give cyclohexen-2-ethylidene acetic acid etiiyl ester (8.47 g; yield = 47%). This ester (2.44 g) was added to an LDA (1.1 eq.)-HMPA (1.3 eq.) solution that had been prepared by the same method as in Example 26. The mixture was stirred at -78°C for 1 h and, after adding methyl iodide (2.30 g, 1.1 eq.), stirring was continued for an additional 1 h. To die reaction mixture, a separately prepared LDA-HMPA solution was added and, after stirring for 1 h, methyl iodide (3.13 g, 1.5 eq.) was added. The reaction mixture was stirred first at -78°C for 1 h, then at room temperature for 30 min. A saturated aqueous solution of ammonium chloride (100 ml) was added lo quench the reaction and, diereafter, extraction was conducted three times with pentane (100 ml). The organic layer was washed witii a saturated aqueous solution of sodium chloride and dried witii anhydrous magnesium sulfate. After filtration, the filtrate was concentrated under vacuum and die resulting residue was fractionally purified by silica gel column chromatography (solvent system:ethyl acetate/hexane = 5/95), producing 2-(l,3-cyclohexadienyl)-propionic acid etiiyl ester (2.58 g; yield = 100%). Starting with this ester, the procedures of Examples 1 and 6 were repeated to yield titled compound No. 307 and its regio-isomer compound No. 352. These compounds had die following NMR spectra: Compound No. 307 Η NMR (CDC1 3 ) δ ppm: 0.87 (3H, t, J -**-* 7.3 Hz), 1.12 (3H, t, J = 7.3 Hz). 1.15-1.34 (4H, m), 1.39 (6H, s), 1.89-1.95 (8H, m), 2.43 (2H, t, J = 7.3 Hz), 3.46 (2H, br s), 4.03 (2H, q, J = 7.3 Hz), 4.25 (IH, br s), 6.97 (4H, br s), 7.38-7.55 (3H, m), 7.93 (IH, d, J = 7.8 Hz). Compound No. 352 'H NMR (CDCl,) δ ppm: 0.86 (3H, t, J = 7.3 Hz), 1.12 (3H, t, J = 7.3 Hz), 1.13-1.38 (4H, m), 1.31 (6H, s), 1.91-2.65 (10H, m), 3.69 (2H, s), 3.98 (2H, q, .1 = 7.3 Hz), 5.57 ( I H. br s), 7.06 (2H, d, J = 8.4 Hz), 7.26 (2H, d, J = 8.4 Hz), 7.38-7.59 (3H, m), 8.04 ( IH, d, J = 6.5 Hz). EXAMPLE 31 Preparation of l -buty]-8-metiιyl-3-oxo-2-[2'-(l H-tetrazol-5-yl)-biphenyl-4- ylmethyll-5,6,7,8-tetrahydro-3H-pyrazolo[ 1 ,2-aJpyridazin-5-carboxylic acid diethyl amide (compound No. 161) and 3-butyl-8-methyl- l-oxo-2-[2'-(l H- tetrazol-5-yl)-biphenyl-4-ylmethyI]-5,6J,8-tetrahydro- lH-pyrazolol l,2- aJpyridazin-5-carboxylic acid diethyl amide (compound No. 355) Starting with sorbic acid dietiiylamide, die procedure of Example 6 was repeated to yield the titled compounds. They had die following NMR spectra: Compound No. 161 Η NMR (CDCl,) δ ppm: 0.89 (3H, t, J = 7 Hz). 1.08 (3H, t, J = 7 Hz), 1.19 (3H, t, J = 7 Hz), 1.32 (3H, d, J = 6 Hz), 1.1-1.6 (4H, m), 1.8-2.2 (4H, m), 2.2-2.6 (2H, m), 3.1-3.7 (6H, m), 4.05-4.25 (IH, m), 4.62 (IH, q, J = 5 Hz), 6.8-7.1 (4H, m), 7.35-7.6 (3H, m), 7.8-7.95 (IH, m). Compound No. 355 Η NMR (CDCl,) δ ppm: 0.88 (3H, t, J = 7 Hz), 1.14 (3H, t, J = 7 Hz), 1.27 (3H, t, J = 7 Hz), 1.41 (3H, d, J = 6 Hz), 1.0-1.5 (4H, m), 1.6-2.2 (4H, ), 2.2-2.35 (2H, m), 3.2-3.7 (6H, m), 4.32 (IH, q, J = 6 Hz), 4.60 (IH, t, J = 6 Hz), 6.94, 7.02 (each 2H, d. J = 8 Hz), 7.3- 7.6 (3H, m), 7.82 (IH, d, J = 7 Hz). EXAMPLE 32 Preparation of 1-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιylJ- 5,6,7,8-tetrahydro-3H-pyrazolo[ 1.2-a]pyridazin-5-yl (-cyclopropanecarboxyhc acid etiiyl ester (compound No. 358) Starting with 1,2-dibromoethane, the procedure of Example 28 was repeated to form 2- (2-bromoethyl)-hexa-3,5-dienic acid ethyl ester, from which l-buta-l ,3-dienyl- cyclopropanecarboxylic acid ethyl ester (b.p. 80°C/7 mmHg) was prepared. This compound had the following NMR spectrum: 'H NMR (CDCl,) δ ppm: 1.02-1.1 1 (2H, m), 1.26 (3H, t. J = 7 Hz), 1.45-1.55 (2H, m), 4.15 (2H, q, J = 7 Hz), 5.02 (IH, d, J = 5 Hz), 5.12 ( IH, d, J = 17 Hz), 5.90 ( IH, dd, J = 16 Hz, 10 Hz), 6.25-6.45 (2H, m). Starting with this diene, the procedure of Example 6 was repeated to yield the titled compound. It had die following NMR spectrum: Η NMR (CDCl,) δ ppm: 0.25-0.45 ( IH, m), 0.7-0.95 (2H, m), 0.88 (3H, t, J = 7 Hz), 1.0-1.15 (IH, m), 1.15-1.55 (4H, ), 1.22 (3H, t, J = 7 Hz), 1.65-2.0 (2H, m). 2.05-2.6 (2H, m), 2.90 (IH, t, J = 1 1 Hz), 3.35-3.6 (2H, m), 3.65-3.85 ( IH, m), 4.0-4.25 (2H, m), 5.1 1 (I H, d, J = 4 Hz), 7.00 (4H, d, J = 4 Hz), 7.35-7.60 (3H, m), 7.8-7.95 (IH, m). EXAMPLE 33 Preparation of l-( 3-oxo- l-propyl-2-[2'-(lH-tetrazol-5-yl)-hiphenyl-4-ylmethyI |- 5,6,7,8-tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid ethyl ester (compound No. 300) Starting witii 3-propyl-2-f2'-(N-triphenylmethyl-tetrazol-5-yl)-biphenyl-4-ylmethyl |- pyrazolo-1-one and l-buta-l,3-dienyl-cyclohexanecarboxylic acid etiiyl ester, the procedure of Example 6 was repeated to yield the titled compound. It had die following NMR spectrum: Η NMR (CDC1 3 ) δ ppm: 0.92 (3H, t, J = 7 Hz), 1.21 (3H, t, J = 7 Hz), 0.9-1.35 (2H, m), 1.4-1.8 (8H, m), 2.0-2.28 (6H, m), 2.28-2.55 (2H, m), 2.67 (IH, t, J = 1 1 Hz), 3.50, 3.57 (each IH, d, J = 16 Hz), 3.71 (IH, d, J = 10 Hz), 3.9-4.25 (2H, ), 4.46 (IH, d, J = 6 Hz), 6.98, 7.02 (each 2H, d, J = 8 Hz), 7.35-7.6 (3H, m), 7.81 ( IH, d, J = 6 Hz). EXAMPLE 34 Preparation of 1-f l-butyl-3-oxo-2f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl|- 5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid (compound No. 394) l-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl-5,6,7,8-tetrahydro-3H- pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid etiiyl ester (compound No. 301) (303 mg, 0.52 mmol) prepared in Example 28 was dissolved in methyl cellosolve (5 ml) and the solution was refluxed under heating with 3N sodium hydroxide (2 ml). After the solvent was concentrated under vacuum, pH was adjusted to 2 by adding 10% HCl. The resulting white solid was extracted witii methylene chloride. The extract was dried with anhydrous sodium sulfate and distilled off under vacuum. The resulting residue was fractionally purified by silica gel column chromatography (solvent system :methanol/chloroform = 1/100-1/25), producing the titled compound (130 mg; yield = 45%). It had the following NMR spectrum: 'H NMR (CDCl,) δ ppm: 0.83 (3H, s), 1.0-2.5 (20H, ), 2.84 (IH, m), 3.48 (IH, d, J = 16 Hz), 3.62 (IH, d, J = 16 Hz), 4.69 (IH, d, J = 7 Hz), 6.95 (2H, d, J = 8 Hz), 7.01 (2H, d. J = 8 Hz), 7.35-7.6 (3H, m), 7.87 (IH, d, J = 8 Hz). EXAMPLE 35 Preparation of 3-butyl-8-isopropyl-5-methyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-5,8-ethano-pyrazolof 1 ,2-aJpyridazin- 1 -one (compound No. 388) 4-Methylbenzylcyanide (20 g) was dissolved in dimethylformamide (250 ml), and methyl iodide (47.5 g) was added to the solution. The resulting reaction solution was cooled to -20°C and, following the addition of potassium t-butoxide (37.5 g), the reaction temperature was raised to room temperature and the mixture was further stirred overnight. To the reaction mixture, 1 M potassium hydrogensulfate was added to have its pH adjusted to 4, followed by three extractions witii dichloromethane (100 ml). The organic layers were combined, washed with a saturated NaCl solution (30 ml) five times, and dried with anhydrous magnesium sulfate. After filtration, tlie filtrate was concentrated under vacuum and the resulting residue was subjected to silica gel column chromatography (ethyl acetate/hexane = 5/95) to yield 2-mcthyl-2- p-tolyl-propionitrile in an amount of 21.3 g (yield: 88%)). The nitrile (10 g) was subjected to the Birch reduction witii documented known litiiium- cdiylamine-ethyl alcohol [J. Org. Chem., .38 ( 1 1 ), 201 1 (1973)] to yield l-methyl-4-isopropyl- cyclohexa-l,4-diene in an amount of 9.6 g (purity: 80%). A portion (5 g) of the 1,4-diene was dissolved in dimethyl sulfoxide (20 ml) and potassium t-butoxide (6.6 g) was added to die solution under cooling with ice. The reaction mixture was stirred at room temperature for 1 h and, thereafter, it was diluted with water (100 ml) and subjected to three extractions with pentane (30 ml). The organic layers were combined, washed witii a saturated NaCl solution (20 ml) four times and dried with anhydrous magnesium sulfate. After filtration, the filtrate was concentrate under vacuum and die resulting residue was subjected to silica gel column chromatography (ethyl acetate/hexan = 5/95) to yield l-methyl-4-isopropyl-cyclohexa-l,3-dienc in an amount of 3.7 g (purity: 48%)). Starting from the 1,3-diene, the procedure of Example 6 was repeated, giving the titled compound. This compound had die following NMR spectrum: 'H NMR (CDCI 3 ) δ ppm: 0.87 (3H, t, J = 7 Hz), 0.89 (6H, d, J = 7 Hz), 1.21-2.00 (12H, m), 1.58 (3H, s), 2.55 (2H, t, J = 7 Hz). 3.43 (IH, m), 3.47 (2H, br s), 6.97 (4H, s), 7.22- 7.55 (3H, m), 7.82 (IH, d, J = 7 Hz). EXAMPLE 36 Preparation of 3-butyl-5,8-dimetiιyl-2-f [2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl J-amino) -5,6,7, 8-tetrahydro-5,8-ethano-pyrazolo[ l,2-a]pyridazin-l -one (compound No. 400) Starting from 3-oxoheptanoic acid etiiyl ester, the procedure of Example 1 was repeated to perform reaction, first with hydrazine monohydrate, then with lead tetraacetate in the presence of l,4-dimethylcyclohexa-l,3-diene, yielding a Diels-Alder adduct, 3-butyl-5,8-dimethyl-5,8- dihydro-5,8-etiιano-pyrazolo| 1 ,2-aJpyridazin- 1 -one. The adduct (1 g) was subjected to catalytic reduction in metiianol (20 ml) at atmospheric pressure in the presence of 5% palladium/carbon as a catalyst. After filtering off die catalyst, the filtrate was concentrated under vacuum and die resulting residue was fractionally purified by silica gel column chromatography (solvent system: chloroform/metiianol = 50/1 - 20/1), yielding 3-butyl-5,8-dimethyl-5,6,7,8-tctrahydro-5,8-etiιano-pyrazolo| 1,2-aJpyridazin-l-one in an amount of 0.74 g (yield: 14%). This compound (0.64 g) was dissolved in 10% HCl (4 ml) and acetic acid (2 ml); followed by dropwise addition of a solution that had sodium nitrite (160 mg) dissolved in water ( 1 ml) al -10°C, die solution mixture was stirred at -10°C for 1 h. The reaction solution was neutralized with saturated sodium hydrogencarbonate, diluted with water and extracted with methylene chloride. The methylene chloride layer was dried witii anhydrous sodium sulfate. After filtration, the filtrate was concentrated under vacuum to yield 3-butyl-5,8-dimethyl-2- nitroso-5,6,7,8-tetrahydro-5,8-ethano-pyrazolo[ l,2-a]pyridazin-l-one as a crude product. The crude product was reduced catalytically in methanol (20 ml) at atmospheric pressure for 1.5 h in the presence of 5% palladium/carbon (50 mg) as a catalyst. After filtering off die catalyst, the filtrate was concentrated under vacuum to yield 2-amino-3-butyl-5,8-dimethyl- 5.6,7,8-tetrahydro-5,8-ethano-pyrazolo| l,2-a]pyridazin-l-one as a crude product. This crude product was mixed with N-triphenylmethyl-5-|2-(4'- bromomethylbiphenylyl)]tetrazole (1.11 g) in dimethylformamide (12 ml) under stirring at room temperature for 2.5 h in the presence of potassium carbonate (535 mg). The reaction solution was diluted with ethyl acetate, washed witii water and dried witii anhydrous sodium sulfate. After filtration, the filtrate was concentrated under vacuum and die resulting residue was fractionally purified by silica gel column chromatography (solvent system: chloroform/metiianol = 100/1 - 50/1 - 25/1), yielding the titled compound in an amount of 291 mg (yield: 17%); four steps). This compound had the following NMR spectrum: -H NMR (CDC1 3 ) δ ppm: 0.92 (3H, t, J = 7 Hz), 1.37 (2H, sextet, J = 7 Hz), 1.45-1.95 (10H, m), 2.57 (2H, t, J = 7 Hz), 3.73 (2H, s), 7.16 (4H, s), 7.43-7.60 (3H, m), 8.03 (IH, dd. J = 8, 1 Hz). EXAMPLE 37 Preparation of l-f 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmellιyl]- 5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl) -cyclohexanecarboxylic acid ediyl ester (compound No. 302) and 1-f l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5, 6,1, 8-tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-yl ( - cyclohexanecarboxylic acid etiiyl ester (compound No. 338) Starting witii 3-oxooctanoic acid etiiyl ester, tlie procedure of Example 1 was repeated lo synthesize 3-pentyl-2-[2'-(N-triphenylmethyl-tetrazol-5-yl)-biphenyl-4-ylmethyl 1-pyrazolo- 1 -one. from which tl e titled compounds were prepared by repeating tlie procedure of Example 6. These compounds had die following NMR spectra: Compound No. 302 Η NMR (CDCI 3 ) δ ppm: 0.87 (3H, t, J = 7 HZ), 1.0-1.85 (14H, m), 1.23 (3H, t, J = 7 Hz), 2.0-2.3 (6H, m), 2.3-2.6 (2H, m), 2.6-2.8 (IH, m), 3.61 (2H, b s), 3.65-3.8 (IH, m), 3.95- 4.25 (2H, m), 4.50 (IH, d, J = 6 Hz), 7.07, 7.16 (each 2H, d, J = 8 Hz), 7.35-7.65 (3H, m), 8.02 (IH, d, J = 7 Hz). Compound No. 338 'H NMR (CDCI 3 ) δ ppm: 0.87 (3H, t, J = 7 Hz), 1.0-1.8 (14H, m), 1.22 (3H, t, J = 7 Hz), 2.0-2.3 (6H, m), 2.3-2.6 (2H, m), 3.4-3.8 (3H, m), 3.9-4.3 (2H, m), 4.48 (IH. d, J = 6 Hz) 6.95-7.2 (4H, m), 7.35-7.65 (3H, m), 7.9-8.05 (IH, m). EXAMPLE 38 Preparation of 1-f l-butyl-6-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,8-dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid ethyl ester 4-metiιyl-hexa-2,4-dienoic acid ethyl ester was synthesized by a documented known method [J. Am. Chem. Soc, 106, 3554 (1984)]. Starting from this compound, die procedure of Example 28 was repeated to yield l-(2-methyl-buta- l,3-dienyl)-cyclohexanecarboxylic acid ethyl ester (b.p. 90-100°C/2 mmHg). This compound had die following NMR spectrum: Η NMR (CDCl,) δ ppm: 1.23 (3H, t, J = 7 Hz), 1.3-1.65 (6H, m), 1.65-1.8 (2H, m). 1.7 (3H, s), 1.9-2.1 (2H, ), 4.15 (2H, q, J = 7 Hz), 4.97 (IH, d, J = 14 Hz), 5.12 ( IH, d, J = 17 Hz), 6.25-6.5 (IH, m). Starting from this diene, the procedure of Example 1 was repeated to yield die titled compound, which had the following NMR spectrum. 'H NMR (CDCl,) δ ppm: 0.91 (3H, t, J = 7 Hz), 0.95- 1.8 (12H, m), 1.25 (3H, t, J = 7 Hz). 1.8-2.0 (5H, m), 2.2-2.7 (2H, ), 3.51 , 3.61 (each IH, d, J = 16 Hz), 3.75-3.95 (IH, m), 4.0-4.25 (3H, m), 4.90 ( IH, b s), 5.5-5.7 ( IH, m), 6.85-7.2 (4H, m), 7.3-7.6 (3H, m), 7.92 (IH, d, J = 8 Hz). EXAMPLE 39 Preparation of 1 -f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl)- 5,6,7, 8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl (-4,4-dimethyl- cyclohexanecarboxylic acid ethyl ester (compound No. 370) l,5-dibromo-3,3-dimethylpentane was synthesized by a documented known mediod fChem. Pharm. Bull., 3J3, 5048 (1985)]. Starting from this compound, die procedure of Example 28 wa repeated to yield l-buta-l,3-dienyl-4,4-dimethyl-cyclohexanecarboxylic acid etiiyl ester (b.p. 80- 85°C/3 mmHg). This compound had die following NMR spectrum: 'H NMR (CDC1 3 ) δ ppm: 0.88 (6H, s), 1.24 (3H, t, J = 7 Hz), 1.1-1.4 (4H, m), 1.5-1.7 (2H, m), 2.0-2.2 (2H, m), 4.14 (2H, q, J = 7 Hz), 5.05 (IH, d, J = 9 Hz), 5.17 (IH, d, J = 16 Hz), 5.65 (IH, d, J = 15 Hz), 6.05-6.4 (2H, m). Starting from this diene, the procedure of Example 6 was repeated to yield die tided compound, which had the following NMR spectrum: Η NMR (CDC1 3 ) δ ppm: 0.73, 0.80 (each 3H, s), 0.89 (3H, t, J = 7 Hz), 1.0-1.6 (8H, 111), 1.23 (3H. t, J = 7 Hz), 1.6-1.85 (2H, m), 1.9-2.3 (6H, m), 2.3-2.6 (2H, m), 2.6-2.75 (IH, m), 3.60 (2H, s), 3.65-3.8 (IH, m), 3.95-4.25 (2H, m), 4.56 (IH, d, J = 6 Hz), 7.05, 7.13 (each 2H, d, J = 8 Hz), 7.35-7.6 (3H, m), 7.99 (IH, d, J = 7 Hz). EXAMPLE 40 Preparation of l-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethy]- 5,6,7,8-tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl} -cyclohexanecarboxylic acid butyl ester (compound No. 403) Three grams of l-buta-l,3-dienyl-cyclohexanecarhoxylic acid ediyl ester as prepared by die procedure of Example 28 was dissolved in a solvent system composed of a mixture of mediyl cellosolve (10 ml) and water (4 ml) and reacted with 6 N sodium hydroxide (4 ml) under reflux by heating. The reaction solution was cooled with water and diluted with water, followed by addition of 10%) HCl for pH adjustment to 2. The white solid precipitate was subjected to extraction with methylene chloride and die extract dried with anhydrous sodium sulfate. The solvent was distilled off under vacuum, yielding l-buta-l,3-dienyl- cyclohexanecarboxylic acid (2.74 g) as a crude product. A portion (728 mg) of this crude product was dissolved in dimethylformamide (5 ml). Following the successive addition of potassium t-butoxide (520 mg) and n-butyl bromide (0.60 g), die mixture was stirred first at room temperature for 75 min, then under heating at 60-80°C for 4 h. A saturated ammonium chloride solution was added to the reaction solution and the mixture was subjected to extraction with ethyl acetate. The organic layer was washed witii water and dried with anhydrous sodium sulfate. The solvent was distilled off under vacuum, yielding l-buta-l,3-dienyl-cyclohexanecarboxylic acid butyl ester in an amount of 0.79 g (yield: 83%). Starting from this diene, the procedure of Example 6 was repeated to yield die titled compound, which had the following NMR spectrum: 'H NMR (CDCl,) δ ppm: 0.91 (3H, t, J = 7 Hz), 0.92 (3H, t, J = 7 Hz), 1.0-1.8 (m), 2.0-2.8 (m), 3.57 (IH, d, J = 19 Hz), 3.62 (IH, d, J = 19 Hz), 3.73 (IH, m), 3.9-4.2 (2H, m), 4.49 (IH, d, J = 6.5 Hz), 7.05 (2H, d, J = 8 Hz), 7.12 (2H, d, J = 8 Hz), 7.4-7.6 (3H, m), 7.97 (IH, d, J = 7 Hz). EXAMPLE 41 Preparation of 1-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl)- 5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid t-butyl ester (compound No. 409) Starting from t-butyl sorbate, die procedure of Example 28 was repeated to yield 1-buta- 1 ,3-dienyl-cyclohexanecarboxylic acid t-butyl ester (b.p. 90-95°C/3 mmHg). This compound had the following NMR spectrum: 'H NMR (CDCl,) δ ppm: 1.2-1.7 (8H, m), 1.44 (9H, s), 2.0-2.15 (2H, m), 5.04 ( I H, d, J = 10 Hz), 5.15 ( IH, d, J = 17 Hz), 5.63 (IH, d, J = 15 Hz), 6.0-6.2 (IH, m), 6.2-6.4 (I H, m). Starting from this diene, the procedure of Example 6 was repeated to yield the tided compound, which had the following NMR spectrum: Η NMR (CDCl j ) δ ppm: 0.91 (3H, t, J = 7 Hz), 1.0-1.8 (12H, m), 1.45 (9H, s), 2.0-2.3 (6H, m), 2.3-2.6 (2H, m), 2.6-2.8 (IH, m), 3.57, 3.63 (each IH, d, J = 13 Hz), 3.7-3.85 (IH, m), 4.52 (IH, d, J = 6 Hz), 7.06, 7.15 (each 2H, d, J = 8 Hz), 7.35-7.65 (3H, m), 8.01 (IH, d, J = 8 Hz). EXAMPLE 42 Preparation of l-( l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,7,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid isopropyl ester (compound No. 415) l-buta-l,3-dienyl-cyclohexanecarboxylic acid etiiyl ester (540 mg, 2.59 mmol) was dissolved in t-butanol (3 ml). After addition of potassium t-butoxide (440 mg, 3.92 mmol), the solution was stirred at 60°C for 15 h. The reaction solution was concentrated under vacuum, dissolved in purified water and washed witii diethyl ether, followed by addition of HCl for pH adjustment to 2. After extraction with ethyl acetate, the ethyl acetate layer was washed with a saturated NaCl solution and dried widi anhydrous sodium sulfate. The solvent was distilled off under vacuum to yield l-buta-l,3-dienyl-cyclohexanecarboxylic acid (300 mg). This compound had the following NMR spectrum: NMR (CDCl,) δ ppm: 1.1-1.8 (8H, m), 2.0-2.2 (2H, m), 5.08 ( IH. cl, J = 10 Hz), 5.20 (IH, d, J = 16 Hz), 5.67 ( IH, d, J = 15 Hz), 6.1-6.4 (2H, m). A portion (720 mg, 3.99 mmol) of this compound was dissolved in dimethylformamide (5 ml). Following the addition of potassium t-butoxide (540 mg, 4.81 mmol), the mixture was stirred at room temperature for 10 min. Thereafter, isopropyl bromide (540 mg, 4.39 mmol) was added and the mixture was stirred at 60°C for 3 h. After cooling to room temperature, the reaction solution was diluted with water (10 ml) and subjected to two extractions with dietiiyl ether (30 ml). The organic layers were combined, washed with a saturated NaCl solution and dried with anhydrous sodium sulfate. The solvent was distilled off under vacuum to yield 1- buta-l,3-dienyl-cyclohexanecarboxylic acid isopropyl ester in an amount of 540 mg (yield: 60.7%)). This compound had die following NMR spectrum: Η NMR (CDC1 3 ) δ ppm: 1.1-1.7 (8H, m), 1.22 (6H, d, J = 6 Hz), 2.0-2.2 (2H, m), 4.9- 5.1 (2H, m), 5.15 (IH, d, J = 17 Hz), 5.64 (IH, d, J = 15 Hz), 6.0-6.4 (2H, m). Starting from this diene, the procedure of Example 6 was repeated to yield die tided compound, which had die following NMR spectrum: 'H NMR (CDCI 3 ) δ ppm: 0.91 (3H, t, J = 7 Hz), 0.95-1.8 (12H, m), 1.23, 1.24 (each 3H, d, J = 6 Hz), 2.0-2.3 (6H, m), 2.3-2.6 (2H, m), 2.6-2.8 (IH, m), 3.59, 3.65 (each IH, d, J = 16 Hz), 3.7-3.8 (IH, m), 4.52 (IH, d, J = 6 Hz), 4.9-5.1 ( IH. m), 7.07, 7.17 (each 2H. d, J = 8 Hz), 7.35-7.65 (3H, m), 8.04 (IH, d, J = 8 Hz). EXAMPLE 43 Preparation of 3-butyl-3-cyclohexyl-2-|2'-( lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-pyrazolol 1,2-aJpyridazin-l-one (compound No. 421 E-buta- 1 ,3-dienyl-cyclohexane was synthesized by a documented known mediod [Tetrahedron Lett., 24, 4029 (1983)]. Starting from this compound, die procedure of Example 6 was repeated to yield die titled compound, which had the following NMR spectrum: NMR (CDCl,) δ ppm: 0.88 (3H, t, J = 7 Hz), 0.9-1.9 (13H, t), 1.9-2.55 (8H, m), 2.7-2.85 (IH, m), 3.4-3.6 (2H, m), 3.7-3.8 (IH, m), 4.0-4.15 (IH, m), 6.9-7.1 (4H, m), 7.3-7.6 (3H, m), 7.7-7.9 (IH, m). EXAMPLE 44 Preparation of 3-butyl-8,8-dimethyl-7,9-methano-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,6a,7,8,9,10, 10a-octahydro-pyrazolof l,2-a]cinnolin-l-on (compound No. 433) Mediyl triphenylphosphonium bromide (98%; 8.8 g, 0.0241 mmol) was dissolved in anhydrous tetrahydrofuran (80 ml). The solution was stirred at -78°C under stirring in a nitrogen stream wliile a solution having a hexane solution of 1.6 M n-butyl lithium (15 ml) diluted with hexane (30 ml) was added dropwise. After 1-h stirring, a solution having 98% ( lR)-(-)-myrtenal (3.1 g, 0.0202 mol) dissolved in anhydrous tetrahydrofraun (4 ml) was added dropwise. After 1.5-h stirring, the reaction temperature was raised to room temperature and the mixture was stirred for 1 h, followed by reaction for 1 h under reflux by heating. The reaction solution was cooled to room temperature, diluted witii water (50 ml) and subjected to two extractions with n-pentane (100 ml). The organic layers were combined, washed witii a saturated NaCl solution and dried widi anhydrous sodium sulfate. The solvent was distilled off under atmospheric pressure and n-pentane was added to die residue, followed by filtering off die insoluble matter. Thereafter, n-pentane was distilled off under atmospheric pressure to yield 6,6-dimetiιyl-2-vinyl-bicyclo[3.3.1]hept-2-ene (3.01 g) as a yellow liquid substance. Starting from this diene, d e procedure of Example 6 was repeated to yield die titled compound, which had the following NMR spectrum: Η NMR (CDC1 3 ) δ ppm: 0.88 (3H, t, J = 7 Hz), 0.90 (3H, s), 1.1-1.55 (6H, m), 1.26 (3H, s), 1.7-2.1 (4H, m), 2.2-2.6 (4H, m), 2.6-2.8 (IH, ), 3.42, 3.51 (each IH, d. J = 15 Hz), 3.5-3.7 (IH, m), 3.7-3.85 (IH, m), 4.65-4.8 (IH, m), 6.9-7.1 (4H ,m), 7.3-7.6 (3H, m), 7.83 (IH, d, J = 7 Hz). EXAMPLE 45 Preparation of l-( l-butyl-3-oxo-2-(2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmethylJ- 5,6,7,8-tetrahydro-3H-pyrazolo| l,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid t-butyl amide (compound No. 436) and l-{ 3-butyl-l-oxo-2-f2'-( lH-tetrazol-5- yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-yl ) - cyclohexanecarboxylic acid t-butyl amide (compound No. 439) Starting from l-buta-l,3-dienyl-cyclohexanecarboxylic acid, the procedure of Example 19 was repeated to yield l-buta- l,3-dienyl-cyclohexanecarboxylic acid t-butyl amide. This compound had die following NMR spectrum: 'H NMR (CDCl,) δ ppm: 1.31 (9H, s), 1.3-1.7 (8H, m), 1.8-2.1 (2H, 111), 5.08 ( IH, d, J = 8 Hz), 5.20 (IH, d, J = 16 Hz), 5.4-5.55 (IH, b s), 5.63 (IH, d, J = 16 Hz), 6.1-6.5 (2H, m). Starting from this diene, the procedure of Example 6 was repeated to yield the titied compounds, which had die following NMR spectrum: Compound No. 436 Η NMR (CDCl,) δ ppm: 0.91 (3H, t, J = 7 Hz), 1.1- 1.75 (12H, m), 1.34 (9H, s), 1.8- 2.35 (6H, m), 2.35-2.6 (2H, m), 2.6-2.8 (IH, m), 3.6 (2H, b s), 3.7-3.85 (IH, m), 4.38 (IH, d, J = 7 Hz), 5.70 (IH, s), 7.05, 7.12 (each 2H, d. J = 8 Hz), 7.4-7.65 (3H, m), 7.98 (IH. d, J = 7 Hz). Compound No. 439 Η NMR (CDCl,) δ ppm: 0.90 (3H, t, J = 7 Hz), 1.0- 1.7 (12H, m), 1.33 (9H, s), 1.85- 2.35 (6H, m). 2.35-2.6 (2H, m). 2.6-2.8 (IH, m), 3.56 (2H, b s), 3.7-3.8 (IH, m), 4.37 (IH, d, .1 = 6 Hz), 5.70 (IH, s), 7.01, 7.06 (each 2H, d. J = 8 Hz), 7.35-7.6 (3H, m), 7.90 (IH, d. J = 8 Hz). EXAMPLE 46 Preparation of l-{ l-bulyl-3-oxo-2-[2'-(l H-tctrazol-5-yl)-biρhenyl-4-ylmethyl |- 5,6,7,8-tetxahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid (2-hydroxyethyl)amide (compound No. 442) l-buta-l,3-dienyl-cyclohexanecarboxylic acid (712 mg, 3.95 mmol) and etiianolaminc (265 mg, 4.34 mmol) were dissolved in dimethylformamide (7 ml) and die solution was stirred under cooling with ice. After successive addition of diphenylphosphoryl azide (1.3 g, 4.72 mmol) and triethylamine (880 mg, 8.70 mmol) to the stirred solution, die latter was allowed to warm by itself to room temperature as it was stirred for 20 h. The reaction mixture was diluted witii ethyl acetate, washed first with purified water, then with a saturated NaCl solution, and dried widi anhydrous sodium sulfate. The solvent was distilled off under vacuum and die residue was purified by silica gel column chromatography (chloroform/metiianol = 20/1) to yield l-buta- l ,3-dienyI-cyclohexanecarboxylic acid (2-hydroxyethyl)amide in an amount of 770 mg (yield: 87%). This compound had die following NMR spectrum: Η NMR (CDC1 3 ) δ ppm: 1.2-1.6 (6H, m), 1.6-1.8 (2H, m), 1.85-2.1 (2H, m), 3.38 (2H, q, J = 5 Hz), 3.68 (2H, t, J = 5 Hz), 5.1 1 (IH, d, J = 10 Hz), 5.22 (IH, d, J = 17 Hz), 5.65 (I H, d, J = 16 Hz), 6.1-6.5 (2H, m). Starting from this diene, the procedure of Example 6 was repeated to yield die titled compound, which had the following NMR spectrum: 'H NMR (CDCl,) δ ppm: 0.90 (3H, t, J = 7 Hz), 1.1-2.0 (12H, m), 2.0-2.4 (6H, m), 2.4-2.7 (2H, m), 2.7-2.9 (IH, m), 3.2-3.9 (7H, m), 4.60 (IH, d, J = 6 Hz), 6.9-7.2 (4H, m), 7.3- 7.65 (3H, m), 7.9-8.05 (IH, m). EXAMPLE 47 Preparation of pentanoic acid 2-[(l-{ l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6J,8-tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl (- cyclohexanecarbonyl)-amino|-ethyl eslcr (compound No. 460) l-{ l-bulyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyI-4-ylmetiιyl]-5,6,7,8-tetrahydro-3H- pyrazolof l ,2-a]pyridazin-5-yl ) -cyclohexanecarboxylic acid (2-hydroxyethyl)amide (compound No. 442; 187 mg, 0.313 mmol) was dissolved in mediylene chloride ( 1 ml) and the solution was stirred at room temperature. To the stirred solution, valeroyl chloride (45 mg, 0.373 mmol) and triethylamine (100 mg, 0.988 mmol) were added and the mixture was stirred al room temperature for 1 h. The reaction mixture was diluted widi mediylene chloride, washed first witii 5%) HCl, then witii a saturated NaCl solution (twice), and dried witii anhydrous sodium sulfate. The solvent was distilled off under vacuum and die residue was purified by silica gel column chromatography (chloroform/metiianol = 25/1) to yield die titled compound (94 mg), which had die following NMR spectrum: 'H NMR (CDC1 3 ) δ ppm: 0.87 (3H, t, J = 7 Hz), 0.90 (3H, t, J = 7 Hz), 1.0-1.9 (16H, m), 1.9-2.8 (9H, m), 2.27 (2H, t, J = 7 Hz), 3.3-3.8 (5H, m), 4.16 (2H, t, J = 5 Hz), 4.41 (I H, d, J = 7 Hz), 6.5-6.6 (IH, m), 7.04, 7.1 1 (each 2H, d, J = 8 Hz), 7.35 -7.65 (3H, m). 7.93 (IH, d, J = 8 Hz). EXAMPLE 48 Preparation of 3-butyl-8-[ l-piperidine-l-carbonyl)-cyclohexyl]-2-[2'-( lH-tetrazol- 5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazolo[ l,2-a]pyridazin-l-one (compound No. 448) l-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetrahydro-3H- pyrazolof l,2-a]pyridazin-5-yl)-cyclohexanecarboxylic acid (compound No. 394; 1 10 mg, 0.198 mmol) was dissolved in mediylene chloride (3 ml) and the solution was stirred at room temperature. To die stirred solution, triphenyl chlorometiiaiie (70 mg, 0.251 mmol) and iricthylamine (1 ml) were added and die mixture was stirred at room temperature for 20 h. The reaction mixture was diluted with methylene chloride, washed first witii 5% HCl, then with a saturated NaCl solution (twice), and dried with anhydrous sodium sulfate. The solvent was distilled off under vacuum and tlie residue was purified by silica gel column chromatography (chloroform/methanol = 50/1) to yield 1-f l-butyl-3-oxo-2-f2'-(l-trityl-lH-tetrazol-5-yI)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolo| l,2-aJpyridazin-5-yl)-cyclohexanecarboxylic acid (122 mg). This compound had the following NMR spectrum: Η NMR (CDCl,) δ ppm: 0.83 (3H, I, J = 8 Hz), 0.95-1.9 (14H, m), 2.0-2.45 (6H, m), 2.5-2.65 (IH, m), 3.51, 3.63 (each IH, d. J = 15 Hz). 3.6-3.7 (IH, m), 4.67 (IH, d, J = 7 Hz), 6.92 (6H, d, J = 7 Hz), 7.01, 7.07 (each 2H. d, J = 8 Hz). 7.15-7.55 (9H, m), 7.84 (IH, d. J = 7 Hz). Starting from this compound and piperidine, the procedure of Example 46 was repeated to give 3-butyl-8-[l-piperidine-l-carbonyl)-cyclohexyl]-2-[2'-(l-trityl-lH-tetrazol-5-yl)-biphenyl- 4-ylmethy]-5,6,7,8-tetrahydro-pyrazolo[l,2-a]pyridazin-l-one. This compound was subsequently deprotected as in Example 1 to yield the tided compound, which had the following NMR spectrum: 'H NMR (CDCl,) δ ppm: 0.86 (3H, t, J = 7 Hz), 0.95-1.85 (20H, m), 2.0-2.5 (6H, m), 2.6-2.75 (IH, m), 3.15-3.85 (7H, m), 4.64 (IH, d, J = 7 Hz), 7.02, 7.14 (each 2H, d, J = 8 Hz), 7.3-7.6 (3H, m), 7.84 (IH, d, J = 8 Hz). EXAMPLE 49 Preparation of 3-butyl-8-[ l-(mo holine-4-carbonyl)-cyclohexyl]-2-[2'-(lH- tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazoIof 1 ,2-aJpyridazin- 1 - one (compound No. 466) Starting from 1-f l-butyl-3-oxo-2-[2'-(l-trityl-lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5, 6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]-pyridazin-5-yl (-cyclohexanecarboxylic acid and moφholine, the procedure of Example 48 was repeated to yield die titled compound, which had die following NMR spectrum: 'H-NMR (CDCI 3 ) δ ppm: 0.92 (3H, t, J = 6 Hz), 1.1 - 1.9 (14H, m), 2.0-2.35 (4H, m), 2.35-2.6 (2H, m), 2.6-2.8 (IH, m), 3.2-3.8 (5H, m), 4.0-4.3 (2H, m), 4.43-4.59 (IH, b s), 7.05- 7.35 (4H, m), 7.4-7.65 (3H, m), 8.0-8.15 ( I H, b s).

Claims: CLAIMS 1. A pyrazole derivative represented by die general formula: wherein R 1 is: (a) a hydrogen atom, (b) -CF 3 , (c) C.-Q alkyl group, (d) C,-C 8 alkoxy group, (e) C,-Cg alkyldiio group, (f) C*-Cg alkylamino group, (g) ( Cg alkenyl group, (h) C 6 -C 10 aryl group, (i) C 6 -C, 0 aralkyl group, or (j) a C,-Cg alkyl, C,-C 8 alkoxy, C,-C 8 alkyldiio, C,-Cg alkylamino, C 2 -Cg alkenyl, C 6 -C, 0 aryl or C 6 -C 10 aralkyl substituted by a (i) halogen atom, (ii) C*-C 8 alkyl group, (iii) fluoroalkyl group, (iv) cycloalkyl group, (v) hydroxy group, (vi) a C,-C 8 alkoxy group, (vii) nitro group, (viii) carboxyl group, (ix) C,-C 8 alkoxycarbonyl group, (x) amino group, or (xi) cyano group; wherein the moiety -C(R 1 )-*C I-Z- is (a) -CHtR-'J-CIH-Z- (b) -C(R 1 )=C-Z- or or (c) -CH(R 1 )-C=Z-; with the provisos that when -C R- -C I-Z- is -CH(R 1 )-CH-Z- or -C(R1)=C-Z-, -Z- is a single bond, -CHR'-, -NR'-, an oxygen atom or -S(θ)„-; and when -C is -CIKR 1 )-CI=Z-, =Z- is a double bond, =CR'- or =N-, (where R' is a hydrogen atom or a ^-C e alkyl group and n is 0, 1 or 2) ; wherein R is a hydrogen atom or a group selected from among die following groups: wherein X is (a) -CH 2 -, (b) -NR'-, (c) an oxygen atom, or (d) -S(O),,-, (wherein R' is a hydrogen atom or a C,-C 8 alkyl group and n is 0, 1 or 2); where each occurrence of X 1 , X 2 and X 3 can be the same or different and is a (a) hydrogen atom, (b) halogen atom, (c) C.-C 8 alkyl group, (d) C,-Cg alkoxy group, (e) nitro group, (f) cyano group, (g) lH-tetrazol-5-yl group or an alkali metal salt thereof, (h) -CO,R 3 group, (i) -CONR'R" group, (j) -CONHSO,R 4 group, (k) amino group, (1) -NHS0 2 CF 3 group (m) -S0 3 H group, or (11) a group selected from among the following groups: wherein Y is a (a) cyano group, (b) lH-tetrazol-5-yl group or an alkali metal sail tiiereof, (c) -CO,R 3 group, (d) -CONR'R" group, (e) -CONHS0 2 R 4 group, (f) amino group, (g) -NHS0 2 CF 3 group or (h) -SO 3 H group; wherein R 2 is a (a) hydrogen atom, (b) halogen atom, (c) C,-Cg alkyl group, (d) -CF 3 group or (e) -CF 2 CF 3 group; wherein R 3 is a (a) hydrogen atom, (b) alkali metal atom, or (c) C,Cg alkyl group; where each occurrence of R' and R" can be die same or different and is (a) hydrogen atom, (b) C | -C 8 alkyl group, or (c) R' and R" taken together to form an alicyclic structure; wherein R 4 is a (a) C*-Cg alkyl group, (b) C 3 -C 7 cycloalkyl group, or (c) C 6 -C !0 aryl group; wherein R 5 is a (a) C,-C 8 alkyl group, (b) C | -C 8 alkoxy group, (c) C,-C*. cycloalkyl group, (d) C,-C 7 cycloalkoxy group, (e) C„-C| 0 aryl group or (f) C c ,-C 10 aryloxy group; where each occurrence of R 1 '. R 7 and R 8 is the same or different and is a (a) hydrogen atom, (b) halogen atom, (c) C,-C 8 alkyl group, (d) C,-C 8 alkoxy group, (e) nitro group, (f) cyano group, (g) -C0 2 R 3 group or (h) -CONR'R" group; wherein m is 1 when =Z- represents a double bond and in all other cases, m is 2; wherein -P- is represented as A-B-C-D, A-B=C-D or A=B-C=D, which, in die absence of A or D, are B-C-D, B=C-D, B-G=D, A-B-C, A-B=C or A=B-C and represent (a) -CH(R 9 )-CH(R' t> )-CH(R 1 1 )-, (b) -C(R )=C(R lϋ )-CH(R )-, (c) -CH(R 9 )-C(R lϋ )=C(R u )-, (d) -CH(R 9 )-CH(R u ')-C(=0)-, (e) -C(=O)-CH(R 10 )-CH(R")-, or (I) -CH(R )-C(=0)-CH(R")- and which, in the presence of A and D, are A-B-C-D, A-B=C-D or A=B-C=D and represent (g) -C(R 9 )(R 12 )-CH(R U, )-CH(R * * )-C(R 13 )(R 14 )-, (h) -C(R 9 )(R 12 )-C(R lυ )=C(R")-C(R 13 )(R 14 )-, (i) -C(R 9 )=C(R 10 )-C(R U )=C(R 13 )-, (j) -C(=0)-CH(R K, )-CH(R 11 )-C(R 13 )(R 14 )-, (k) -C(R 9 )(R 12 )-C(=0)-CH(R' ')-C(R 13 )(R 14 )-, (1) -C(R 9 )(R 12 )-CH(R 10 )-C(=O)-C(R 13 )(R 14 )-, or (m) -C(R 9 )(R 12 )-CH(R 11 ')-CH(R U )-C(=0)- where each occurrence of R 9 , R lu , R", R 12 , R 13 and R 14 is die same or different and is a (a) hydrogen atom, (b) C*C 8 alkyl group, (c) C,-C 8 fluoroalkyl group, (d) -[C(R , )(R 2u )] X-R 15 group, (e) -[C(R 19 )(R 20 )] r CO,R lϋ group, (i) -[C(R 19 )(R 2u )] r R 17 group, (g) -fC(R 19 )(R 2u )] r C(=0)R' group, (h) -[C(R 19 )(R υ )] r CONR l R 22 group, or (i) -fC(R 19 )(R 20 )] C(=O)NR'C(=O)NR'R" group; provided dial R 9 and R lυ , R lu and R 11 or R" and R 13 may combine togetiier to foπn (a) an alicyclic structure, (b) 5- or 6-membered heteroaryl ring containing from one to tiiree heteroatoms (0, N, S), (c) Q-Q 0 heteroaryl ring, (d) an alicyclic structure, C 6 -C H) aryl ring, or 5- or 6- membered heteroaryl ring containing one to three heteroatoms (O, N, S) substituted by a (i) a halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group or (ix) a cyano group; provided further that R 12 and R 14 may combine together to form -(CH 2 ),- group, where j is 0, 1 , 2, 3 or 4, i is 1, 2 or 3, and R' and R" each independently represent a hydrogen atom or a C.-Q alkyl group, or they may combine together to form an alicyclic structure; where each occurrence of R 19 and R 2ϋ in each [C(R I9 )(R 2U )] unit are die same or different and represent a (a) hydrogen atom, (b) Q-Q alkyl group, (c) Q-Q alkoxy group, (d) Q-Q alkoxycarbonyl group or (e) -Qn aralkyl group or, (f) they may combine together to form an alicyclic structure that is optionally substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (ix) -NR'R" group or (x) cyano group, provided that R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or diey may combine together to form an alicyclic structure; wherein X is (a) -CH 2 -, (b) -NR'-, (c) oxygen atom, or (d) -S(O),,-, provided tiiat R' is a hydrogen atom or a Q-Q alkyl group and n is 0, 1 or 2; wherein R 15 is a (a) hydrogen atom or (b) Q-Q alkyl group that is optionally substituted by a (i) hydroxy group, (ii) cyano group, (iii) -COOR' group, (iv) -CONR'R" group, (v) lH-tetrazol-5-yl group, or (vi) ether group, provided that R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or d ey may combine together to form an alicyclic structure; wherein R 16 is a (a) hydrogen atom, (b) alkali metal atom, or (c) Q-Q alkyl group, (d) Q-Q cycloalkyl group, (e) -Qn aralkyl group, (f) Q-Q cycloalkyl or Q-Q 0 aryl group substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group, (ix) cyano group, or a straight -chained or branched Q-Q alkyl or alkenyl group that are optionally substituted by -0-C(=0)-R"\ -O- C(=0)-0-R ls or -C(=0)-0- R' s , where R 18 is a Q-Q alkyl group or a Q-Q cycloalkyl group, provided that R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or they may combine together to form an alicyclic structure; wherein R 17 is a (a) cyano group or (b) lH-tetrazol-5-yl group or (c) Q-Q cycloalkyl group, (d) Q-Q cycloalkenyl group, (e) C 6 -Q 0 aryl group, or (f) 5- or 6-membered heteroaryl ring containing from one to three heteroatoms (O, N, S), (g) Q-Q cycloalkyl, Q-Q cycloalkenyl, Q,-Q 0 aryl, or 5- or 6-membered heteroaryl ring containing from one to three heteroatoms (O, N, S) substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group or (ix) cyano group, provided tiiat R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or diey may combine together to form an alicyclic structure; where each occurrence of R 21 and R 22 is the same or different and represent a (a) hydrogen atom, (b) Q-Q alkyl group, (c) Q-Q alkyl group substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) amino group, (ix) cyano group, (x) -0-C(=0)-R ls , or (xi) they may combine together to form an alicyclic structure; wherein R 18 is a (a) Q-Q alkyl group or (b) Q-Q cycloalkyl group; or a pharmacologically acceptable ester or salt of said pyrazole derivative. 2. A pyrazole derivative according to claim 1 which is represented by die general formula: wherein -Z- is (a) a single bond, (b) -NH-, (c) an oxygen atom, or (d) -S(0) n -; and n is 0, 1 or 2; wherein R 1 is: (a) a hydrogen atom, (b) -CF„ (c) Q-Q alkyl group, (d) Q-Q alkoxy group, (c) Q-Q alkyldiio group, (f) Q-Q alkylamino group, (g) Q-Q alkenyl group, (h) C,,-C| 0 aryl group, (i) C fl -C ιn aralkyl group, or (j) a Q-Q alkyl, Q-Q alkoxy, Q-Q alkyltiiio, Q-Q alkylamino, Q-Q alkenyl, C fl -Q 0 aryl or Q-Q„ aralkyl substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) fluoroalkyl group, (iv) cycloalkyl group, (v) hydroxy group, (vi) a Q-Q alkoxy group, (vii) nitro group, (viii) carboxyl group, (ix) Q-Q alkoxycarbonyl group, (x) amino group, or (xi) cyano group; wherein Y is a (a) cyano group, (b) lH-tetrazol-5-yl group or an alkali metal salt tiiereof. (c) -C0 2 R 3 group, (d) -CONR'R" group, (e) -CONHS0 2 R 4 group, (f) amino group, (g) -NHS0 2 CF 3 group or (h) -S0 3 H group; wherein R 3 is a (a) hydrogen atom, (b) alkali metal atom, or (c) QQ alkyl group; where each occurrence of R' and R" can be the same or different and is (a) hydrogen atom, (b) Q-Q alkyl group, or (c) R' and R" taken togetiier to lorm an alicyclic structure; wherein R 4 is a (a) Q-Q alkyl group, (b) Q-Q cycloalkyl group, or (c) Q,-Q 0 aryl group; wherein -P- is represented as A-B-C-D, A-B=C-D or A=B-C=D, which, in the absence of A or D, are B-C-D, B=C-D, B-C=D, A-B-C, A-B=C or A=B-C and represent (a) -CH(R 9 )-CH(R l0 )-CH(R π )-, (b) -C(R )=C(R lυ )-CH(R n )-, (c) -CH(R 9 )-C(R IU )=C(R")-, (d) -CH(R )-CH(R H, )-C(=0)-, (e) -C(=0)-CH(R u ')-CH(R")-, or (0 -CH(R )-C(=0)-CH(R")- and which, in the presence of A and D, are A-B-C-D, A-B=C-D or A=B-C=D and represenl (g) -C(R )(R l2 )-CH(R κ yCH(R")-C(R 13 )(R 14 )-, (h) -C(R 9 )(R 12 )-C(R lϋ )=C(R 1 ')-C(R 13 )(R 14 )-, (i) -C(R 9 )=C(R lu )-C(R π )=C(R 13 )-, (j) -C(=0)-CH(R 10 )-CH(R")-C(R 13 )(R 14 )-, (k) -C(R 9 )(R 12 )-C(=0)-CH(R' ')-C(R 13 )(R 14 )-, (1) -C(R 9 )(R 12 )-CH(R lϋ )-C(=0)-C(R 13 )(R 14 )-, or (m) -C(R 9 )(R 12 )-CH(R 10 )-CH(R")-C(=O)- where each occurrence of R 9 , R 10 , R", R 12 , R 13 and R 14 is die same or different and is a (a) hydrogen atom, (b) QQ alkyl group, (c) Q-Q fluoroalkyl group, (d) -fC(R 19 )(R 2u )] X-R 15 group, (e) -fC(R 19 )(R 2ϋ )] r C0 2 R 16 group, (1) -fC(R 19 )(R 2ϋ )] J -R 17 group, (g) -fC(R 19 )(R 2u )] r C(=0)R' group, (h) -fC(R l9 )(R 2 ")] J -CONR 2, R 22 group, or (i) -fC(R 19 )(R 2ϋ )] r C(=0)NR'C(=0)NR'R" group; provided tiiat R 9 and R lυ , R lu and R" or R 11 and R 13 may combine together to form (a) an alicyclic structure, (b) 5- or 6-membered heteroaryl ring containing from one to three heteroatoms (O, N, S), (c) Q-Q 0 heteroaryl ring, (d) an alicyclic structure, Q-Qo aryl ring, or 5- or 6- membered heteroaryl ring containing one to tiiree heteroatoms (O, N, S) substituted by a (i) a halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group or (ix) a cyano group; provided further that R 12 and R 14 may combine together to form -(CH 2 ),- group, where j is 0, 1, 2. 3 or 4, i is 1. 2 or 3, and R' and R" each independendy represent a hydrogen atom or a Q-Q alkyl group, or they may combine togetiier to form an alicyclic structure; where each occurrence of R 19 and R 2U in each [C(R 1 )(R 20 )] unit are the same or different and represent a (a) hydrogen atom, (b) Q-Q alkyl group, (c) Q-Q alkoxy group, (d) Q-Q alkoxycarbonyl group or (e) Q-Q 0 aralkyl group or, (f) they may combine together to form an alicyclic structure that is optionally substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (ix) -NR'R" group or (x) cyano group, provided tiiat R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or they may combine together to form an alicyclic structure; wherein X is (a) -CH 2 -, (b) -NR'-, (c) oxygen atom, or (d) -S(0) n -, provided thai R' is a hydrogen atom or a Q-Q alkyl group and n is 0, 1 or 2; wherein R 15 is a (a) hydrogen atom or (b) Q-Q alkyl group that is optionally substituted by a (i) hydroxy group, (ii) cyano group, (iii) -COOR' group, (iv) -CONR'R" group, (v) lH-tetrazol-5-yl group, or (vi) ether group, provided tiiat R' and R" each independently represenl a hydrogen atom or a Q-Q alkyl group or they may combine together to form an alicyclic structure; wherein R 16 is a (a) hydrogen atom, (b) alkali metal atom, or (c) Q-Q alkyl group, (d) Q-Q cycloalkyl group, (e) Q-Q α aralkyl group, (f) Q-Q cycloalkyl or Q-Q 0 aryl group substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group, (ix) cyano group, or a straight-chained or branched Q-Q alkyl or alkenyl group that are optionally substituted by -0-C(=0)-R ls , -O- C(=0)-0-R 18 or -C(=0)-0- R 1S , where R 1S is a Q-Q alkyl group or a Q-Q cycloalkyl group, provided that R' and R" each independendy represent a hydrogen atom or a Q-Q alkyl group or they may combine togetiier to form an alicyclic structure; wherein R 17 is a (a) cyano group or (b) lH-tetrazol-5-yl group or (c) Q-Q cycloalkyl group, (d) Q-Q cycloalkenyl group, (e) Q-Q,, aryl group, or (f) 5- or 6-membered heteroaryl ring containing from one to tiirce heteroatoms (O. N, S), (g) Q-Q cycloalkyl, Q-Q cycloalkenyl, Q-Q,, aryl, or 5- or 6-membercd heteroaryl ring containing from one to three heteroatoms (O, N, S) substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group or (ix) cyano group, provided tiiat R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or they may combine together to form an alicyclic structure; where each occurrence of R 21 and R 22 is the same or different and represent a (a) hydrogen atom, (b) Q-Q alkyl group, (c) Q-Q alkyl group substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) amino group, (ix) cyano group, (x) -0-C(=0)-R 18 , or (xi) they may combine togetiier to form an alicyclic structure; wherein R 18 is a (a) Q-Q alkyl group or (b) Q-Q cycloalkyl group; or a pharmacologically acceptable ester or salt of said pyrazole derivative. 3. A pyrazole derivative according to claim 1 which is represented by die general formula: wherein R 1 is: (a) a hydrogen atom, (b) -CF„ (c) Q-Q alkyl group, (d) Q-Q alkoxy group, (e) Q-Q alkyldiio group, (f) Q-Q alkylamino group, (g) Q-Q alkenyl group, (h) Q-Q 0 aryl group, (i) Q-Q 0 aralkyl group, or (j) a Q-Q alkyl, Q-Q alkoxy, Q-Q alkyldiio, Q-Q alkylamino, Q-Q alkenyl. Q-Q 0 aryl or Q-Q 0 aralkyl substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) fluoroalkyl group, (iv) cycloalkyl group, (v) hydroxy group, (vi) a Q-Q alkoxy group, (vii) nitro group, (viii) carboxyl group, (ix) Q-Q alkoxycarbonyl group, (x) amino group, or (xi) cyano group; wherein Y is a (a) cyano group, (b) lH-tetrazol-5-yI group or an alkali metal salt thereof, (c) -CO,R 3 group, (d) -CONR'R" group, (e) -CONHS0 2 R 4 group, (f) amino group, (g) -NHS0 2 CF 3 group or (h) -S0 3 H group; wherein R 3 is a (a) hydrogen atom, (b) alkali metal atom, or (c) QQ alkyl group; where each occurrence of R' and R" can be die same or different and is (a) hydrogen atom, (b) Q-Q alkyl group, or (c) R' and R" taken together to form an alicyclic structure; wherein R 4 is a (a) Q-Q alkyl group, (b) Q-Q cycloalkyl group, or (c) Q-Q n aryl group; wherein -P- is represented as A-B-C-D, A-B=C-D or A=B-C=D, which, in the absence of A or D, are B-C-D. B=C-D, B-C=D, A-B-Q A-B=C or A=B-C and represent (a) -CH(R 9 )-CH(R 10 )-CH(R")-, (b) -C(R 9 )=C(R I0 )-CH(R π )-, (c) -CH(R 9 )-C(R 10 )=C(R n )-, (d) -CH(R 9 )-CH(R 10 )-C(=O)-, (e) -C(=0)-CH(R lϋ )-CH(R")-, or (1) -CH(R 9 )-C(=0)-CH(R u )- and which, in die presence of A and D, are A-B-C-D, A-B=C-D or A=B-C=D and represent (g) -C(R 9 )(R 12 )-CH(R lυ )-CH(R")-C(R 13 )(R 14 )-, (h) -C(R )(R 12 )-C(R lϋ )=C(R π )-C(R 13 )(R 14 )-, (i) -C(R 9 )=C(R 10 )-C(R")=C(R 13 )-, (j) -C(=O)-CH(R 10 )-CH(R 11 )-C(R 13 )(R 14 )-, (k) -C(R 9 )(R 12 )-C(=0)-CH(R u )-C(R 13 )(R 14 )-, (1) -C(R )(R 12 )-CH(R 1 ")-C(=0)-C(R π )(R 14 )-, or (m) -C(R 9 )(R 12 )-CH(R lυ )-CH(R")-C(=0)- where each occurrence of R 9 , R 1 ", R", R 12 , R π and R 14 is die same or different and is a (a) hydrogen atom, (b) QQ alkyl group, (c) Q-Q fluoroalkyl group, (d) -fC(R ,9 )(R 20 )l r X-R 15 group, (e) -[C(R 1 )(R 2u )] r CO,R 10 group, (f -[C(R 19 )(R 2υ )] r R 17 group, (g) -fC(R 19 )(R 2,, )].-C(=0)R' group, (h) -fC(R 1 )(R 2 ')] r CONR 21 R 22 group, or (i) -[C(R 19 )(R 2ϋ )] J -C(=0)NR'C(=0)NR'R" group; provided dial R 9 and R HI , R 1 " and R" or R" and R 13 may combine togetiier to foπn (a) an alicyclic structure, (b) 5- or 6-membered heteroaryl ring containing from one to three heteroatoms (O, N, S), (c) C 6 -Q n heteroaryl ring, (d) an alicyclic structure, C 6 -Q„ aryl ring, or 5- or 6- membered heteroaryl ring containing one to three heteroatoms (O, N, S) substituted by a (i) a halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group or (ix) a cyano group; provided further that R 12 and R 14 may combine together to form -(CH 2 ),- group, where j is 0, 1 , 2, 3 or 4, i is 1, 2 or 3, and R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group, or they may combine together to form an alicyclic structure; where each occurrence of R 19 and R 2ϋ in each fC(R 19 )(R 20 )] unit are the same or different and represent a (a) hydrogen atom, (b) Q-Q alkyl group, (c) Q-Q alkoxy group, (d) Q-Q alkoxycarbonyl group or (e) Q-Qn aralkyl group or, (f) they may combine together lo foπn an alicyclic structure dial is optionally substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group. (vii) Q-Q alkoxycarbonyl group, (ix) -NR'R" group or (x) cyano group, provided tiiat R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or they may combine together to form an alicyclic structure; wherein R lϋ is a (a) hydrogen atom, (b) alkali metal atom, or (c) Q-Q alkyl group, (d) Q-Q cycloalkyl group, (e) Q-Qπ aralkyl group, (f) Q-Q cycloalkyl or Q-Q 0 aryl group substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group, (ix) cyano group, or a straight-chained or branched Q-Q alkyl or alkenyl group that are optionally substituted by -0-C(=0)-R 18 , -O- C(=0)-0-R 18 or -C(=0)-0- R 1S , where R 1S is a Q-Q alkyl group or a Q-Q cycloalkyl group, provided diat R' and R" each independendy represent a hydrogen atom or a Q-Q alkyl group or they may combine together to form an alicyclic structure; wherein R 17 is a (a) cyano group or (b) lH-tetrazol-5-yl group or (c) C,-Q cycloalkyl group, (d) Q-Q cycloalkenyl group, (e) Q-Q 0 aryl group, or (f) 5- or 6-membered heteroaryl ring containing from one to three heteroaloms (O, N, S), (g) Q-Q cycloalkyl, Q-Q cycloalkenyl, Q-Q,, aryl, or 5- or 6-membcrcd heteroaryl ring containing from one to three heteroatoms (O, N, S) substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group or (ix) cyano group, provided that R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or they may combine together to form an alicyclic structure; where each occurrence of R 21 and R 22 is die same or different and represent a (a) hydrogen atom, (b) Q-Q alkyl group, (c) Q-Q alkyl group substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) amino group, (ix) cyano group, (x) -0-C(=0)-R 18 , or (xi) they may combine together to form an alicyclic structure; wherein R 1S is a (a) Q-Q alkyl group or (b) Q-Q cycloalkyl group; or a pharmacologically acceptable ester or salt of said pyrazole derivative. 4. A pyrazole derivative according to claim 1 which is represented by the general formula: wherein R 1 is: (a) a hydrogen atom, (b) -CF 3 , (c) Q-Q alkyl group, (d) Q-Q alkoxy group, (e) Q-Q alkyldiio group, (f) Q-Q alkylamino group, (g) Q-Q alkenyl group, (h) Q-Qo aryl group, (i) Q-Q 0 aralkyl group, or (j) a Q-Q alkyl, Q-Q alkoxy, Q-Q alkylthio, Q-Q alkylamino, Q-Q alkenyl, Q-Q 0 aryl or Q-Q 0 aralkyl substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) fluoroalkyl group, (iv) cycloalkyl group, (v) hydroxy group, (vi) a Q-Q alkoxy group, (vii) nitro group, (viii) carboxyl group, (ix) Q-Q alkoxycarbonyl group. (x) amino group, or (xi) cyano group; wherein Y is a (a) cyano group, (b) lH-tetrazol-5-yl group or an alkali metal salt thereof, (c) -CO,R 3 group, (d) -CONR'R" group, (e) -CONHS0 2 R 4 group, (i) amino group, (g) -NHS0 2 CF 3 group or (h) -SO 3 H group; wherein R 3 is a (a) hydrogen atom, (b) alkali metal atom, or (c) QQ alkyl group; where each occurrence of R' and R" can be the same or different and is (a) hydrogen atom, (b) Q-Q alkyl group, or (c) R' and R" taken together to form an alicyclic structure; wherein R 4 is a (a) Q-Q alkyl group, (b) Q-Q cycloalkyl group, or (c) Q-Q,, aryl group; wherein ^ is a single bond or a double bond; where each occurrence of R 9 , R 10 , R", R 12 , R 13 and R 14 is the same or different and is a (a) hydrogen atom, (b) QQ alkyl group, (c) Q-Q fluoroalkyl group, (d) -[C(R 19 )(R 20 )] j -X-R 15 group, (e) -[C(R 19 )(R 2(1 )] J -C0 2 R 16 group, (f) -fC(R 19 )(R 2u )] r R 17 group, (g) -[C(R 19 )(R 20 )] r C(=O)R' group, (h) -[C(R 19 )(R 20 )] j -CONR 21 R 22 group, or (i) -fC(R 19 )(R 2ϋ )] J -C(=0)NR'C(=0)NR'R" group; provided that R 9 and R 10 , R 10 and R 11 or R u and R 13 may combine together to form (a) an alicyclic structure, (b) 5- or 6-membered heteroaryl ring containing from one to diree heteroatoms (O, N, S), (c) Q.-Q n heteroaryl ring, (d) an alicyclic structure, Q-Q*, aryl ring, or 5- or 6- membered heteroaryl ring containing one to three heteroaloms (O, N, S) substituted by a (i) a halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group or (ix) a cyano group; provided further that R 12 and R 14 may combine togetiier to form -(CH 2 ),- group, where j is 0, 1 , 2, 3 or 4, i is 1, 2 or 3, and R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group, or they may combine together to form an alicyclic structure; where each occurrence of R 19 and R 20 in each [C(R 1 )(R 2 ")] unit are die same or different and represent a (a) hydrogen atom, (b) Q-Q alkyl group, (c) Q-Q alkoxy group, (d) Q-Q alkoxycarbonyl group or (e) Q-Q 0 aralkyl group or, (f) they may combine together to form an alicyclic structure tiiat is optionally substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (ix) -NR'R" group or (x) cyano group, provided that R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or Ihey may combine together to form an alicyclic structure; wherein X is (a) -CH 2 -, (b) -NR'-, (c) oxygen atom, or (d) -S(O),,-, provided tiiat R' is a hydrogen atom or a Q-Q alkyl group and n is 0, 1 or 2; wherein R 15 is a (a) hydrogen atom or (b) Q-Q alkyl group diat is optionally substituted by a (i) hydroxy group, (ii) cyano group, (iii) -COOR' group, (iv) -CONR'R" group, (v) lH-tetrazoI-5-yl group, or (vi) ether group, provided that R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or they may combine together to form an alicyclic structure; wherein R 16 is a (a) hydrogen atom, (b) alkali metal atom, or (c) Q-Q alkyl group, (d) Q-Q cycloalkyl group, (e) Q-Q 0 aralkyl group, (1) Q-Q cycloalkyl or Q,-Q 0 aryl group substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group, (ix) cyano group, or a straight-chained or branched Q-Q alkyl or alkenyl group tiiat are optionally substimted by -0-C(=0)-R lli , -O- C(=0)-0-R ls or -C(=0)-0- R 1S , where R 18 is a Q-Q alkyl group or a Q-Q cycloalkyl group, provided diat R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or they may combine together to form an alicyclic structure; wherein R 17 is a (a) cyano group or (b) lH-tetrazol-5-yl group or (c) Q-Q cycloalkyl group, (d) Q-Q cycloalkenyl group, (e) Q,-Q„ aryl group, or (f) 5- or 6-membered heteroaryl ring containing from one to tiiree heteroatoms (O. N, S), (g) Q-Q cycloalkyl, Q-Q cycloalkenyl, C,,-Q„ aryl, or 5- or 6-membered heteroaryl ring containing from one to three heteroatoms (O, N, S) substiluted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group or (ix) cyano group, provided that R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or diey may combine together to form an alicyclic structure; where each occurrence of R 21 and R 22 is die same or different and represent a (a) hydrogen atom, (b) Q-Q alkyl group, (c) Q-Q alkyl group substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) amino group, (ix) cyano group. (viii) amino group, (ix) cyano group, (x) -0-C(=0)-R 18 , or (xi) they may combine togetiier to form an alicyclic structure; wherein R 18 is a (a) Q-Q alkyl group or (b) Q-Q cycloalkyl group; or a pharmacologically acceptable ester or salt of said pyrazole derivative. 5. A pyrazole derivative according to claim 1 which is represented by the general formula: wherein R 1 is: (a) a hydrogen atom, (b) -CF 3 , (c) Q-Q alkyl group, (d) Q-Q alkoxy group, (e) Q-Q alkyldiio group, (f) Q-Q alkylamino group, (g) Q-Cg alkenyl group, (h) Q-Q 0 aryl group, (i) Q-Q 0 aralkyl group, or (j) a Q-Q alkyl, Q-Q alkoxy, Q-Q alkylthio, Q-Q alkylamino, Q-Q alkenyl, Q-C l0 aryl or C 6 -Q 0 aralkyl substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) fluoroalkyl group, (iv) cycloalkyl group, (viii) carboxyl group, (ix) Q-Q alkoxycarbonyl group, (x) amino group, or (xi) cyano group; wherein Y is a (a) cyano group, (b) lH-tetrazol-5-yl group or an alkali metal salt thereof, (c) -C0 2 R 3 group, (d) -CONR'R" group, (e) -CONHS0 2 R 4 group, (f) amino group, (g) -NHS0 2 CF 3 group or (h) -SO 3 H group; wherein R 3 is a (a) hydrogen atom, (b) alkali metal atom, or (c) QQ alkyl group; where each occurrence of R' and R" can be die same or different and is (a) hydrogen atom, (b) Q-Q alkyl group, or (c) R' and R" taken togetiier to form an alicyclic structure; wherein R 4 is a (a) Q-Q alkyl group, (b) Q-Q cycloalkyl group, or (c) Q-Q 0 aryl group; wherein ^ is a single bond or a double bond; where each occurrence of R 9 , R 10 , R n , R 12 , R 13 and R 14 is die same or different and is a (a) hydrogen atom, (b) QQ alkyl group, (c) Q-Q fluoroalkyl group, (d) -[C(R 19 )(R 2ϋ )] r X-R 15 group, (e) -rC(R 19 )(R 2ϋ )] j -C0 2 R 10 group, (f) -[C(R 19 )(R 2ϋ )] j -R 17 group, (g) -fC(R 19 )(R 2ϋ )] r C(=0)R' group, (h) -[C(R 19 )(R 20 )] r CONR 21 R 22 group, or (i) -fC(R 19 )(R 20 )] j -C(=O)NR'C(=O)NR'R" group; where j is 0, 1, 2, 3 or 4 and R ' and R" each independently represenl a hydrogen atom or a Q-Q alkyl group, or they may combine together to foπn an alicyclic structure; where each occurrence of R ly and R 20 in each |C(R W )(R : ")| unit are the same or different and represent a (a) hydrogen atom, (b) Q-Q alkyl group, (c) Q-Q alkoxy group, (d) Q-Q alkoxycarbonyl group or (e) Q-Qo aralkyl group or, (0 diey may combine togetiier to form an alicyclic structure tiiat is optionally substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (ix) -NR'R" group or (x) cyano group, provided tiiat R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or they may combine together to form an alicyclic structure; wherein X is (a) -CH 2 -, (b) -NR'-, (c) oxygen atom, or ( ) -S(0), , provided that R' is a hydrogen atom or a Q-Q alkyl group and n is 0, 1 or 2; wherein R 15 is a (a) hydrogen atom or (b) Q-Q alkyl group diat is optionally substituted by a (i) hydroxy group, (ii) cyano group, (iii) -COOR' group, (iv) -CONR'R" group, (v) lH-tetrazol-5-yl group, or (vi) ether group, provided tiiat R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or diey may combine together to form an alicyclic structure; wherein R 1 " is a (a) hydrogen atom, (b) alkali metal atom, or (c) Q-Q alkyl group, (d) Q-Q cycloalkyl group, (e) Q-Q 0 aralkyl group, (f) Q-Q cycloalkyl or C 6 -C ln aryl group substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group, (ix) cyano group, or a straight -chained or branched Q-Q alkyl or alkenyl group that are optionally substituted by -0-C(=0)-R 1K , -O- C(=0)-0-R 18 or -C(=0)-0- R ιs . where R 18 is a Q-Q alkyl group or a Q-Q cycloalkyl group, provided that R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or they may combine togetiier to form an alicyclic structure; wherein R 17 is a (a) cyano group or (b) lH-tetrazol-5-yl group or (c) Q-Q cycloalkyl group, (d) Q-Q cycloalkenyl group, (e) Q-Q 0 aryl group, or (f) 5- or 6-membered heteroaryl ring containing from one to tiiree heteroatoms (O, N, S), (g) Q-Q cycloalkyl, C 3 -Q cycloalkenyl, Q-Q 0 aryl, or 5- or 6-membered heteroaryl ring containing from one to three heteroatoms (O, N, S) substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group or (ix) cyano group, provided tiiat R' and R" each independently represent a hydrogen atom or a Q-Q alkyl group or diey may combine together to form an alicyclic structure; where each occurrence of R 21 and R 22 is die same or different and represent a (a) hydrogen atom, (b) Q-Q alkyl group, (c) Q-Q alkyl group substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Cj-Q alkoxycarbonyl group, (viii) amino group, (ix) cyano group, (x) -0-C(=0)-R 18 , or (xi) d ey may combine together to form an alicyclic structure; wherein R 18 is a (a) Q-Q alkyl group or (b) Q-Q cycloalkyl group; or a pharmacologically acceptable ester or salt of said pyrazole derivative. 6. A pyrazole derivative according to claim 1 which is represented by die general formula: wherein R 1 is: (a) a hydrogen atom, (b) -CF„ (c) C,-Cg alkyl group, (d) Q-Q alkoxy group, (e) Q-Q alkylthio group, (f) Q-Q alkylamino group, (g) Q-Q alkenyl group, (h) Q-Q 0 aryl group, (i) Q-Q n aralkyl group, or (j) a Q-Q alkyl, Q-Q alkoxy, Q-Q alkyldiio, Q-Q alkylamino, Q-Q alkenyl, Q-Q n aryl or C 6 -C κ , aralkyl substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) fluoroalkyl group, (iv) cycloalkyl group, (v) hydroxy group, (vi) a Q-Q alkoxy group, (vii) nitro group, (viii) carboxyl group, (ix) Q-Q alkoxycarbonyl group, (x) amino group, or (xi) cyano group; wherein Y is a (a) cyano group, (b) lH-tetrazol-5-yl group or an alkali metal salt thereof, (c) -C0 2 R 3 group, (d) -CONR'R" group, (e) -CONHSO,R 4 group, (f) amino group, (g) -NHS0 2 CF 3 group or (h) -SO,H group; wherein R 3 is a (a) hydrogen atom, (b) alkali metal atom, or (c) QQ alkyl group; where each occurrence of R' and R" can be the same or different and is (a) hydrogen atom, (b) Q-Q alkyl group, or (c) R' and R" taken togetiier to form an alicyclic structure; wherein R 4 is a (a) Q-Q alkyl group, (b) Q-Q cycloalkyl group, or (c) Q-Qn aryl group; wherein - is a single bond or a double bond; where either one of R 9 and R 13 represents die following group: provided that when R 9 represents the following group: R 10 , R 11 and R 13 each and independently represent a hydrogen atom, a Q-Q alkyl group or a Q-Q fluoroalkyl group, and further provided that when R 13 represents the following group: R 9 , R 10 and R" each and independently represent a hydrogen atom, a Q-Q alkyl group or a Q-Q fluoroalkyl group; wherein ring A is an alicyclic structure that is optionally substituted by a (a) halogen atom, (b) Q-Q alkyl group, (c) a hydroxy group, (d) Q-Q alkoxy group, (e) nitro group, (f) carboxyl group, (g) Q-Q alkoxycarbonyl group, (h) amino group, or (i) cyano group; wherein W represents -C0 2 R 1C or -CONR 21 R 22 ; wherein R 16 is a (a) hydrogen atom, (b) alkali metal atom, or (c) Q-Q alkyl group, (d) Q-Q cycloalkyl group, (e) Q,-Q(. aralkyl group, (f) Q-Q cycloalkyl or Q-Q f , aryl group substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) -NR'R" group, (ix) cyano group, or a straight-chained or branched Q-Q alkyl or Q-Q„ alkenyl group that are optionally substituted by -0-C(=0)-R 18 , -O- C(=0)-0-R 18 or -C(=0)-0- R ls , where R 18 is a Q-Q alkyl group or a Q-Q cycloalkyl group, provided that R' and R" each independendy represent a hydrogen atom or a Q-Q alkyl group or they may combine togetiier to foπn an alicyclic structure; where each occurrence of R 21 and R 22 is die same or different and represent a (a) hydrogen atom, (b) Q-Q alkyl group, (c) Q-Q alkyl group substituted by a (i) halogen atom, (ii) Q-Q alkyl group, (iii) hydroxy group, (iv) Q-Q alkoxy group, (v) nitro group, (vi) carboxyl group, (vii) Q-Q alkoxycarbonyl group, (viii) amino group, (ix) cyano group, (x) -0-C(=0)-R 18 , or (xi) they may combine together to form an alicyclic structure; wherein R 18 is a (a) Q-Q alkyl group or (b) Q-Q cycloalkyl group; or a pharmacologically acceptable ester or salt of said pyrazole derivative. 7. The compound according to claim 1, which is selected from die group consisting of: 1 ) 3-propyl-2-f2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetralιydro- pyrazolo| 1,2-ajpyridazin-l-one, 2) 3-butyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro- pyrazolol 1 ,2-aJpyridazin- 1 -one, 3) 3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetralιydro- pyrazolo[ l ,2-a]pyridazin-l-one, 4) 3-propyl-2-f2'-( lH-tetrazol-5-yl)-biphcnyl-4-ylmethyl]-5,8-dihydro-pyrazolo| l ,2- a|pyridazin-l-one, 5) 3-butyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-pyrazolo| l ,2- a]pyridazin-l-one, 6) 3-pentyl-2-f2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmetiιyll-5,8-dihydro-pyrazolo[ 1 ,2- ajpyridazin-l-one, 7) 3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-pyrazolof l,2-a]pyridazin- 1-one, 8) 3-butyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-pyrazolof 1,2-aJpyridazin-l - one, 9) 3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmcthylj-pyrazolo[ l ,2-aJpyridazin- 1-one, 10) 6,7-dimethyl-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyI-4-ylmethyl]-5,6,7,8- tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 1 1) 3-butyl-6J-dimethyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 12) 6,7-dimethyl-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 13) 6J-dimethyl-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro- pyrazolo[ l,2-a]pyridazin-l-one, 14) 3-butyl-6,7-dimethyl-2-[2 , -(lH-tetrazol-5-yI)-biphenyl-4-ylmethyl]-5,8-dihydro- pyrazolof 1 ,2-a]pyridaziιι- 1-one, 15) 6J-dimethyl-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,8-dihydro- pyrazolof 1 ,2-a]pyridazin- 1 -one, 16) 6,7-dimethyl-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- pyrazolof 1 ,2-a]pyridazin- 1 -one, 17) 3-butyl-6J-dimethyl-2-f2 , -(lH-letrazol-5-yl)-biphenyl-4-ylmedιyl|-pyrazolυl l,2- a]pyridazin-l-one, 18) 6,7-dimethyl-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl|-pyrazolo| l,2- a]ρyridazin-l-one, 19) 3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetralιydro-5,8- cthano-pyrazolof 1 ,2-a]pyridazin- 1 -one, 20) 3-butyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyll-5,6,7,8-tetrahydro-5,8- edιano-pyrazolo[ l,2-a]pyridazin-l-one, 21) 3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-5,8- ediano-pyrazolof l,2-a]pyridazin-l-one, 22) 3-ρropyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-5,8-ethano- pyrazolof 1 ,2-a]pyridazin- 1 -one, 23) 3-butyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-5,8-etiιano- pyrazolof 1 ,2-ajpyridaziιι-l-one, 24) 3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,8-dihydro-5,8-etiιano- pyrazolof l,2-a]pyridazin-l-one, 25) 5,8-dimethyl-3-proρyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-5,8-ethano-pyrazolof 1 ,2-a]pyridazin- 1 -one, 26) 3-butyl-5,8-dimethyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7.8- tetrahydro-5,8-ethano-pyrazolof l,2-a]pyridazin-l-one, 27) 5,8-dimetiιyl-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl|-5,6,7,8- tetrahydro-5,8-ethano-pyrazolof 1 ,2-a]pyridazin- 1 -one, 28) 5,8-dimethyl-3-propyI-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,8-dihydro- 5,8-ethano-pyrazolof 1 ,2-a]pyridazin- 1 -one, 29) 3-butyl-5,8-dimethyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,8-dihydro- 5,8-ethano-pyrazolof 1 ,2-a]pyridazin- 1-one, 30) 5.8-dimedιyl-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyll-5,8-dihydro- 5,8-ethano-pyrazolo[ 1.2-a]pyridazin-l-one, 31) 5,8-dietiιyl-3-proρyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-5,8-ethano-pyrazolo[ l,2-a]pyridazin-l-one, 32) 3-butyl-5,8-dietiιyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-5 ,8-etiιano-pyrazolof 1 ,2-a]pyridazin- 1 -one, 33) 5,8-diethyl-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-5 ,8-ethano-pyrazolof 1 ,2-a]pyridazin- 1 -one, 34) 5,8-dietiιyl-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro- 5,8-ethano-pyrazolo[l,2-a]pyridazin-l-one, 35) 3-butyl-5,8-diedιyl-2-|2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl |-5,8-dihydro-5.8- edιano-pyrazolo[ l,2-aJpyridazin-l-one, 36) 5,8-diethyl-3-pentyl-2-[2'-(lH-letrazol-5-yl)-biphenyl-4-ylmethyl ]-5,8-dilιydro- 5,8-etiιano-pyrazolof 1 ,2-ajpyridazin- 1 -one, 37) 3-oxo- l -propyl-2-[2 , -(l H-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6,7.8-tetralιydro- 3H-pyrazolo| l ,2-aJpyridazin-5-carboxylic acid, 38) l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetralιydr()- 3H-pyrazolo| l,2-a]pyridazin-5-carboxylic acid, 39) 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tctralιydro- 3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid, 40) l-oxo-3-propyl-2-[2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmedιyll-5,6,7,8-tetralιydro- 1 H-pyrazolof l ,2-a]pyridazin-5-carboxylic acid, 41) 3-butyl-l-oxo-2-[2'-( l H-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6,7.8-tetrahydro- 1 H-pyrazolof 1 ,2-aJpyridazin-5-carboxylic acid, 42) l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-bipheιιyl-4-ylmethyl]-5,6,7,8-tetralιydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid, 43) 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-3H- pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid, 44) l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yI)-biρhenyI-4-ylmethyIl-5,8-dihydro-3H- pyrazolof l,2-a]pyridazin-5-carboxylic acid, 45) 3-oxo-l-pentyl-2-f2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-3H- pyrazolof l,2-a]pyridazin-5-carboxylic acid, 46) l-oxo-3-propyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,8-dihydro-l H- pyrazolof l,2-a]pyridazin-5-carboxylic acid, 47) 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,8-dihydro-lH- pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid, 48) l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmethyl]-5,8-dihydro- l H- pyrazolof l,2-ajpyridazin-5-carboxylic acid, 49) 3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-pyrazolo[ l ,2- aJpyridaziιι-5-carboxylic acid, 50) l-butyl-3-oxo-2-[2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmethyl]-3H-pyrazolo[ l,2- a]pyridazin-5-carboxylic acid, 51) 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-pyrazolo[ l,2- aJpyridazin-5-carboxylic acid, 52) l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-lH-pyrazolof l,2- a]pyridazin-5-carboxylic acid, 53) 3-butyl-l-oxo-2-[2'-( l H-teirazol-5-yl)-bipheιιyl-4-ylmetiιyl |-lH-pyrazolo[ l ,2- a]pyridazin-5-carboxylic acid, 54) l-oxo-3-pentyl-2-[2'-( lH-tetrazol-5-yl)-biplιenyl-4-ylmethyl f-l H-pyrazolo| l ,2- aJpyridazin-5-carboxylic acid, 55) 8-metiιyl-3-oxo-l-propyl-2-[2'-( l H-tetrazol-5-yl)-biphenyl-4-ylmethyl 1-5,6,7,8- tetrahydro-3H-pyrazolo| l,2-a]pyridazin-5-carboxyIic acid, 56) l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyl]-5,6J,8- tctralιydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid, 57) 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyn-5,6,7,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid, 58) 8-metiιyI-l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmelhyll-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid, 59) 3-butyl-8-methyl- l-oxo-2-I2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylf-5,6J.8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid, 60) 8-methyl-l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyl]-5, 6,7,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid, 61) 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid, 62) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid, 63) 8-methyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,8- dihydro-3H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid, 64) 8-methyl-l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5.8- dihydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid, 65) 3-butyl-8-methyI-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-lH-pyrazoIo[ l,2-a]pyridazin-5-carboxylic acid, 66) 8-methyl-l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid, 67) 8-metiιyl-3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-3H- pyrazolof l,2-a]pyridazin-5-carboxylic acid, 68) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H- pyrazolof l,2-a]pyridazin-5-carboxylic acid, 69) 8-metiιyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H- pyrazolof l,2-a]pyridazin-5-carboxylic acid, 70) 8-methyl- 1 -oxo-3-propyl-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 1 H- pyrazolof l,2-a]pyridazin-5-carboxylic acid, 71 ) 3-butyl-8-metiιyl- 1 -oxo-2-|2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl )- 1 H- pyrazolof l,2-a]pyridazin-5-carboxylic acid, 72) 8-methyl-l-oxo-3-pentyl-2-I2'-( l H-tetrazol-5-yl)-biphenyl-4-ylmethyl |- l H- pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid, 73) 3-oxo- 1 -propyl-2-[2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmcthyl ]-3.6,7.8-tetrahydπ>- 5,8-ethano-pyrazolof l,2-aJpyridazin-5-carboxylic acid, 74) l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmethyl]-3,6.7.8-tetrahydro- 5,8-etiιano-pyrazolof l,2-a]pyridazin-5-carboxylic acid, 75) 3-oxo-l-pentyI-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl|-3.6J.8-tetralιydro- 5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid, 76) l -oxo-3-propyl-2-f2'-( l H-tetrazol-5-yI)-biphenyl-4-ylmethyl]-1.6J.8-tetralιydro- 5,8-ethano-pyrazolof l,2-a]pyridazin-5-carboxylic acid, 77) 3-butyl- 1 -oxo-2-[2'-( 1 H-tetrazoI-5-yl)-biphenyl-4-ylmethyl]- 1 ,6.7,8-tetrahydro- 5,8-etiιano-pyrazolof l,2-a]pyridazin-5-carboxylic acid, 78) l-oxo-3-pentyl-2-f2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmetiιylJ-l,6J,8-teϋ * alιydro- 5,8-ethano-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid, 79) 8-metiιyI-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-bipheny]-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo| l,2-a]pyridazin-5-carboxylic acid methyl ester, 80) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid methyl ester, 81) 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6.7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid mediyl ester, 82) 8-methyl-l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-y])-biphenyl-4-ylmethyl 1-5.6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid mediyl ester, 83) 3-butyl-8-metiιyl- l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyI]-5,6J,8- tetrahydro-1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid mediyl ester, 84) 8-methyl-l-oxo-3-pentyl-2-f2'-(lH-terrazol-5-yl)-biphenyI-4-ylmetiιyll-5,6J,8- tetrahydro-lH-pyrazolof l,2-a]pyridazin-5-carboxylic acid mediyl ester, 85) 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyI-4-ylmethyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]ρyridazin-5-carboxylic acid methyl ester, 86) l-butyl-8-metl yl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyI]-5,8- dihydro-3H-pyrazolof l,2-a]ρyridazin-5-carboxylic acid methyl ester, 87) 8-methyI-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]ρyridazin-5-carboxylic acid mediyl ester, 88) 8-methyI- 1 -oxo-3-propyl-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-1 H-pyrazolof l,2-a]ρyridazin-5-carboxylic acid methyl ester, 89) 3-butyl-8-methyl- l-oxo-2-|2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl |-5,8- dihydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid methyl ester, 90) 8-methyl-l-oxo-3-pcntyl-2-[2'-( lH-tetra/.ol-5-yl)-biphenyl-4-ylmethyl 1-5.8- dihydro-lH-pyrazolo| l,2-a]pyridazin-5-carboxylic acid methyl ester, 91) 8-metiιyl-3-oxo- l-propyl-2-[2'-( l H-tetra/.ol-5-yl)-biphenyl-4-ylmcthyl 1-5,6,7,8- tctrahydro-3H-pyrazolo| l,2-ajpyridazin-5-carboxylic acid ethyl ester. 92) l-butyl-8-methyl-3-oxo-2-[2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmcthyl]-5,6J,8- tctrahydro-3H-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid ethyl ester, 93) 8-metiιyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid ethyl ester, 94) 8-methyl- 1 -oxo-3-propyl-2-| 2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmcthyI |-5,6,7,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid ethyl ester, 95) 3-butyl-8-metiιyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro- 1 H-pyrazolof l ,2-a]pyridazin-5-carboxylic acid ethyl ester, 96) 8-metlιyl-l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ-5,6,7,8- tetrahydro-1 H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid etiiyl ester, 97) 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolof l,2-aJpyridazin-5-carboxylic acid ethyl ester, 98) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmctiιyl |-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid ethyl ester, 99) 8-metlιyl-3-oxo-l-pentyl-2-|2'-(l H-tetraz.ol-5-yl)-biphenyl-4-ylmetiιyl]-5,8- dihydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid ethyl ester, 100) 8-meUιyl-l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid etiiyl ester, 101) 3-butyl-8-metliyl- l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid etiiyl ester, 102) 8-methyl-l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid etiiyl ester, 103) 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyl]-3.6J,8-tctrahydro- 5,8-ethano-pyrazolof l,2-a]pyridazin-5-carboxylic acid mediyl ester, 104) l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6,7,8-tetrahydro- 5,8-etiιano-pyrazolo[ l ,2-a]pyridazin-5-carboxylic acid methyl ester, 105) 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6J,8-tetralιydro- 5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid methyl ester, 106) 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6J,8-tetralιydro- 5,8-ethano-pyrazolo[l,2-a]pyridazin-5-carboxylic acid ethyl ester, 107) l-butyl-3-oxo-2-[2'-(l H-tetrazol-5-yl)-biplιenyl-4-ylmetiιyl |-3,6.7.8-tetrahydro- 5,8-ethano-pyrazolo[ l ,2-a]pyridazin-5-carboxylic acid ethyl ester, 108) 3-oxo-l-pentyl-2-f2'-( l H-tetrazol-5-yl)-biphcnyl-4-ylmethyl ]-3,6J,8-tetra]ιydro- 5,8-cthano-pyrazolof l,2-ajpyridazin-5-carboxylic acid etiiyl ester, 109) 3-oxo-l -proρyl-2-f2'-( lH-tetrazol-5-yl)-biphcnyl-4-ylmethyl ]-3H,8H-5.8-ctlιano- pyrazolof l ,2-a]pyridazin-5-carboxylic acid, 1 10) l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmetiιyIf-3H,8H-5,8-etiιano- pyrazolof l,2-a]pyridazin-5-carboxylic acid, 1 1 1) 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-3H,8H-5,8-ethano- pyrazolo[ l ,2-aJpyridazin-5-carboxylic acid, 1 12) l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyl ]- l H,8H-5,8-cthano- pyrazolo| 1 ,2-a]pyridazin-5-carboxylic acid, 1 13) 3-butyl- 1 -oxo-2-[ 2'-( 1 H-tetrazol-5-yl)-biplιenyl-4-ylmethyI f- 1 H,8H-5,8-etiιano- pyrazolo| 1 ,2-a]pyridazin-5-carboxylic acid, 1 14) l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-bipheιιyl-4-ylmethyl]-lH,8H-5,8-etiιano- pyrazolof l,2-a]pyridazin-5-carboxylic acid, 115) 3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H,8H-5,8-ethano- pyrazolo[ l ,2-a]pyridazin-5-carboxylic acid methyl ester, 1 16) l-butyl-3-oxo-2-f2'-( lH-tetrazol-5-yI)-biphenyl-4-ylmethyI]-3H,8H-5,8-cthano- pyrazolo[ l,2-a]pyridazin-5-carboxylic acid methyl ester, 117) 3-oxo-l-pentyl-2-|2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyI]-3H,8H-5.8-etiιano- pyrazolof l,2-a]pyridazin-5-carboxylic acid mediyl ester, 1 18) l-oxo-3-proρy]-2-[2'-( lH-tctrazol-5-yl)-biphenyl-4-ylmedιyl]-lH,8H-5.8-edιano- pyrazolo[ l ,2-a]pyridazin-5-carboxylic acid methyl ester, 1 19) 3-butyl-l-oxo-2-[2'-(lH-tctrazol-5-yl)-biphenyl-4-ylmethyll-l H,8H-5,8-edιano- pyrazolof l,2-a]pyridazin-5-carboxylic acid methyl ester, 120) l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-lH,8H-5.8-etiιano- pyrazolof l,2-a]pyridazin-5-carboxylic acid mediyl ester, 121) 8-metiιyl-3-oxo-l-propyl-2-f2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmetiιyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 2-eti oxycarbonylphenyl ester, 122) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid 2-etiιoxycarbonylphenyl ester, 123) 8-methyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid 2-etiιoxycarbonylphenyl ester, 124) 8-metiιyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 2-ethoxycarbonylphenyl ester. 125) l-butyl-8-methyl-3-oxo-2-[2'-(l H-tctrazol-5-yl)-biphenyl-4-ylmelhyl |-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 2-ethoxycarbonylphenyl ester, 126) 8-methyl-3-oxo-l-pentyl-2-[2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,8- dihydro-3H-pyrazolo| l ,2-a]pyridazin-5-carboxylic acid 2-ethoxycarbonylphenyl ester, 127) 8-methyl-3-oxo-l -propyl-2-I2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tctrahydro-3H-pyrazolo| l ,2-ajpyridazin-5-carboxyIic acid 3-ethoxycarbonylphenyl ester, 128) l-butyl-8-methyl-3-oxo-2-|2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid 3-etiιoxycarbonylphenyl ester, 129) 8-methyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-bipheny]-4-ylmethyl]-5,6,7.8- tetralιydro-3H-pyrazolo| l ,2-a]pyridazin-5-carboxylic acid 3-ethoxycarbonylphenyl ester, 130) 8-methyl-3-oxo- 1 -propyl-2-f 2 '-( 1 H-tetrazol-5-yI)-biphenyI-4-ylmcthyl ]-5,8- dihydro-3H-pyrazolo[ l ,2-a]pyridazin-5-carboxylic acid 3-ethoxycarbonylphenyl ester, 131) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,8- dihydro-3H-pyrazolof 1.2-a]pyridazin-5-carboxylic acid 3-ethoxycarbonylphenyl ester, 132) 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 3-edιoxycarbonylphenyl ester, 133) 8-methyl-3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 4-etiιoxycarbonylphenyl ester, 134) l-butyl-8-metiιy]-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 4-etiιoxycarbonylphenyl ester, 135) 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmcthyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid 4-etiιoxycarbonylphenyl ester, 136) 8-methyl-3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid 4-ethoxycarbonylphenyl ester, 137) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyl]-5,8- dihydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid 4-ethoxycarbonylphenyl ester, 138) 8-methyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid 4-ethoxycarbonylphenyl ester, 139) 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6J,8-tetrahydro- 5,8-edιano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 2-etiιoxycarbonylphenyl ester, 140) l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6J,8-tetrahydro- 5,8-etiιano-pyrazolof l,2-a]pyridazin-5-carboxylic acid 2-etiιoxycarbonylphenyl ester, 141) 3-oxo- 1 -pentyl-2-[2 '-( 1 H-tetrazol-5 : yl)-biphenyl-4-ylmethyl]-3,6,7,8-tetrahydro- 5,8-etiιano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 2-etiιoxycarbonylphenyl ester, 142) 3-oxo-l-propyl-2-f2'-(lH-tetrahydro-5-yl)-biphenyl-4-y_methyl]-3,6J,8- tetrahydro-5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 3-ethoxycarbonylphenyl ester. 143) l-butyl-3-oxo-2-|2 , -( lH-tetrahydro-5-yl)-biphenyl-4-ylmethyl]-3,6,7.8-tetralιydiO- 5,8-edιano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 3-edιoxycarbonylphenyl esler, 144) 3-oxo-l-pentyl-2-[2'-( l H-tetralιydro-5-yl)-biphenyl-4-ylmethyl]-3,6J.8- tctrahydro-5,8-ethano-ρyrazolo| l,2-a]pyridazin-5-carboxylic acid 3-ethoxycarbonylphenyl ester. 145) 1 -oxo-3-propyl-2-[2'-( l H-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 1.6.7.8-tetralιydro- 5.8-ethano-pyrazolo| l,2-aJpyridazin-5-carboxylic acid 2-ethoxycarbonylphcnyl ester, 146) 3-butyl-l-oxo-2-[2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmethyl]-l,6,7,8-tetrahydro- 5.8-etiιaιιo-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 2-etiιoxycarbonylphenyl ester, 147) l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmelhyl]-l,6J,8-teLralιydro- 5,8-edιano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 2-ethoxycarbonylphenyl ester, 148) l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- l,6J,8-tetralιydro- 5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-carnoxylic acid 3-ethoxycarbonylphenyl ester, 149) 3-butyl-l-oxo-2-[2'-(l H-tetrazol-5-yl)-biphenyI-4-ylmetiιyl]-1.6.7,8-telralιydro- 5,8-edιano-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid 3-ethoxycarbonylphenyl ester. 150) l-oxo-3-pentyl-2-f2'-( lH-tetrazol-5-yl)-biplιenyl-4-ylmethyl]-l,6.7,8-tetralιydro- 5,8-etiιano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid 3-ethoxycarbonylphenyl ester, 151) l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-l,6,7,8-tetrahydro- 5,8-ethano-pyrazolof l,2-a]pyridazin-5-carboxylic acid 4-etiιoxycarbonylphenyl ester, 152) 3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyI-4-ylmethyl]-l,6J,8-tetrahydro- 5,8-ethano-ρyrazolof l,2-a]pyridazin-5-carboxylic acid 4-ethoxycarbonylphenyl ester, 153) l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- l ,6J,8-tetralιydro- 5.8-ethano-pyrazolof 1.2-a]pyridazin-5-carboxylic acid 4-ethoxycarbonylphenyl ester, 154) 8-metiιyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylf-5,6,7,8- tetrahydro-3H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid dimethylamide, 155) l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid dimediylamide, 156) 8-metiιyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6,7,8- tctrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid dimethylamide, 157) 8-methyl-3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid dimediylamide, 158) l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,8- dihydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid dimethylamide, 159) 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolo[l,2-a]pyridazin-5-carboxylic acid dimethylamide, 160) 8-metiιyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid dietiiylamide, 161) l-butyl-8-metiιyl-3-()xo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl 1-5,6,7. - lctrahydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid dietiiylamide, 162) 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-bipheιιyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid dietiiylamide, 163) 8-melhyl-3-oxo- 1 -propyl-2-[ 2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl 1-5,8- dihydro-3H-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid diethylamide, 164) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,8- dihydro-3H-pyrazolo[ l,2-aJpyridazin-5-carboxylic acid diethylamide, 165) 8-metiιyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid diethylamide, 166) 8-metiιyl-3-oxo-l-propyl-2-[2'-(l H-tetrazol-5-yl)-biphcnyl-4-ylmethyl]-5,6,7,8- tctrahydro-3H-pyrazolo| l,2-aJpyridazin-5-carboxylic acid t-butylamide, 167) l-butyl-8-metiιyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl 1-5.6,7, 8- lctrahydro-3H-pyrazolo[ l ,2-a]pyridazin-5-carboxylic acid t-butylamide, 168) 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetralιydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid t-butylamide, 169) 3-oxo-l-propyl-2-f2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmethyI]-3,6J,8-tetrahydro- 5,8-ethano-pyrazolof l,2-a]pyridazin-5-carboxylic acid diethylamide, 170) l-butyl-3-oxo-2-f2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6.7,8-tetrahydro- 5,8-etiιa]io-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid dietiiylamide, 171 ) 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphcnyl-4-ylmcthyl]-3,6J,8-tetralιydro- 5,8-ethano-pyrazolof l,2-a]pyridazin-5-carboxylic acid diethylamide, 172) 3-oxo-l-propyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-3,6J,8-tetralιydro- 5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid t-butylamide, 173) l-butyl-3-oxo-2-[2'-(lH-tefrazo]-5-yl)-biphenyl-4-ylmethyl]-3,6,7,8-tetrahydro- 5,8-ethano-pyrazolof l,2-a]pyridazin-5-carboxylic acid t-butylamide, 174) 3-oxo-l-pentyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6J,8-tetralιydro- 5,8-etiιano-pyrazolo[ l ,2-a]pyridazin-5-carboxylic acid t-butylamide, 175) 2-(f 8-methyI-3-oxo-l-propyI-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl |- 5,6,7, 8-tetralιydro-3H-pyrazolof l ,2-a]pyridazin-5-carbonyl )-amino)-benzoic acid ethyl ester, 176) 2-({ l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6,7.8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-carbonyl )-amino)-benzoic acid ethyl ester, 177) 2-({ 8-methyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyI]- 5,6J,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-carbonyl ]-amino)-benzoic acid etiiyl ester, 178) 2-({ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6,7,8- tetrahydro-5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-carbonyl }-amino)-benzoic acid etiiyl ester, 179) 2-(( l-butyl-3-oxo-2-[2'-( l H-tetrazol-5-yl)-bipheιιyl-4-ylmethyl ]-3.6,7, - tcirahydro-5,8-ethano-pyrazolo[ l,2-aJpyridazin-5-carbonyl )-amino)-benzoic acid ethyl ester, 180) 2-( { 3-oxo- l-penty]-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl ]-3,6.7.8- tetralιydro-5,8-etiιano-pyrazolo| l,2-a]pyridazin-5-carbonyl }-amino)-benzoic acid ethyl ester, 181 ) f 8-methyl-3-oxo-l-propyl-2-|2'-( lH-teirazol-5-yl)-biphcnyl-4-ylmcthyl 1-5,6,7.8- tctrahydro-3H-pyrazolo[ l ,2-a]pyridazin-5-yl ) -acetic acid, 182) f l-butyl-8-metiιyl-3-oxo-2-I2'-( l H-tetraz.ol-5-yl)-biplιeιιyI-4-ylmethylf-5,6J,8- tctrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl } -acetic acid, 183) f 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl 1-5,6,7,8- teirahydro-3H-pyrazolof l,2-aJpyridazin-5-yl (-acetic acid, 184) 3- f 8-metiιyl-3-oxo- 1 -propyl-2-|2'-( 1 H-tetrazol-5-yl)-hiphenyl-4-ylmcthyI ]- 5,6,7, 8-tetralιydro-3H-pyrazolo[ l,2-alpyridazin-5-yl (-propionic acid, 185) 3-f l-butyl-8-methyl-3-oxo-2-f2'-(l H-tetra7.ol-5-yl)-biphenyl-4-ylmethyl |-5,6J.8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-propionic acid. 186) 3- f 8-methyl-3-oxo- 1 -pentyl-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl ]- 5,6J,8-tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl } -propionic acid, 187) 4- ( 8-methyl-3-oxo- 1 -propyl-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmetiιyl ]- 5, 6,1, 8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl ] -butyric acid, 188) 4- f 1 -butyl-8-methyl-3-oxo-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl (-5,6,7,8- tetrahydro-3H-pyrazolof 1 ,2-a]pyridazin-5-yl ) -butyric acid, 189) 4-( 8-medιyl-3-oxo- l-penty]-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylnιethyl l- 5, ,7, 8-tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl } -butyric acid, 190) ( 8-mcthyl-3-oxo-l-propyl-2-[2'-(lH-tetraz.ol-5-yl)-biphcnyl-4-ylmethyl 1-5,6,7,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl } -acetic acid ediyl ester, 191) f l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl ] -acetic acid ethyl ester, 192) { 8-methyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-acetic acid ediyl ester, 193) 3-{ 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyl |- 5, 6J,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl( -propionic acid ediyl ester, 194) 3-f l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl ) -propionic acid ethyl ester, 195) 3-{ 8-methyl-3-oxo-l-pentyl-2- [2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolo| l,2-a]pyridazin-5-yl )- propionic acid etiiyl ester, 196) ( 3-oxo-l-propyl-2-f2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetrahydro- 3H-pyrazolo[ l,2-a]pyridazin-5-yl (-acetic acid ethyl ester, 197) { l-butyl-3-oxυ-2-f2'-(lH-teu-azol-5-yl)-biphenyl-4-ylmethyl]-5.6,7,8-lctrahydro- 3H-pyrazolo[ l,2-aJpyridazin-5-yl (-acetic acid ethyl ester, 198) f 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl|-5.6J.8-tcμalιydro- 3H-pyrazolo[ l,2-a]ρyridazin-5-yl (-acetic acid etiiyl ester, 199) 3- ( 3-oxo- 1 -propyl-2-[2'-( 1 H-tctrazol-5-yl)-biρhenyl-4-ylmefhyl |-5,6,7.8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-propionic acid ethyl ester, 200) 3-{ l-butyl-3-oxo-2-[2'-(lH-tctrazol-5-yl)-biphenyl-4-ylmetiιyl(-5,6,7,8- tetrahydro-3H-pyrazolo| 1 ,2-a]pyridazin-5-yl (-propionic acid ethyl ester, 201) 3-{3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5.6J,8- tetrahydro-3H-pyrazolo| l,2-a]pyridazin-5-yl (-propionic acid etiiyl ester, 202) 8-hydroxymetiιyl-5-methyl-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmedιyl]-5,6J,8-tetrahydro-pyrazolo[ l,2-a]pyridazin-l-onc, 203) 3-butyl-8-hydroxymetiιyl-5-methyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl |- 5.6.7,8-tetrahydro-pyrazolo[ l,2-a]pyridaziι -l-one, 204) 8-hydroxymethyl-5-methyl-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 205) {8-methyl-3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6J,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-ylmethoxy( -acetic acid ethyl ester, 206) { l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-ylmethoxy) -acetic acid ethyl ester, 207) { 8-methyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6,7.8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-ylmethoxy} -acetic acid etiiyl ester, 208) 2-{ 8-methyl-3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,7,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-ylmethoxy}-benzoic acid ethyl ester, 209) 2-( l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7.8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-ylmethoxy(-benzoic acid ethyl ester, 210) 2-{ 8-methyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ- 5.6J,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-ylmethoxy(-benzoic acid etiiyl ester, 21 1) 3-f 8-methyl-3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl(- 5,6J,8-tetrahydro-3H-ρyrazolo[ l,2-a]pyridazin-5-ylmethoxy}-benzoic acid ethyl ester, 212) 3-f l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl|-5.6.7.8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-ylmethoxy}-benzoic acid etiiyl ester, 213) 3-f 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmeti yl]- 5,6J,8-tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-ylmethoxy}-benzoic acid etiiyl ester, 214) 2-f 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5.6J,8-tetralιydro-3H-pyrazolo| l ,2-a]pyridazin-5-ylmetiιoxy-metiιyl )-benzoic acid ethyl ester, 215) 2-f l-butyl-8-methyl-3-oxo-2-[2 , -(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6,7,8- tetrahydro-3H-pyrazolo[ l ,2-a]pyridazin-5-ylmethoxy-methyl (-benzoic acid etiiyl ester, 216) 2- ( 8-methyI-3-oxo- 1 -pentyl-2-[2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmetlιyl |- 5.6J,8-tetrahydro-3H-pyrazolo| l ,2-a]pyridazin-5-ylmetiιoxy-methyl (-benzoic acid ethyl ester. 217) 3-j 8-medιyl-3-oxo- l-propyl-2-|2'-( l H-tctrazol-5-yl)-biphenyl-4-ylmedιyl |- 5.6,7,8-tetralιydro-3H-pyrazolof l,2-a]pyridazin-5-ylmethoxy-metiiyl (-benzoic acid ethyl ester, 218) 3-{ l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl 1-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-ajpyridazin-5-ylmethoxy-methyl }-benzoic acid etiiyl ester, 219) 3-( 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylf- 5,6,7,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-ylmetlιoxy-metlιyl )-benzoic acid ethyl ester, 220) 8-hydroxymethyl-3-propyl-2-f2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmethyl (-5,6,7.8- tetralιydro-5,8-ethano-pyrazolo[ l,2-a]pyridazin-l-one, 221) 3-butyl-8-hydroxymethyl-2-|2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl (-5,6,7,8- tetralιydro-5,8-ethano-pyrazolo[ 1,2-aJpyridazin-l-one, 222) 8-hydroxymethyI-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl (-5,6,7,8- tetrahydro-5,8-ethano-pyrazolof 1 ,2-a]pyridazin- 1 -one, 223) 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6J,8-tetrahydro- 5, 8-ethano-pyrazolof l,2-a]pyridazin-5-ylmethoxy) -acetic acid etiiyl ester, 224) l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-3,6,7,8-tetrahydro- 5,8-etiιano-pyrazolof l ,2-a]pyridazin-5-ylmethoxy}-acetic acid etiiyl ester, 225) 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6,7,8-tetrahydro- 5, -ethano-pyrazolof l,2-a]pyridazin-5-ylmedιoxy ) -acetic acid etiiyl ester, 226) 2-{ 3-oxo-l-propyI-2-[2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmethyl]-3,6,7,8- tetrahydro-5,8-ethano-pyrazolof l,2-a]pyridazin-5-ylmethoxy-methyl }-benzoic acid ediyl ester, 227) 2-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6,7,8- tetrahydro-5,8-ethano-pyrazolof l,2-a]pyridazin-5-ylmethoxy-medιyl (-benzoic acid etiiyl ester, 228) 2-f 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,6J,8- tetralιydro-5,8-ethano-pyrazolo[ l,2-a]pyridazin-5-ylmethoxy-methyl }-benzoic acid ediyl ester, 229) 2-{ 8-metlιyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetl yl]- 5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl}-benzoic acid etiiyl ester, 230) 2-{ l-butyl-8-methyl-3-oxo-2-12'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6,7,8- tetrahydr()-3H-pyrazolof l,2-a]pyridazin-5-yl }-benzoic acid etiiyl ester, 231) 2-f 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6J,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl(-benzoic acid etiiyl ester, 232) 3-{ 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιylJ- 5,6J,8-tetralιydro-3H-pyrazoloI l ,2-aJpyridazin-5-yl )-benzoic acid etiiyl ester, 233) 3-f l-butyl-8-meUιyl-3-oxo-2-f 2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-benzoic acid ethyl ester, 234) 3-f 8-metlιyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmelhyll- 5,6J,8-tetralιydro-3H-pyrazolo| l,2-a]pyridazin-5-yl)-benzoic acid ethyl ester, 235) 2-{ 8-medιyl-3-oxo-l-propyl-2-I2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl l- 5.6,7, 8-tetrahydro-3H-pyrazolo[ l ,2-a]pyridazin-5-ylmetiιyl (-benzoic acid etiiyl ester. 236) 2-{ l-butyl-8-methyl-3-oxo-2-|2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyl |-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-ylmethyl )-benzoic acid ediyl ester, 237) 2-( 8-medιyl-3-oxo-l -pentyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethylf- 5,6J,8-tetrahydro-3H-pyrazolo[ l,2-ajpyridazin-5-ylmetiιyl (-benzoic acid ethyl ester, 238) 3-( 8-methyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6J.8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yImethyl (-benzoic acid ethyl ester, 239) 3-l l-butyl-8-metiιyl-3-oxo-2-[2'-(lH-tctrazol-5-yI)-biphenyl-4-ylmethyl|-5,6,7,8- tctrahydro-3H-pyrazolof l,2-a)pyridazin-5-ylmethyl}-benzoic acid ediyl ester, 240) 3-f 8-methyl-3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]- 5,6,7,8-tefrahydro-3H-pyrazolof l,2-a]pyridazin-5-ylmethyl}-benzoic acid ethyl ester, 241 ) { 8-methyl-3-oxo- 1 -propyl-2-f 2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmetlιyl]-5 , 6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl (-acetonitrile, 242) f l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetralιydro-3H-pyrazolof 1 ,2-a]ρyridazin-5-yl } -acetonitrile, 243) ( 8-metiιyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5.6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-acetonitrile, - 244) l-methoxy-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolo[l,2-a]pyridazin-5-carboxylic acid mediyl ester, 245) l-ethoxy-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolof l,2-aJpyridazin-5-carboxylic acid mediyl ester, 246) 8-methyl-3-oxo-l-propoxy-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid mediyl ester, 247) 8-metiιyl-l-methylsulfaιιyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmelhyl]- 5.8-dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid mediyl ester, 248) l-ethylsulfanyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmcthyl]-5,8- dihydro-3H-pyrazolof l.2-a]pyridazin-5-carboxylic acid mediyl ester, 249) 8-methyl-3-oxo-l-propylsulfanyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmeti yπ- 5.8-dihydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid mediyl ester, 250) f -oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-3,6,7,8-tetrahydro- 5, 8-etiιano-pyrazolo[ l,2-a]pyridaziιι-5-ylmetiιoxy ( -acetic acid methyl ester, 251) f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmetiιyl]-3,6,7,8-tetralιydro- 5.8-cthano-pyrazolo[ l,2-a]pyridazin-5-ylmetiιoxy (-acetic acid methyl ester, 252) ( 3-oxo-l-pentyl-2-f2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl |-3,6J,8-tctralιydro- 5, -ed ano-pyrazolo[ l,2-a]pyridazin-5-ylmethoxyi -acetic acid methyl ester, 253) f 8-methyl- l-oxo-3-propyl-2-|2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmetiιyl 1-5.6,7.8- tetrahydro-1 H-pyrazolof l,2-a]pyridazin-5-yl (-acetonitrile, 254) f 3-buty]-8-methyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl (-acetonitrile, 255) { 8-metiιyl-l-oxo-3-pentyl-2-[2 , -(lH-tetrazol-5-yI)-biρhenyl-4-ylmetiιyl]-5,6,7,8- tetralιydro-lH-pyrazoIo[ 1 ,2-a]pyridazin-5-yl (-acetonitrile, 256) 3-( 8-metiιyl-l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5, 6,7.8-tetralιydro- 1 H-pyrazolof l,2-a]pyridaziιι-5-yl ( -propionic acid ethyl ester, 257) 3-{ 3-butyl-8-methyl-l-oxo-2-[2'-(lH-tetra7.ol-5-yl)-biphenyl-4-ylmethyIl-5,6J.S- tetrahydro-lH-pyrazoIo[ l,2-a]pyridazin-5-yl (-propionic acid ethyl ester, 258) 3- { 8-methyl- 1 -oxo-3-pentyl-2- [2 '-( 1 H -tetrazol-5-yl)-bipheny 1-4-ylmethy I ]- 5, 6.7,8-tetrahydro-l H-pyrazolof l,2-a]pyridazin-5-yl) -propionic acid ethyl ester, 259) 3-butyl-5,8-dimethyl-2-f f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyl |-amino (- 5,6,7,8-tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 260) 1 -butyl-8-metiιyl-3-oxo-2- ( [2'-( 1 H-tetrazo]-5-yl)-bipheιιyl-4-ylmethyl 1-amino } - 5,6,7,8-tefrahydro-3H-pyrazolo[ l ,2-a]pyridazin-5-carboxyIic acid etiiyl ester, 261) l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazoI-5-yI)-biphenyl-4-ylmetlιoxyl-5,6,7,8- tctralιydro-3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid ethyl ester, 262) l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylsulfanylf- 5,6J,8-tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-carboxylic acid etiiyl ester, 263) l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-yl]-ethylidene- hexahydro-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid etiiyl ester, 264) 2-i 3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-3H- pyrazolof l ,2-a]pyridazin-5-yl (-benzoic acid mediyl ester, 265) 2-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-3H- pyrazolo[ l,2-a]pyridazin-5-yl(-benzoic acid mediyl ester, 266) 2-{ 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-3H- pyrazolo( l,2-a]pyridazin-5-yl(-benzoic acid methyl ester, 267) 3-( 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyl]-5,8-dihydro-3H- pyrazolo[ l,2-a]pyridazin-5-yl (-benzoic acid methyl ester, 268) 3-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-3H- pyrazolof l,2-a]pyridazin-5-yl )-benzoic acid methyl ester, 269) 3-{3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-5.8-dihydro-3H- pyrazolo[ l,2-a]pyridaziιι-5-yl )-benzoic acid mediyl ester, 270) 3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6J,8-tetralιydro- 3H-pyrazolo[l,2-a]pyridazin-5-carboxylic acid methyl ester, 271) l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl|-5,6,7.8-tetrahydro- 3H-pyrazolo[ l,2-a]pyridazin-5-carboxylic acid methyl ester, 272) 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-5,6J.8-tetralιydro- 3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid mediyl ester, 273) 8-methyl-3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid l-(2,2-dimetiιyl-propionyloxy)-etiιyl ester, 274) l-butyl-8-metiιyl-3-oxo-2-[2'-(lH-tctrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6J,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-carboxylic acid l-(2,2-dimethyl-propionyloxy)-ethyl ester, 275) 8-methyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-carboxylic acid l-(2,2-dimethyl-propionyloxy)-ethyl ester, 276) Piperidine-1-carboxylic acid { 8-methyl-3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolo[ 1 ,2-aJpyridazin-5-carbonyl (-amide, 277) Piperidine-1-carboxylic acid { l-butyl-8-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-carbonyl (-amide, 278) Piperidine-1-carboxylic acid ( 8-metfιyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yI)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-carbonyl (-amide, 279) 2,2-dimethyl-propionic acid 2-(3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl- 4-ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-acetoxy methyl ester, 280) 2,2-dimetiιyl-propionic acid 2-( l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-acetoxy methyl ester, 281) 2,2-dimethyl-propionic acid 2-{3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl- 4-ylmetiιyl]-5,6,7,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl (-acetoxy methyl ester, 282) {3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6J,8-tetrahydro- 3H-pyrazolof l,2-a]pyridazin-5-yl (-acetic acid 2-isopropyl-5-methyl-cyclohexyl ester, 283) f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro- 3H-pyrazolo[l,2-a]pyridazin-5-yl (-acetic acid 2-isopropyl-5-methyl-cyclohexyl ester, 284) {3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetralιydro- 3H-pyrazolof l,2-a]pyridazin-5-yl (-acetic acid 2-isopropyl-5-methyl-cyclohexyl ester, 285) 8-acetyl-5-methyl-3-propyl-2-|2'-(lH-tctrazol-5-yl)-biphenyl-4-ylmetiιyl |-5,6,7,8- tetraliydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 286) 8-acetyl-3-butyl-5-medιyl-2-f2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J.8- tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 287) 8-acetyl-5-metiιyl-3-pentyl-2-[2'-(lH-tetraz.ol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tctrahydro-pyrazolof 1 ,2-aJpyridazin- 1 -one, 288) 2-{ 8-methyl-3-oxo-l-propyl-2-f2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyl |- 5,6J,8-tetrahydro-3H-pyrazolo[ l ,2-a]pyridazin-5-ylmethyl }-malonic acid diethyl ester, 289) 2-f l-butyl-8-methyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl |-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-aJpyridazin-5-ylmethyl}-malonic acid dietiiyl ester, 290) 2-( 8-methyl-3-oxo- l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl ]- 5,6J,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-ylmethyl }-malonic acid diethyl ester, 291 ) 2- f 3-oxo- 1 -propyl-2-[ 2 '-( 1 H-tetrazol-5-yI)-biphenyl-4-ylmethyI (-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl }-3-phenyl-propionic acid ethyl ester, 292) 2-{ l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl }-3-phenyl-propionic acid ethyl ester, 293) 2-( 3-oxo-l-ρentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyI]-5,6,7,8- tetralιydro-3H-pyrazolof l,2-a]pyridazin-5-yl (-3-phenyl-propionic acid ethyl ester, 294) 2-methyl-2-f 3-oxo-l -propyl-2-(2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5.6J,8-tetrahydro-3H-pyrazolof l ,2-a]pyridazin-5-yl( -propionic acid ethyl ester, 295) 2-( l-butyI-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl]-2-methyl-propionic acid etiiyl ester, 296) 2-methyl-2-f 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl} -propionic acid ethyl ester, 297) 2-ethyl-2-{3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-butyric acid ethyl ester, 298) 2-f l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl (-2-ethyl-butyric acid etiiyl ester, 299) 2-ethyl-2-{ 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-butyric acid etiiyl ester, 300) l-{ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid ethyl ester, 301) l-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl( -cyclohexanecarboxylic acid ethyl ester, 302) l-{ 3-oxo-l-ρentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl ( -cyclohexanecarboxylic acid etiiyl ester, 303) l-{ 3-oxo- l-propyl-2-[2'-( lH-letrazol-5-yl)-biphenyl-4-ylmethyl|-5,6J,8- tetralιydro-3H-pyrazolof l,2-a]pyridazin-5-yl )-cyclopentanecarboxylic acid etiiyl ester, 304) l -f l-butyl-3-oxo-2-f2'-(l H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- teirahydro-3H-pyrazolo[ l,2-aJpyridazin-5-yl }-cyclopentanecarboxylic acid etiiyl ester, 305) l-f 3-oxo- l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl|-5,6,7,8- tetrahydro-3H-pyrazolo| l,2-a]pyridazin-5-yl (-cyclopentanecarboxylic acid ethyl ester, 306) 2-methyl-2-{ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl l- 3, 6,7, 8-tetrahydro-5, -cthano-pyrazolo| l,2-aJpyridazin-5-yl ) -propionic acid et yl ester, 307) 2-( l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyI-4-ylmetiιyl]-3,6,7,8- tetrahydro-5,8-etiιano-pyrazolof l,2-a]pyridazin-5-yl }-2-metiιyl-propionic acid etiiyl ester, 308) 2-methyl-2- { 3-oxo- 1 -pentyl-2-f2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl |- 3,6,7,8-tetrahydro-5,8-et ano-pyrazolo[ l,2-ajpyridazin-5-yl (-propionic acid etiiyl ester, 309) { l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetralιydro- 1 H-pyrazolof 1.2-a]pyridazin-5-yl (-acetic acid etiiyl ester, 310) f 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl (-acetic acid ethyl ester, 31 1) f l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl ( -acetic acid ethyl ester, 312) l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-bipheny]-4-ylmethyl]-5,6J,8-tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid methyl ester, 313) 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6,7,8-tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid methyl ester, 314) 1 -oxo-3-pentyl-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid methyl ester, 315) 8-methyl-l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid 1 -(2,2-dimethyl-propionyloxy)-ethyl ester, 316) 3-butyl-8-methyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-lH-pyrazoIo[ l,2-a]pyridazin-5-carboxylic acid l-(2,2-dimetiιyl-propionyloxy)-ethyl ester, 317) 8-methyl-l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid l-(2,2-dimetiιyl-propionyloxy)-etiιyl ester, 318) 2-metiiyl-2-f l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5, ,1, 8-tetrahydro-l H-pyrazolof l,2-a]pyridazin-5-yl( -propionic acid ethyl ester, 319) 2-{3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetralιydro-lH-pyrazolo| l,2-aJpyridazin-5-yl )-2-medιyl-propionic acid etiiyl ester, 320) 2-metiιyl-2-f l-oxo-3-pentyl-2-|2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyI]- 5, 6,7.8-tetrahydro-l H-pyrazolof l ,2-a]pyridazin-5-yl (-propionic acid ethyl ester, 321) 8-metiιyl-l-oxo-3-propyl-2-|2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl |-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-aJpyridazin-5-carboxylic acid t-butyl-amide, 322) 3-butyl-8-methyl- l -oxo-2-|2'-( l H-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6J,8- tetrahydro- 1 H-pyrazolof l ,2-a]ρyridazin-5-carboxylic acid t-butyl-amide, 323) 8-metiιyl-l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid t-butyl-amide, 324) 2-edιyl-2- { l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl 1-5,6,7,8- tetraliydro- 1 H-pyrazolof l ,2-a]pyridazin-5-yl (-butyric acid etiiyl ester, 325) 2-{ 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6.7,8- tetrahydro-lH-pyrazolo| l ,2-aJpyridazin-5-yl }-2-ethyl-butyric acid etiiyl ester, 326) 2-ethyl-2-f l-oxo-3-pentyl-2-[2'-( lH-tetrazol-5-yl)-biphenyl-4-ylmethyll-5,6J,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl (-butyric acid ethyl ester, 327) 2,2-dimethyl-propionic acid 2-{ l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl- 4-ylmethyI]-5,6,7,8-tetrahydro-lH-pyrazolof l,2-a]pyridazin-5-yl )-acetoxymethyl ester, 328) 2,2-dimethyl-propionic acid 2-f 3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro- 1 H-pyrazolof l,2-a]ρyridazin-5-yl )-acetoxymethyl ester, 329) 2,2-dimetiιyl-propionic acid 2-f l-oxυ-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl- 4-ylmetlιyl]-5,6J,8-tetrahydro-lH-pyrazolof l ,2-a]pyridazin-5-yl }-acetoxymethyl ester, 330) { 1 -oxo-3-propyl-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8-tetralιydro- 1 H-pyrazolof l ,2-a]pyridazin-5-yl (-acetic acid 2-isopropyl-5-methyl-cyclohexyl ester, 331) f 3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-yImethyl]-5,6J,8-tetrahydro- 1 H-pyrazolof 1, 2- a]pyridazin-5-yl (-acetic acid 2-isopropyl-5-methyl-cyclohexyl ester, 332) { l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8-tetrahydro- 1 H-pyrazolof 1, 2- a]pyridazin-5-yl (-acetic acid 2-isopropyl-5-methyl-cyclohexyl ester, 333) 8-methyl-l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid (piperidine-l-carbonyl)-amide, 334) 3-butyl-8-methyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid (piperidine-l-carbonyl)-amide, 335) 8-metiιyl-l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid (piperidine-l-carbonyl)-amide, 336) l-{ l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-lH-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid etiiyl ester, 337) l-{ 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tctraliydro- 1 H-pyrazolof 1 ,2-aJpyridazin-5-yl ) -cyclohexanecarboxylic acid etiiyl ester, 338) l-f l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl(-5.6J.8- tetrahydro-lH-pyrazolo| l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid ethyl ester, 339) 2-{ 8-methyl-l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmcthyl |- 5,6.7,8-tetrahydro-lH-pyrazolo[ l ,2-a]pyridazin-5-ylmethyl )-malonic acid dietiiyl ester. 340) 2-{ 3-butyl-8-methyl- l-oxo-2-[2'-(l H-tctraz.ol-5-yl)-biphenyl-4-ylmetlιyl |-5,6.7,8- tetrahydro-1 H-pyrazolof l,2-a]pyridazin-5-ylmethyl l-malonic acid diethyl ester, 341) 2-f 8-methyl-l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl|- 5, 6,7,8-tetrahydro-l H-pyrazolof l,2-a]pyridazin-5-ylmetiιyl (-malonic acid diethyl ester, 342) 5-acetyl-8-metiιyl-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-pyrazolof 1,2-ajpyridazin- 1 -one, 343) 5-acetyl-3-butyl-8-methyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetlιyl]-5,6J,8- tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 344) 5-acetyl-8-med yl-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl (-5,6,7.8- tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 345) 2-{ l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-yl }-3-phenyl-propionic acid ethyl ester, 346) 2-f 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmethyl]-5,6J,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl (-3-phenyl-propionic acid ethyl ester, 347) 2-f l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-yl )-3-phenyl-propionic acid ediyl ester, 348) l-{ l-oxo-3-propyl-2-[2'-(lH-tetrazoI-5-yl)-biphenyl-4-ylmetiιyl]-5.6J,8- tetrahydro-lH-pyrazolof l,2-a]pyridazin-5-yl (-cyclopentanecarboxylic acid etiiyl ester, 349) 1-f 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5, 6,7,8- tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-yl }-cyclopentanecarboxylic acid ethyl ester, 350) l-f l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-lH-pyrazolo[ l,2-a]pyridazin-5-yl (-cyclopentanecarboxylic acid ethyl ester, 351) 2-methyl-2-f l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyI |- 1, 6,7, 8-tetrahydro-5,8-ethano-pyrazolof l,2-a]pyridazin-5-yl ( -propionic acid ediyl ester, 352) 2-( 3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-l,6,7,8- tetralιydro-5,8-etiιano-pyrazolo[ l,2-a]pyridazin-5-yl (-2-methyl-propionic acid etiiyl ester, 353) 2-meUιyl-2-{ l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- l,6J,8-tetrahydro-5.8-ethano-pyrazolo[ l,2-a]pyridazin-5-yl (-propionic acid ethyl ester, 354) 8-methyl-l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid diethylamide, 355) 3-butyl-8-methyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-carboxylic acid dietiiylamide, 356) 8-methyl-l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-carboxylic acid diethylamide, 357) l-{ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl ) -cyclopropanecarboxyhc acid etiiyl ester, 358) l-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl (-cyclopropanecarboxyhc acid ethyl ester, 359) 1 - { 3-oxo- 1 -pentyl-2-[2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl ]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl (-cyclopropanecarboxyhc acid ediyl ester, 360) 1-f l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyI]-5,6,7,8- tetrahydro-1 H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclopropanecarboxyhc acid etiiyl ester, 361) 1-f 3-butyl- 1 -oxo-2-f2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl ]-5,6,7,8- tetrahydro-1 H-pyrazolof l,2-a]pyridazin-5-yl ( -cyclopropanecarboxyhc acid ethyl ester, 362) l-( l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl( -cyclopropanecarboxyhc acid etiiyl ester, 363) l-{ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyI-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl(-cycloheptanecarboxylic acid etiiyl ester, 364) l-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl}-cycloheptanecarboxylic acid etiiyl ester, 365) l-{ 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl (-cycloheptanecarboxylic acid ethyl ester, 366) 1-f l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-lH-pyrazolo[l,2-a]pyridazin-5-yl(-cycloheptanecarboxylic acid etiiyl ester. 367) l-f 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl ]-cycloheptanecarboxylic acid ethyl ester, 368) l-f l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-lH-pyrazolo[l,2-a]pyridazin-5-yl}-cycloheptanecarboxylic acid etiiyl ester, 369) 4,4-dimethyl-l-{ 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-yImethylJ- 5, 6,7,8-tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl} -cyclohexanecarboxylic acid etiiyl ester, 370) 1-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl (-4,4-dimethyl-cyclohexanecarboxylic acid etiiyl ester, 371 ) 4,4-dimethyl- 1 - { 3-oxo- 1 -pentyl-2- [2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethy 1 ] - 5,6J,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl(-cyclohexanecarboxylic acid ethyl ester, 372) 4,4-dimethyl-l-{ l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyI]- 5, 6,7,8-tetrahydro-l H-pyrazolof l,2-a]pyridazin-5-yl( -cyclohexanecarboxylic acid ethyl ester, 373) l-{3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl}-4,4-dimethyl-cyclohexanecarboxylic acid ethyl ester, 374) 4,4-dimethyl- 1 - ( 1 -oxo-3-pentyl-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5, 6,7, 8-tetrahydro-l H-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid etiiyl ester, 375) l-(6-metlιyl-3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl|-5,8- dihydro-3H-pyrazolof l,2-a]pyridazin-5-yl( -cyclohexanecarboxylic acid ethyl ester, 376) l-{ l-butyl-6-methyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,8- dihydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl} -cyclohexanecarboxylic acid etiiyl ester, 377) l-{6-methyl-3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,8- dihydro-3H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid etiiyl ester, 378) l-{6-medιyl-l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmedιyl]-5,8- dihydro-1 H-pyrazolof l,2-a]pyridazin-5-yl) -cyclohexanecarboxylic acid etiiyl ester, 379) l-{3-butyl-6-methyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl( -cyclohexanecarboxylic acid ethyl ester, 380) l-{6-methyl-l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8- dihydro-1 H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid ethyl ester, 381) 3,4-dimethyl- 1 - { 3-oxo- 1 -propyl-2-f 2 '-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,7,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl(-cyclopent-3-enecarboxylic acid ediyl ester, 382) 1-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl }-3,4-dimethyl-cyclopent-3-enecarboxylic acid ethyl ester, 383) 3,4-dimethyl-l-{3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]- 5,6,7, 8-tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl}-cyclopent-3-enecarboxylic acid ethyl ester, 384) 3,4-dimethyl-l-{ l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5, 6,7, 8-tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl(-cyclopent-3-enecarboxylic acid etiiyl ester, 385) l-(3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetliyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl }-3,4-dimethyl-cyclopent-3-enecarboxylic acid etiiyl ester, 386) 3,4-dimethyl- 1-f l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethylJ- 5, 6,7,8-tetrahydro-l H-pyrazolof l,2-a]pyridazin-5-yl(-cyclopent-3-enecarboxylic acid etiiyl ester, 387) 8-isopropyl-5-methyl-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6J,8-tetrahydro-5,8-ethano-pyrazolof l,2-a]pyridazin-l-one, 388) 3-butyl-8-isopropyl-5-methyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,7,8-tettahydro-5,8-ethano-pyrazolo[l,2-a]pyridazin-l-one, 389) 8-isopropyl-5-methyl-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6J,8-tetrahydro-5,8-ethano-pyrazolo| l,2-a]pyridazin-l-one, 390) 5-isopropyl-8-methyl-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl |- 5,6J,8-tetralιydro-5,8-etiιano-pyrazolof l,2-a]ρyridazin-l-onc, 391) 3-butyl-5-isopropyl-8-metiιyl-2-|2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl |- 5,6,7,8-tetrahydro-5,8-etiιano-pyrazolo[ l,2-a]pyridazin-l-one, 392) 5-isopropyl-8-methyl-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl(- 5,6,7,8-tetrahydro-5,8-etiιano-pyrazolof l,2-a]pyridazin-l-one, 393) l-f 3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid, 394) 1-f l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid, 395) l-f 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazoloI 1 ,2-aJpyridazin-5-yl } -cyclohexanecarboxylic acid, 396) l-f l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-lH-pyrazolo[l,2-a]pyridazin-5-yl( -cyclohexanecarboxylic acid, 397) l-{ 3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-1 H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid, 398) l-f l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid, 399) 5,8-dimethyl-3-propyl-2-{ [2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino(- 5,6,7,8-tetrahydro-5,8-ethano-pyrazolof 1 ,2-a]pyridazin- 1 -one, 400) 3-butyl-5,8-dimethyl-2-{ [2'-(lH-tetrazol-5-yl)-bipheny]-4-ylmethyl]-amino(- 5,6,7,8-tetrahydro-5,8-ethano-pyrazolof l,2-a]pyridazin-l-one, 401) 5,8-dimethyl-3-pentyl-2-f [2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino(- 5,6J,8-tetrahydro-5,8-ethano-pyrazolo[l,2-a]pyridazin-l-one, 402) l-(3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid butyl ester, 403) l-( l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid butyl ester, 404) 1-f 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid butyl ester, 405) l-f l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid butyl ester, 406) l-{3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid butyl ester, 407) l-{ l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetraliydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid butyl ester, 408) l-{3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl( -cyclohexanecarboxylic acid t-butyl ester, 409) l-( l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5.6.7,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid t-butyl ester, 410) l-{3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyn-5,6,7,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid t-butyl ester, 41 1) 1-f l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-lH-pyrazolo[l,2-a]pyridazin-5-yl}-cyclohexanecarboxylic acid t-butyl ester, 412) l-{3-butyl-l-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-1 H-pyrazolof l,2-a]pyridazin-5-yl( -cyclohexanecarboxylic acid t-butyl ester, 413) l-f l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-1 H-pyrazolof l,2-a]pyridazin-5-yl} -cyclohexanecarboxylic acid t-butyl ester, 414) l-f 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl( -cyclohexanecarboxylic acid isopropyl ester, 415) l-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid isopropyl ester, 416) l-f 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid isopropyl ester, 417) 1-f l-oxo-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-lH-pyrazolo[l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid isopropyl ester, 418) l-{3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-1 H-pyrazolof l,2-a]pyridazin-5-yl] -cyclohexanecarboxylic acid isopropyl ester, 419) l-f l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-lH-pyrazolof l,2-a]pyridazin-5-yl( -cyclohexanecarboxylic acid isopropyl ester, 420) 8-cyclohexyI-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 421) 3-butyl-8-cyclohexyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 422) 8-cyclohexyl-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyI-4-ylmethyl]-5,6,7,8- tetrahydro-pyrazolof l,2-a]pyridazin- 1 -one, 423) 5-cyclohexyl-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 424) 3-butyl-5-cyclohexyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-pyrazolof l,2-a]pyridazin-l-one, 425) 5-cyclohexyl-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]-5,6J,8- tetrahydro-pyrazolof l,2-a]pyridazin- 1 -one, 426) 3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,6a,7,8,9,10,10a- octahydro-pyrazolof l,2-a]cinnolin-l-one, 427) 3-butyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,6aJ,8.9,10,10a- octaliydro-pyrazolof l,2-a]cinnolin-l-one, 428) 3-pentyl-2-[2'-(lH-tetrazol-5-yI)-biphenyl-4-ylmethyl]-5,6,6a,7,8,9, 10,10a- octahydro-pyrazolof 1 ,2-a]cinnolin- 1 -one, 429) 7,9-methano-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmetiιyl]- 5,6,6a,7,8,9, 10, 1 Oa-octahydro-pyrazolof 1 ,2-a]cinnoIin- 1 -one, 430) 3-butyl-7,9-methano-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5,6,6a,7,8,9, 10, 1 Oa-octahydro-pyrazolof 1 ,2-a]cinnolin- 1 -one, 431) 7,9-methano-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-bipheny)-4-ylmethyl]- 5,6,6a,7,8,9,10,10a-octahydro-pyrazolo[l,2-a]cinnolin-l-onc, 432) 8,8-dimetiιyl-7,9-metiιano-3-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl |* 5,6,6a,7,8,9,10,10a-octahydro-pyrazolo[l,2-a]cinnolin-l-one, 433) 3-butyl-8,8-dimethyl-7,9-methano-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyll- 5,6,6a,7,8,9,10,10a-octahydro-pyrazolof l ,2-a]cinnolin-l-one, 434) 8,8-dimethyl-7,9-methano-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]- 5 ,6,6a,7,8,9, 10, 1 Oa-octahydro-pyrazolof 1 ,2-a]cinnolin- 1 -one, 435) l-{3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetralιydro-3H-pyrazoIof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid t-butyl-amide, 436) l-f l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid t-butyl-amide, 437) l-{ 3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-bipheny]-4-ylmethyl]-5,6,7,8- tetralιydro-3H-pyrazolof l,2-a]pyridazin-5-yl( -cyclohexanecarboxylic acid t-butyl-amide, 438) l-{ l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid t-butyl-amide, 439) l-f 3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid t-butyl-amide, 440) 1-f l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro- 1 H-pyrazolof 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid t-butyl-amide, 441) l-{ 3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid (2-hydroxy-ethyl)- amide, 442) 1-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid (2-hydroxy-ethyl)- amide, 443) l-{3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl ) -cyclohexanecarboxylic acid (2-hydroxy-ethyl)- amide, 444) l-{ l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmediyl]-5,6,7,8- tetraliydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid (2-hydroxy-etiιyl)- amide, 445) 1-f 3-butyl- 1 -oxo-2-[2'-( 1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid (2-hydroxy-ethyl)- amide, 446) l-f l-oxo-3-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-1 H-pyrazolof l,2-a]pyridazin-5-yl) -cyclohexanecarboxylic acid (2-hydroxy-ethyl)- amide, 447) 8-[ l-(piperidine-l-carbonyl)-cyclohexyl]-3-propyl-2-[2'-(lH-tetrazoI-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazolo[l,2-a]pyridazin-l-one, 448) 3-butyl-8-[l-(piperidine-l-carbonyl)-cyclohexyl]-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6J,8-tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1-one, 449) 3-pentyl-8-[ l-(piperidine-l-carbonyl)-cyclohexyl]-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6J,8-tetrahydro-pyrazolof 1 ,2-a]pyridazin- 1 -one, 450) 5-[ l-(piperidine-l-carbonyl)-cyclohexyl]-3-propyl-2-f2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazolo[ 1 ,2-a]pyridazin- 1 -one, 451) 3-butyl-5-f l-(piperidine-l-carbonyl)-cyclohexyl]-2-f2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazolo[ 1 ,2-a]pyridazin- 1 -one, 452) 3-pentyl-5-[ l-(piperidine-l-carbonyl)-cyclohexyl]-2-f2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazolo[l,2-a]pyridazin-l-one, 453) l-f 3-oxo-l-propyl-2-f2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmethyl]-5,6J,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid diethylamide, 454) l-f l-butyl-3-oxo-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid diethylamide, 455) l-{3-oxo-l-pentyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl } -cyclohexanecarboxylic acid diethylamide, 456) l-f l-oxo-3-ρropyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6J,8- tetrahydro-lH-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid diethylamide, 457) l-{3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,6,7,8- tetrahydro-lH-pyrazolo[l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid diethylamide, 458) l-f l-oxo-3-pentyl-2-f2'-(lH-tetrazol-5-yl)-biρhenyl-4-ylmethyl]-5,6,7,8- tetrahydro-1 H-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarboxylic acid diethylamide, 459) Pentanoic acid 2-[(l-( 3-oxo-l-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmetiιyl]-5,6J,8-tetrahydro-3H-pyrazolof l,2-a]pyridazin-5-yI )-cyclohexanecarbonyl)-amino]- ethyl ester, 460) Pentanoic acid 2-[(l- ( l-butyl-3-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolo[ 1 ,2-a]pyridazin-5-yl (-cyclohexanecarbonyl)-aminoj- etiiyl ester, 461) Pentanoic acid 2-[(l-{ 3-oxo-l-pentyl-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-3H-pyrazolo[ l,2-a]pyridazin-5-yl (-cyclohexanecarbonyl)-amino]- ethyl ester, 462) Pentanoic acid 2-f(l-{ l-oxo-3-propyl-2-[2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6J,8-tetrahydro- 1 H-pyrazolof l,2-a]pyridazin-5-yl (-cyclohexanecarbonyl)-amino(- etiiyl ester, 463) Pentanoic acid 2-f(l-{ 3-butyl-l-oxo-2-f2'-(lH-tetrazol-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-l H-pyrazolof l,2-a]pyridazin-5-yl )-cyclohexanecarbonyl)-amino]- ethyl ester, 464) Pentanoic acid 2-[(l-{ l-oxo-3-pentyl-2-[2'-(lH-tetrazoI-5-yl)-biphenyl-4- ylmethyl]-5,6,7,8-tetrahydro-lH-pyrazolo[l,2-a]pyridazin-5-yl(-cyclohexanecarbonyl)-amino]- ethyl ester, 465) 8-f l-(mθφholine-4-carbonyl)-cyclohexyl]-3-propyl-2-f2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazoIof l,2-a]pyridazin-l-one, 466) 3-butyl-8-[ l-(moφholine-4-carbonyl)-cyclohexyl]-2-f2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazolo[ l,2-a]pyridazin-l-one, 467) 8-[ l-(moφholine-4-carbonyl)-cyclohexyl]-3-pentyl-2-f2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6J,8-tetrahydro-pyrazolo[l,2-a]pyridazin-l-one, 468) 5-[ l-(moφholine-4-carbonyl)-cyclohexyl]-3-propyl-2-[2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazolo[l,2-a]pyridazin-l-one, 469) 3-butyl-5-[ l-(moφholine-4-carbonyl)-cyclohexyl]-2-f2'-(lH-tetrazol-5-yl)- biphenyl-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazolo[ l,2-a]pyridazin-l-one and 470) 5-[ l-(moφholine-4-carbonyl)-cyclohexyl]-3-pentyl-2-[2'-(lH-tetrazol-5-yl)- biphenyl*-4-ylmethyl]-5,6,7,8-tetrahydro-pyrazolof l,2-a]pyridazin- l-one. 8. A pharmaceutical composition for preventing or treating hypertension, congestive heart failure, renal failure, glaucoma or hyperuricemia which comprises as an active ingredient a compound of Claim 1. 9. A pharmaceutical composition according to claim 8 which comprises active ingredient a compound of Claim 1. 10. A pharmaceutical composition according to claim 8 which comprises as an active ingredient an pyrazole derivative of Claim 3. 11. A pharmaceutical composition according to claim 8 which comprises as an active ingredient an pyrazole derivative of Claim 4. 12. A pharmaceutical composition according to claim 8 which comprises as an active ingredient an pyrazole derivative of Claim 5. 13. A pharmaceutical composition according to claim 8 which comprises as an active ingredient an pyrazole derivative of Claim 6.

Inventors: FUJITA YOSHIJI, KOH KEIKO, KUNIHARA MINEO, KUSHIDA HIROSHI, MORITA OSAMU, MUNESADA KIYOTAKA, TANIGUCHI MIKIO, YAMADA HIROYOSHI, FUJITA, YOSHIJI, KOH, KEIKO, KUNIHARA, MINEO, KUSHIDA, HIROSHI, MORITA, OSAMU, MUNESADA, KIYOTAKA, TANIGUCHI, MIKIO, YAMADA, HIROYOSHI
Applicants: FUJITA YOSHIJI, KOH KEIKO, KUNIHARA MINEO, KUSHIDA HIROSHI, MORITA OSAMU, MUNESADA KIYOTAKA, TANIGUCHI MIKIO, UPJOHN CO, YAMADA HIROYOSHI, FUJITA, YOSHIJI, KOH, KEIKO, KUNIHARA, MINEO, KUSHIDA, HIROSHI, MORITA, OSAMU, MUNESADA, KIYOTAKA, TANIGUCHI, MIKIO, THE UPJOHN COMPANY, YAMADA, HIROYOSHI
Application year: 1993
Main classification: C07D487
IPC codes: A61K31, A61P9, A61P13, A61P15, A61P19, A61P27, C07D487